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 SUMMARY 1.
Background 
Gram-negative bacteria of the genus Shigella are the etiological agents of human 
bacterial dysentery, shigellosis. The genus is divided into four serogroups, historically 
treated as species: S. dysenteriae (serogroup A), S. flexneri (serogroup B), S. boydii 
(serogroup C), and S. sonnei (serogroup D). These species are further divided into 
serotypes, defined by the structure and the biochemical differences in the 
oligosaccharide repeating unit (RU) that forms the O antigen (OAg) of the 
lipopolysaccharide (LPS). At present, S. flexneri comprise 14 serotypes and 
subserotypes, S. dysenteriae 15 serotypes, S. boydii 20 serotypes and S. sonnei a 
single serotype. Shigella spp. are among the most frequent causes of diarrhea. A study 
by the WHO of 1999 estimated that 164.7 million cases of shigellosis occur per year, of 
which 1.1 million cases result in death. More recent estimates fix the Shigella disease 
burden at 90 million episodes and 122000 deaths per year.  Approximately 99 % of all 
cases occur in developing countries and, importantly, 69 % of all shigellosis patients are 
children under the age of five. Among Shigella species, S. flexneri and S. sonnei are 
endemic and are linked to most of the infections. Shigella is transmitted by the fecal-oral 
route and after passage through the stomach and the small intestine, the bacteria reach 
the large intestine and invade the colonic and rectal epithelium causing severe tissue 
damage, abscesses and ulceration and the acute mucosal inflammation characteristic of 
shigellosis. Clinical symptoms range from mild watery diarrhea to severe inflammatory 
bacillary dysentery characterized by strong abdominal cramps, fever, nausea, anorexia, 
dehydration and stools containing blood and mucus. The disease is normally self-limiting 
but may become life-threatening, especially in immunocompromised patients and 
malnourished children. Antibiotic resistance and multi-resistant strains are increasing, 
limiting treatment options. Currently, there is no Shigella vaccine available. Natural 
Shigella infection results in protective, serotype-specific immunity. The 
lipopolysaccharide (LPS) is generally accepted as a protective antigen of Shigella. 
Specifically, the outer domain of the LPS, the O antigen, has been correlated with 
immunity against Shigella infection, as infected patients show protection against 
reinfection with the homologous strain. Thus, special efforts in Shigella vaccine 
development have focused on developing O antigen containing vaccines, either 
delivered as live-attenuated vaccine strains or more specifically as O antigen 
conjugates. In fact, a S. sonnei O antigen conjugate showed approximately 70 % 
efficacy in adults and children 3 years old and older. However in younger children, the 
conjugate was not effective. Other strategies involve the development of live-attenuated 
strains. Still, recent candidates are not yet at the stage of efficacy testing. Most of the 
vaccines currently under development are serotype-specific. There is a widespread 
agreement that globally useful Shigella vaccines must protect against a broad spectrum 
of Shigella serotypes: 16 different serotypes are considered to be globally important for 
an epidemiologically valid global vaccine, S. dysenteriae 1, all 14 types of S. flexneri, 
and the S. sonnei single type. 
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Shigella Project at NVGH 
The aim of the Shigella project at the Novartis Vaccines Institute for Global Health 
(NVGH) is to develop a broadly protective, Shigella vaccine. Our approach is based on 
GMMA (Generalized Modules for Membrane Antigens), also known in literature as Outer 
Membrane Vesicles (OMV). GMMA are naturally secreted proteo-liposomes released by 
Gram-negative bacteria from the outer envelope. They reflect the outer membrane 
composition, containing LPS, glycerophospholipids, outer membrane proteins and 
lipoproteins, and enclose some periplasmic components. Genetic modification of 
producing bacteria allows the increase of GMMA release, without affecting their 
resemblance with naturally secreted ones. GMMA are different from detergent-extracted 
outer membrane vesicles (also called OMV in literature) that are produced by detergent-
treatment of homogenized bacteria and show a very different composition and protein 
profile, enriched in cytoplasmatic and inner membrane proteins. The Shigella group has 
engineered GMMA over-producing Shigella strains (S. sonnei 53G, Ss) by deleting the 
tolR gene that encodes for a Tol-Pal system protein linking the outer and the inner 
membranes. This mutation was reported to result in overproduction of GMMA without 
loss of membrane integrity. With the aim to avoid a serotype-specific immunogenicity of 
GMMA, the presence of the O side chain has been abolished by deleting genes involved 
in the synthesis and assembly of LPS. Different approaches to generate O antigen-free 
GMMA were used. As a first step, galU gene was deleted (Ss ∆galU). In this mutant the 
linkage of the OAg repeating units to the core region of LPS is abolished, leading to a 
truncated LPS form composed of lipid A and inner core. In addition, mutant strains 
unable to synthesize the repeating unit of the OAg were generated. In S. sonnei the O 
antigen biosynthetic genes are located on the virulence plasmid (pSS). Therefore we 
either cured the virulence plasmid from S. sonnei 53G (Ss phase II, -pSS) or we 
inactivated the plasmid-encoded OAg gene cluster (Ss ∆wbg). GMMA were purified 
from bacterial culture supernatants, characterized in respect to protein content and used 
as antigen in immunization studies in mice. These studies showed that GMMA are very 
immunogenic, raising high levels of GMMA-specific IgG. 
 
First results and PhD project hypothesis and aims 
The sera raised against GMMA carrying a WT or a mutated LPS were tested for their 
ability to recognize surface epitopes on live bacteria and to cross react with different 
Shigella serotypes. We observed that the staining of the surface of Ss WT in vitro was 
possible only in the presence of OAg-specific antibodies. While other experiments 
showed that S. sonnei GMMA contained conserved proteins that raised an immune 
response, the respective surface antigens were masked in in vitro grown Shigella by the 
presence of exopolysaccharide (EPS) structures and thus were not accessible in the 
surface staining experiment. This has also been reported for other Gram-negative 
bacteria. Surprisingly, sera raised against S. sonnei ∆galU GMMA, that were thought no 
to react with the O antigen and so with the WT strain, stained the homologous WT strain 
in a serotype-specific manner. We hypothesized that the galU mutation in S. sonnei 
might not result in complete loss of O antigen with GMMA produced from this mutant still 
raising an OAg-specific response. Unlike the S. sonnei strains lacking the OAg gene 
cluster, the galU mutant is still able to synthesize the OAg repeating units. These units 
could be assembled on the surface of the bacteria through an alternative pathway that 
does not involve the linkage of the OAg to the LPS. Recently, several Gram-negative 
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bacteria, like enteropathogenic E. coli (EPEC), Salmonella enterica serovar Enteriditis 
and Francisella tularensis, have been shown to express a capsule that based on its 
mechanisms of synthesis and assembly has been classified as a fourth group of capsule 
types. A group 4 capsule (G4C) is a high molecular weight (HMW) capsular 
polysaccharide composed of the same repeating OAg units as the LPS, thus also called 
OAg capsule. It contains more units than the LPS, which are linked to the cell surface by 
an unknown mechanism. So far, Shigella has been reported to be uncapsulated. 
However, genes homologous to those identified in EPEC for the group 4 capsule are 
present in different Shigella strains.  
Our hypothesis is that S. sonnei produces a group 4 capsule and that this capsule is 
still present in the galU mutant. The major aims of the present PhD project were the 
verification of the presence of a group 4 capsule in Shigella sonnei (first year activities 
were dedicated to this aim), the G4C biochemical characterization and the assessment 
of its distribution in other Shigella serotypes (second year activities), the G4C functional 
characterization (third year activities).  
 
Verification of the presence of a group 4 capsule in Shigella sonnei (First year) 
In order to verify that the surface staining of WT S. sonnei with the sera raised against 
Ss ∆galU GMMA was related to the presence of antibodies to the OAg, we absorbed the 
sera with a WT LPS extract before the surface staining, to remove OAg-specific 
antibodies. This pre-absorption abolished the antiserum binding to the surface of WT 
bacteria, while the binding remained unchanged using a mutated LPS (without OAg). 
These results indicated that antibodies directed to an OAg-containing material were 
present in the sera raised against Ss ∆galU GMMA. With the aim of demonstrating that 
not only GMMA, but also the parent Ss ∆galU strain was able to induce on OAg-
dependent response, mice were immunized with whole inactivated bacteria of Ss ∆galU. 
Immune responses equivalent to the responses to the immunization with GMMA were 
obtained, confirming the expression of an OAg-containing material by the Ss ∆galU 
strain. By characterizing the Ss ∆galU lipopolysaccharide with a monovalent antiserum 
specific for the Ss OAg, we demonstrated that a low mobility material could be extracted 
and visualized in western blot analysis. Moreover, the OAg-specific antiserum reacted 
with the surface of Ss ∆galU bacteria. Collectively, these results confirmed that, unlike in 
S. flexneri, the galU mutation in S. sonnei does not result in a complete OAg knock out 
strain. In fact, Ss ∆galU possesses immunogenic OAg material, likely not linked to the 
lipid A-core region of LPS, and this material is incorporated into or attached to GMMA 
when they are released from the bacterial surface. This is in agreement with our 
hypothesis that S. sonnei possesses an OAg capsule. 
 
Biochemical characterization of the S. sonnei group 4 capsule and G4C 
distribution within the genus (Second year) 
The group 4 capsule gene cluster was originally described in pathogenic E. coli (EPEC) 
and was reported to encode for proteins that constitute a polysaccharide secretion and 
assembly system. S. sonnei 53G possesses an intact group 4 capsule gene cluster 
(ymcDCBA, yccZ, etp (yccY), etk (yccC)) with high homology to the cluster found in 
EPEC. In order to test if this operon is also involved in capsule formation in Shigella, we 
inactivated the whole operon in our S. sonnei WT, producing the Ss ∆cps mutant. If the 
gene cluster is essential for G4C synthesis, we expected that Ss ∆cps produces OAg as 
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LPS side chain but not as capsular polysaccharide. Exopolysaccharides (EPS, 
containing LPS and potential capsule) were purified from S. sonnei WT, Ss ∆galU, Ss 
∆cps, and an OAg-deficient strain, for biochemical analyses. EPS extracts were treated 
by mild acid hydrolysis to remove the lipid A moiety from the LPS and pure 
polysaccharide (PS) samples were analyzed by HPLC-SEC in order to evaluate their 
molecular weight distribution. We observed that Ss WT produced an EPS with three 
populations of higher, medium and lower molecular weight. Interestingly, the HMW 
polysaccharide was present in the Ss ∆galU extract while it was absent in the 
polysaccharide sample purified from the S. sonnei G4C operon knock out. This suggests 
that the HMW population is the group 4 capsule polysaccharide. In order to confirm this 
hypothesis, further sugar composition analyses were performed: WT and ∆galU 
exopolysaccharide extracts were fractionated by HPLC-SEC and eluted samples were 
collected to isolate the different populations. The spectra of the HMW fraction analyzed 
by 1H-NMR displayed the typical signals belonging to the 2-Acetamido-2-deoxy-L-fucose 
(FucNAc4N) and the 2-Acetamido-2-deoxy-L-altruronic acid (L-AltNAcA) residues of the 
Shigella sonnei OAg. We then evaluated the presence of LPS core sugars in the PS 
populations purified from the WT strain, having in mind that the capsule should not be 
linked to the bacterial surface through the LPS assembly system. 3-deoxy-D-manno-
octulosonic acid (Kdo) is one of the sugar residues in the inner core region of the LPS of 
Shigella and represents the reducing end of the LPS polysaccharide side chain upon 
lipid A removal by acid hydrolysis. We demonstrated that the HMW-PS did not comprise 
Kdo residues. Subsequently, the surface of the different S. sonnei LPS and capsule 
mutant strains was analyzed by transmission electron microscopy (TEM). A dark and 
compact layer of electron-dense material was observed at the surface of wild type S. 
sonnei bacteria. This layer likely corresponded to extracellular polysaccharides (LPS O 
side chain and OAg capsule) as it was completely absent in the OAg-deficient strain Ss 
∆wbg. S. sonnei ∆cps mutant possessed just a narrow dark layer, probably 
corresponding to the LPS O side chain. On the contrary, Ss ∆galU had a very thick layer 
of capsular material. This material protruded from the outer membrane in a loose 
structure that suggests that the EPS in Ss ∆galU is not tightly attached to the bacterial 
surface. Together these results showed that the group 4 capsule operon is functional in 
Shigella sonnei and is responsible for the formation of a HMW capsule polysaccharide 
comprising the same sugars as the LPS O side chain. The G4C is not linked to the 
bacterial membrane through the lipid A-core region of the LPS since the Ss ∆galU LPS 
deep rough mutant still possesses it. 
With the aim to assess how widespread the group 4 capsule formation might be among 
different Shigella species, we studied the conservation of the group 4 capsule operon in 
different Shigella backgrounds. Genome analysis of several isolates of S. sonnei, S. 
flexneri, S. boydii and S. dysenteriae for the presence of a homologous operon showed 
that the G4C cluster was highly conserved in Shigella sonnei, S. boydii and S. 
dysenteriae but not in S. flexneri. The functionality of the gene cluster in the other 
serogroups still needs to be tested. However, we confirmed group 4 capsule production 
in a different isolate of S. sonnei, indicating that it is not a characteristic of a single strain 
but likely a common feature of most of the S. sonnei isolates. 
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Characterization of the biological function of the capsule in S. sonnei (Third year) 
Bacterial capsules are well established virulence factors, often acting by protecting the 
cell from opsonophagocytosis and complement-mediated killing. Moreover they can 
affect the function of other virulence factors through a shielding effect. We next asked if 
the G4C in S. sonnei had the ability to mask one of the most relevant virulence factors, 
the type III secretion system (T3SS). We examined the ability of an antibody directed to 
the tip of the T3SS to react with the surface of the different S. sonnei strains. We 
observed that the accessibility of the T3SS was enhanced in the Ss capsule negative 
strain, suggesting a possible role for the G4C in modulating the virulence of S. sonnei. 
Therefore, we investigated the impact of the capsule on S. sonnei invasive abilities in 
vitro. In an invasion assay using HeLa epithelial cells, the S. sonnei G4C mutant was 
significantly more invasive than the WT bacteria. Complementation of the Ss ∆cps 
mutant with a plasmid expressing the G4C operon restored the WT-like lower 
invasiveness or even reduced it. These results suggested that the presence of the 
capsule polysaccharide accounts for the changes in cell invasion. The increased ability 
of Ss ∆cps to invade epithelial cells likely results from the fact that in the absence of the 
capsule, virulence factors, as the T3SS, are rapidly available and exposed, thus 
triggering higher cell entry proficiency. On the other hand, Ss ∆cps complemented strain 
was less invasive than the WT strain. This effect is probably caused by ‘over-
complementation’ resulting from the fact that the plasmid used for complementation, and 
so the G4C gene cluster, is present in multiple copies even though a low copy number 
vector was used. Thus, the complemented mutant likely expresses a higher amount of 
capsule polysaccharide showing an attenuated phenotype. Subsequently, the rabbit 
ligated intestinal loop model of experimental shigellosis was used to investigate whether 
the G4 capsule contributes to the invasive abilities of S. sonnei in vivo and to the 
induction of inflammatory host response during the infection. WT S. sonnei infection 
resulted in histopathological changes of infected loops, including the shortening of villi, 
influx of inflammatory cells and lesions, similar to the previously reported phenotype of 
S. flexneri. Infection with the Ss ∆cps strain led to much more dramatic alterations of 
mucosal tissues with rupture and destruction of the intestinal epithelium and several 
regions of infiltration by inflammatory cells. In contrast, villi of loops infected by the Ss 
∆cps complemented strain displayed a decrease in the pattern of pathology. Expression 
analysis of proinflammatory cytokines relevant in the shigellosis model supported the 
observation that S. sonnei in the absence of the G4 capsule had increased 
pathogenicity in the gut and triggered higher intestinal inflammation. As discussed 
above, this likely results from the better exposure and accessibility of virulence factors 
and of the T3SS. In addition, the recognition of invasive bacteria by the innate immune 
system of the host could be enhanced in the absence of the capsule. In the same animal 
model, we studied the influence of the capsule on the ability of S. sonnei to translocate 
and disseminate to systemic sites. Different intestinal loops in the same animal were 
infected with the same number of bacteria of the different strains and after defined time 
points, mesenteric lymph nodes (MLN), liver, spleen and blood were collected and the 
present bacteria were differentiated based on strain-specific characteristics and 
enumerated. In each of the tested organs we predominantly found S. sonnei WT strain 
(approximately accounting for the 70 % of all recovered bacteria), whereas about 25 % 
of the bacteria were the Ss ∆cps strain. Interestingly, these data indicated that while in 
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the intestine the Ss ∆cps capsule mutant showed the most aggressive/invasive 
phenotype, it had impaired ability to disseminate compared to Ss WT. The reason could 
be that uncapsulated bacteria are more susceptible to the host immune responses since 
they lack the protective effect of the capsular polysaccharide. Thus, while the lack of the 
capsule could be beneficial in the early stages of the infection to very efficiently invade 
into the intestinal epithelium, in the later stages capsule-deficient bacteria have a 
disadvantage and succumb to the strong inflammatory response of the host.  
 
Conclusions 
OAg capsules are easily overlooked because serological and structural studies are 
generally interpreted with the expectation that all surface O antigen is LPS-linked. In this 
study we show that a S. sonnei ∆galU deep rough LPS mutant still possesses OAg on 
the surface, indicating a source of OAg linked to the outer membrane by a yet 
unidentified anchor, not the LPS. We demonstrated that S. sonnei forms an O antigen 
capsule whose assembly is dependent on the G4C operon, previously characterized in 
pathogenic E. coli. G4 capsule expression played a role in pathogenicity of S. sonnei 
both in vitro and in vivo. The uncapsulated mutant strain was more invasive and 
triggered stronger inflammation than the WT strain, but possessed impaired abilities to 
disseminate and establish systemic infection. We propose that the capsule may affect 
the virulence of S. sonnei by shielding other surface virulence factors and, at the same 
time, by protecting the bacteria from the innate immune response of the host. The G4C 
gene cluster is highly conserved among different Shigella species, suggesting that this 
could be a common virulence strategy in Shigella. This is a new and interesting finding 
in the Shigella field to achieve a better understanding of the pathogenic mechanism of 
Shigella and in addition of the function of extracellular polysaccharides as virulence 
factors. Finally, the identification of a capsule in Shigella could have implications on the 
design of a vaccine against this enteric disease. 
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 RIASSUNTO 2.
Introduzione 
I batteri Gram-negativi del genere Shigella rappresentano l’agente eziologico della 
dissenteria bacillare umana, la shigellosi. Il genere è suddiviso in quattro sierogruppi, 
storicamente trattati come specie: S. dysenteriae (sierogruppo A), S. flexneri 
(sierogruppo B), S. boydii (sierogruppo C) e S. sonnei (sierogruppo D). Tali specie sono 
ulteriormente suddivise in sierotipi, definiti dalle differenze biochimiche e strutturali 
nell’unità oligosaccaridica ripetitiva che forma l’antigene O (OAg) del lipopolisaccaride 
(LPS). Attualmente, S. flexneri comprende 14 sierotipi and sottoclassi, S. dysenteriae 15 
sierotipi, S. boydii 20 sierotipi e S. sonnei un singolo sierotipo. Shigella rappresenta una 
delle principali cause di diarrea al mondo. Uno studio del WHO del 1999 ha stimato 
164.7 milioni di casi di shigellosi all’anno, di cui 1.1 milioni di casi risultano nel decesso 
degli individui infetti. Stime più recenti hanno riportato un’incidenza di 90 milioni di 
episodi di shigellosi e 122000 decessi all’anno. Approssimativamente, il 99 % dei casi è 
rilevato in paesi in via di sviluppo ed il 69 % di individui infetti è costituito da bambini al 
di sotto dei cinque anni di età. Tra le diverse specie, quelle rilevate più frequentemente 
sono la S. flexneri e la S. sonnei. La Shigella è trasmessa attraverso la via oro-fecale e, 
una volta oltrepassato lo stomaco e l’intestino tenue, raggiunge l’intestino crasso 
invadendo l’epitelio del colon e del retto e causando severe affezioni tissutali, ascessi, 
ulcerazioni e un’acuta infiammazione mucosale caratteristica della shigellosi. I sintomi 
clinici variano da una semplice diarrea liquida ad una più severa dissenteria bacillare 
infiammatoria caratterizzata da forti crampi addominali, febbre, nausea, anoressia, 
disidratazione e feci contenenti sangue e muco. Normalmente la patologia è auto-
limitata ma può diventare mortale, in particolare in soggetti immunocompromessi e 
bambini malnutriti. Ceppi multi-resistenti agli antibiotici vengono isolati sempre più 
frequentemente e ciò limita la possibilità di trattamento. Attualmente, non esiste un 
vaccino efficace contro la Shigella. L’infezione da Shigella porta naturalmente ad una 
immunità protettiva e sierotipo-specifica. Il lipopolisaccaride ed, in particolare, il dominio 
più esterno dell’LPS, l’antigene O, è generalmente riconosciuto come antigene 
protettivo, dato che pazienti infetti sono protetti da un’ulteriore infezione da parte del 
ceppo omologo. Pertanto, i tentativi volti allo sviluppo di un vaccino contro la Shigella si 
sono concentrati su prototipi contenenti l’antigene O, sia formulato in vaccini costituiti da 
ceppi attenuati o come vaccini coniugati. Effettivamente, studi clinici di un vaccino 
coniugato dell’antigene O di S. sonnei hanno dimostrato un’efficacia del 70 %, se 
somministrato ad adulti e bambini al di sopra dei tre anni di età. Sfortunatamente, il 
candidato vaccino non è risultato efficace in neonati e bambini più giovani. Strategie 
alternative prevedono l’utilizzo di ceppi vivi attenuati. In ogni caso, i candidati vaccini più 
recenti non hanno ancora raggiungo la fase di sviluppo clinico volta a valutarne 
l’efficacia. La maggior parte dei vaccini in sviluppo è sierotipo-specifica. Globalmente, si 
crede che un futuro vaccino contro la Shigella debba proteggere da un ampio spettro di 
sierotipi: in particolare, 16 sierotipi sono considerati di importanza globale quali la S. 
dysenteriae tipo 1, tutti i 14 tipi della S. flexneri, and l’unico tipo della S. sonnei. 
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Il progetto Shigella dell’NVGH 
Il principale obiettivo del progetto Shigella del Novartis Vaccines Institute for Global 
Health (NVGH) è quello di sviluppare un vaccino ampiamente protettivo contro la 
Shigella. Il nostro approccio si basa sull’utilizzo di Moduli Generalizzati per Antigeni di 
Membrana, GMMA (Generalized Modules for Membrane Antigens), anche conosciuti in 
letteratura come Vescicole di Membrana Esterna, OMV (Outer Membrane Vesicles). Le 
GMMA sono proteo-liposomi naturalmente rilasciati dalla membrana esterna dei batteri 
Gram-negativi. Le GMMA riflettono la composizione di membrana esterna e contengono 
infatti LPS, fosfolipidi, proteine di membrana esterna e lipoproteine e inoltre includono al 
loro interno alcune componenti periplasmatiche. Attraverso modificazioni genetiche dei 
batteri produttori è possibile facilitare il rilascio delle GMMA, senza però modificarne la 
somiglianza con le vescicole naturalmente rilasciate dai batteri. Le GMMA differiscono 
dalle vescicole estratte tramite trattamento con detergenti. Quest’ultime infatti sono 
prodotte da preparazioni batteriche omogeneizzate e possiedono una composizione 
proteica differente, caratterizzata da un arricchimento in proteine citoplasmatiche e di 
membrana interna. Il gruppo di lavoro sul progetto Shigella ha generato ceppi di Shigella 
(in particolare la S. sonnei 53G) che producono un’aumentata quantità di GMMA, 
attraverso le delezione del gene tolR. Il gene tolR codifica per una proteina del sistema 
Tol-Pal, un complesso proteico volto al mantenimento del legame tra membrana interna 
e membrana esterna. Questa mutazione era già stata caratterizzata in precedenza: il 
risultato è una over-produzione di vescicole che non comporta la perdita dell’integrità di 
membrana. Inoltre, al fine di evitare una potenziale risposta immunitaria di tipo sierotipo-
specifica, i geni responsabili per la sintesi e per la formazione dell’LPS sono stati 
anch’essi mutati per ottenere GMMA che non possiedono l’antigene O sulla propria 
superficie. Il primo approccio è stato quello di creare un mutante di delezione nel gene 
galU ottenendo il ceppo Ss ∆galU: tale mutante non possiede la capacità di legare le 
unità ripetitive dell’OAg alla regione del core dell’LPS, ma possiede quindi un LPS 
troncato e composto solo dal lipide A e dalla regione del core interno. Il secondo 
approccio è stato quello di generare ceppi mutanti incapaci di sintetizzare le unità 
ripetitive dell’OAg. Nella S. sonnei il cluster biosintetico dell’OAg risiede sul plasmide di 
virulenza (pSS). Pertanto abbiamo isolato quelle colonie di S. sonnei che avevano perso 
il pSS (Ss -pSS, phase II) o, alternativamente, abbiamo deleto il cluster per la sintesi 
dell’OAg dal plasmide di virulenza (Ss ∆wbg). Le GMMA rilasciate da tali mutanti sono 
state purificate dal supernatante delle colture batteriche, sono state caratterizzate 
tramite approccio proteomico e sono state utilizzare come antigeni in studi di 
immunogenicità nel topo. Questi studi hanno dimostrato l’alto potere immunogenico 
delle GMMA, dato che i sieri immuni contenevano alti livelli di IgG specifici per gli 
antigeni delle GMMA. 
 
Risultati preliminari, ipotesi del progetto di dottorato e principali obiettivi 
I sieri immuni da immunizzazione con GMMA prodotte da ceppi con un LPS wild type 
(WT) o mutato sono stati testati al fine di stabilire la loro capacità di riconoscere epitopi 
di superficie di batteri vivi o di cross-reagire con diversi sierotipi di Shigella. E’ stato 
osservato che la marcatura di superficie di Ss WT in vitro era possibile solo per mezzo 
di anticorpi contro l’OAg. Anche se ulteriori esperimenti avevano mostrato che le GMMA 
di S. sonnei contenevano proteine altamente immunogeniche, i rispettivi epitopi di 
membrana esterna venivano mascherati dalla presenza dei polisaccaridi di superficie e 
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quindi non risultavano accessibili negli esperimenti di marcatura superficiale di batteri 
vivi. Simili risultati sono stati riportati in letteratura per altri batteri Gram-negativi. 
Inaspettatamente, sieri immuni da immunizzazione con GMMA prodotte dal mutante Ss 
∆galU, i quali venivano considerati privi di anticorpi diretti contro l’OAg, si sono 
dimostrati capaci di reagire con la superficie della Shigella wild type dello stesso 
sierotipo. Abbiamo ipotizzato che la delezione del gene galU nel sierotipo sonnei 
potesse non risultare nella completa scomparsa dell’OAg dal ceppo produttore e di 
conseguenza dalle GMMA derivate. Al contrario di quanto accade nei mutanti per i geni 
coinvolti nella sintesi delle unità ripetitive dell’OAg, il mutante nel gene galU può ancora 
sintetizzare gli zuccheri che compongono l’antigene O. Questi possono essere 
assemblati sulla superficie dei batteri attraverso un processo che non coinvolge il 
legame all’LPS. Di recente, in diversi batteri Gram-negativi quali E. coli enteropatogeno 
(EPEC), Salmonella enterica sierotipo Enteriditis e Francisella tularensis,  è stata 
riscontrata la presenza di una capsula, la quale, secondo il particolare meccanismo di 
sintesi e formazione, è stata classificata nella quarta classe. Una capsula di gruppo 4 
(G4C) è un polisaccaride ad alto peso molecolare composto dalle stesse unità ripetitive 
dell’OAg dell’LPS, e pertanto viene anche definita ‘capsula di OAg’. Una G4C è 
costituita da una quantità maggiore di unità ripetitive rispetto all’LPS, e queste unità 
sono legate alla membrana esterna dei batteri attraverso un meccanismo ancora 
sconosciuto. Al momento, la Shigella è descritta in letteratura come batterio non 
capsulato, d'altronde è stato visto che i geni del cluster responsabile per la formazione 
della capsula di tipo 4 in EPEC sono presenti anche nel genoma di Shigella. 
 La nostra ipotesi sostiene che la S. sonnei produce una capsula di gruppo 4 e che 
questa capsula è presente anche nel mutante di delezione per il gene galU. I principali 
obiettivi del presente progetto di dottorato sono stati volti innanzitutto alla dimostrazione 
del fatto che la S. sonnei possiede una capsula di gruppo 4  (attività del primo anno di 
dottorato), successivamente alla caratterizzazione biochimica del polisaccaride 
capsulare e alla studio di distribuzione di questa caratteristica in altri sierogruppi (attività 
del secondo anno di dottorato), ed infine alla caratterizzazione funzionale di tale capsula 
(attività del terzo anno di dottorato). 
 
Verifica della presenza di una capsula di gruppo 4 in Shigella sonnei 
Abbiamo innanzitutto verificato che la marcatura di superficie dei batteri wild type per 
mezzo dei sieri da immunizzazione con GMMA prodotte da Ss ∆galU fosse dovuta alla 
presenza di anticorpi specifici per l’OAg. Pertanto, abbiamo assorbito tali sieri con un 
estratto di LPS WT prima dell’esperimento di marcatura, al fine di rimuovere eventuali 
anticorpi contro l’OAg. In tal modo la capacità dei sieri di legare la superficie dei batteri 
WT è stata completamente abolita, mentre utilizzando per l’assorbimento un LPS 
mutato (privo di OAg) la marcatura rimaneva invariata. Da questi risultati abbiamo 
dedotto la presenza di anticorpi specifici per l’antigene O nei sieri da immunizzazione 
con GMMA prodotte da Ss ∆galU. Successivamente, per dimostrare che questi 
particolari risultati immunologici non fossero un artefatto derivante dall’immunizzazione 
dei topi con le GMMA, abbiamo ripetuto l’esperimento analizzando i sieri derivati 
dall’immunizzazione con batteri interi inattivati. Anche in questo caso, anticorpi diretti 
verso l’OAg sono stati rilevati nei sieri derivati da immunizzazione con la S. sonnei 
∆galU. Il lipopolisaccaride di Ss ∆galU è stato analizzato in saggi immunologici 
utilizzando un antisiero monovalente specifico per l’antigene O di S. sonnei. Tali saggi 
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hanno dimostrato la presenza di materiale a ridotta mobilità in corsa elettroforetica 
monodimensionale che reagiva con l’antisiero monovalente. Non solo l’estratto 
lipopolisaccharidico, ma anche la superficie dei batteri di Ss ∆galU ha reagito con il 
siero specifico per l’OAg. In definitiva, questi risultati hanno mostrato che, nonostante il 
fatto che in letteratura fosse riportato che la Shigella flexneri deleta del gene galU fosse 
priva di OAg, un materiale simile all’OAg, ma non legato al core dell’LPS, poteva essere 
estratto da Ss ∆galU. Inoltre tale materiale era esposto sulla superficie e incorporato 
nelle GMMA. Queste osservazioni erano in linea con la nostra ipotesi di una capsula di 
OAg in S. sonnei. 
 
Caratterizzazione biochimica della capsula e distribuzione del cluster genico nel 
genere Shigella 
Il cluster genico responsabile per la formazione della capsula di tipo 4 era stato 
precedentemente caratterizzato in un isolato di EPEC ed era stato annotato come 
codificante per un complesso proteico per la secrezione e la costituzione di polisaccaridi 
superficiali. Nel genoma del nostro isolato, S. sonnei 53G, è presente un cluster genico 
per la G4C altamente omolgo a quello identificato in EPEC. Al fine di valutare se il 
cluster per la G4C fosse responsabile della formazione della capsula in S. sonnei, 
abbiamo prodotto un mutante di delezione per tale operone, ottenendo il ceppo Ss 
∆cps. Ci aspettavamo che tale mutante possedesse OAg come catena laterale dell’LPS 
ma non come capsula, nel caso in cui il cluster si fosse dimostrato funzionale nel nostro 
isolato. I polisaccaridi superficiali (EPS) (contenenti sia L’OAg dell’LPS che l’OAg 
capsulare) sono stati purificati da S. sonnei WT, Ss ∆galU, Ss ∆cps, e dal mutante nel 
cluster biosintetico per l’OAg, per poter effettuare saggi biochimici. I vari estratti sono 
stati trattati con idrolisi acida blanda per rimuovere la porzione lipidica dell’LPS ed i 
polisaccaridi purificati sono stati analizzati in cromatografia ad esclusione molecolare 
(HPLC-SEC) per valutare la distribuzione dei pesi molecolari delle specie 
polisaccaridiche. Abbiamo osservato tre popolazioni ad alto, medio e basso peso 
molecolare nell’estratto da batteri WT. Una popolazione ad alto peso molecolare, simile 
a quella identificata nel WT, era presente nel polisaccaride da batteri ∆galU mentre 
nessuna popolazione a tale peso molecolare era presente nel polisaccaride da batteri 
∆cps. Questo ci suggeriva che la popolazione ad alto peso molecolare fosse il 
polisaccaride capsulare. Abbiamo quindi effettuato studi di composizione zuccherina e 
da analisi di NMR monodimensionale abbiamo identificato i picchi caratteristici 
corrispondenti ai due residui costituenti l’OAg di S. sonnei (2-Acetamido-2-deossi-L-
fucosio (FucNAc4N), acido 2-Acetamido-2-deossi-L-ialuronico (L-AltNAcA)) nella 
popolazione ad alto peso molecolare che era stata precedentemente isolata. Inoltre, 
abbiamo valutato la presenza di residui appartenenti al core dell’LPS, come ad esempio 
l’ acido 2-Cheto-3-deossi-D-manno-ottulosonico (Kdo), nelle varie popolazioni 
polisaccaridiche. Da questa analisi, il polisaccaride ad alto peso molecolare è risultato 
privo di Kdo. La superficie dei diversi ceppi mutanti è stata poi caratterizzata tramite 
analisi di microscopia elettronica a trasmissione (TEM). Uno strato elettrondenso 
compatto è stato evidenziato sulla superficie della Shigella sonnei WT, corrispondente 
all’LPS e alla capsula. Questo strato superficiale era assente nel mutante per i geni di 
sintesi dell’OAg, mentre solo uno strato sottile corrispondente all’LPS è stato 
evidenziato sulla superficie dei batteri ∆cps. E’ stato interessante scoprire che il mutante 
galU possedeva uno strato spesso e non molto compatto, probabilmente legato in 
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maniera blanda alla membrana esterna. Considerando nel complesso questi risultati, 
possiamo affermare di aver dimostrato che il cluster codificante per la capsula di gruppo 
4 è funzionale in Shigella sonnei ed è responsabile della formazione di un polisaccaride 
ad alto peso molecolare composto dagli stessi residui zuccherini della catena laterale 
dell’LPS ma non legato alla membrana batterica tramite il core dell’LPS. Si tratta quindi 
di una capsula di OAg. 
Abbiamo poi analizzato i genomi di diversi isolati di Shigella alla ricerca di cluster genici 
omologhi a quello della S. sonnei 53G. Abbiamo potuto constatare che il cluster genico 
per la capsula di gruppo 4 è presente in un alto numero di isolati di Shigella sonnei, S. 
boydii e S. dysenteriae ma non in S. flexneri. In ogni caso, rimane da confermare la 
funzionalità di tali clusters in isolati di altri sierogruppi. 
 
Caratterizzazione funzionale della capsula in Shigella sonnei 
Le capsule batteriche sono considerate importanti fattori di virulenza dal momento che 
proteggono i batteri da meccanismi di opsonofagocitosi e eliminazione mediata dal 
complemento. Inoltre le capsule possono modulare l’attività di altri fattori di virulenza 
attraverso meccanismi di mascheramento. Ci siamo chiesti se la capsula di S. sonnei 
avesse l’abilità di mascherare uno dei fattori di virulenza più importanti di Shigella, il 
sistema di secrezione di tipo terzo (T3SS). Abbiamo testato un anticorpo contro la 
proteina IpaB, all’apice del T3SS, per la sua abilità nel reagire con la superficie dei 
diversi mutanti di S. sonnei e abbiamo notato che l’accessibilità di IpaB era maggiore nel 
mutante non capsulato. Questo ci ha suggerito un ruolo della G4C nel regolare la 
virulenza di Shigella sonnei. Pertanto abbiamo dapprima saggiato la patogenicità dei 
diversi mutanti in un esperimento di invasione in vitro in cellule epiteliali umane (HeLa). 
In questo saggio il ceppo non capsulato si è dimostrato altamente invasivo se 
paragonato al WT. Quando la delezione è stata complementata in trans attraverso il 
clonaggio del cluster per la G4C in un vettore di espressione, il mutante risultante ha 
mostrato livelli di invasività pari, se non minori, al ceppo WT. Tali risultati indicano che la 
presenza della capsula è responsabile della modulazione della virulenza in vitro, 
probabilmente perché nel mutante non capsulato i fattori di virulenza sono più 
facilmente esposti rendendo il ceppo maggiormente virulento nell’invadere le cellule 
ospite. D’altra parte il fenotipo attenuato del mutante in cui la delezione del cluster per la 
G4C è complementata in trans può derivare dal fatto che questo ceppo possiede una 
quantità maggiore di capsula, dal momento che il cluster è presente in più copie rispetto 
al WT. Successivamente, abbiamo valutato la patogenicità dei diversi mutanti in vivo in 
un modello di infezione di anse intestinali nel coniglio. In questo modello è possibile 
studiare le abilità invasive dei ceppi testati e la loro capacità di indurre una risposta 
infiammatoria nell’ospite, tipica dell’infezione da Shigella. Mentre le convenzionali lesioni 
intestinali ed un alto livello di infiammazione intestinale sono stati rilevati dopo infezione 
con il ceppo WT, una drammatica alterazione della mucosa intestinale e livelli di 
infiammazione molto elevati sono risultati dall’infezione con il ceppo non capsulato. Al 
contrario, il mutante in cui la delezione del cluster per la G4C è complementata in trans 
ha portato ad una patologia più lieve. Di nuovo, questo può essere il risultato del fatto 
che in assenza della capsula i fattori di virulenza di superficie sono maggiormente 
esposti tanto da portare ad una maggiore invasività e allo stesso tempo è possibile che 
il sistema immunitario possa riconoscere più facilmente i ceppi non capsulati così da 
indurre una maggiore risposta infiammatoria. In fine, abbiamo studiato in vivo la 


capacità dei diversi mutanti di disseminare a livello sistemico e raggiungere organi 
periferici. A tal proposito, abbiamo raccolto fegato, milza, linfonodi mesenterici e sangue 
da animali infettati a livello intestinale contemporaneamente da ceppi capsulati e non 
capsulati. In ogni organo in esame, abbiamo rilevato prevalentemente la presenza di 
batteri WT capsulati (circa il 70 % del totale dei batteri trovati). Questi risultati mostrano 
che i ceppi non capsulati sono più virulenti in una prima fase dell’infezione a livello 
intestinale, mentre presentano un’incapacità nell’instaurare infezioni a livello sistemico, 
probabilmente perché in assenza del fattore protettivo conferito dalla presenza della 
capsula, soccombono alla forte risposta immunitaria innata dell’ospite.   
 
Conclusioni 
Le capsule di OAg non sono facilmente identificabili in quanto i dati sierologici e 
strutturali sono spesso interpretati nell’ottica che l’antigene O di superfice sia 
completamente legato all’LPS. Nel presente progetto di ricerca abbiamo dimostrato che 
un mutante incapace di legare l’OAg alla regione del core dell’LPS (Ss ∆galU) possiede 
ancora OAg sulla sua superficie, non legato all’LPS. Abbiamo dimostrato che S. sonnei 
produce una capsula di OAg la cui formazione è dipendente dalla presenza di un cluster 
genico, precedentemente caratterizzato per la sua funzione di codificare per un 
complesso proteico volto alla produzione di una capsula di gruppo 4 in EPEC. La 
capsula modula la virulenza di Shigella sonnei sia in vitro che in vivo. Ceppi non 
capsulati sono risultati più virulenti e hanno scatenato una maggiore risposta 
infiammatoria nell’ospite, ma sono risultati incapaci di instaurare infezioni sistemiche. 
L’operone codificante per la G4C è altamente conservato in diversi sierogruppi di 
Shigella, pertanto l’espressione di una capsula potrebbe rappresentare una comune 
strategia di virulenza di tali patogeni umani. In questo lavoro per la prima volta abbiamo 
identificato e caratterizzato una G4C in Shigella sonnei. Questa nuova scoperta ci 
permette di ottenere una migliore comprensione dei meccanismi di patogenesi della 
Shigella e del ruolo dei polisaccaridi di superficie come fattori di virulenza. Inoltre, 
l’identificazione di una capsula in Shigella potrebbe avere implicazioni significative per lo 
sviluppo di un vaccino protettivo. 
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 INTRODUCTION 3.
3.1 Infectious Diseases and Global Health 
Infection diseases are a major burden of disease and the second most common cause 
of death worldwide. World Health Organization (WHO) data reported that in 2008 1 
billion people worldwide were directly affected by one or more infectious diseases [1]. 
Moreover, according to the latest published data in 2012, infectious (including parasitic) 
diseases were responsible for the death of more than 8.7 million people worldwide in 
2008 [2]. Infectious diseases do not respect the socioeconomic status as their 
contribution to the global disease burden has the potential to affect the entire world’s 
population, but the risk is not evenly distributed [3]. People already living in social and 
economic deprivation have a greater exposure to the risk factors for disease and the 
impact of diseases is felt not only in the massive loss of life but also in a high-levels of 
morbidity and the accompanying impact on families, communities and the weak and 
under-resourced health systems in low and middle-income countries [4]. As a matter of 
fact, 98.9 % of Disability-Adjusted Life Years (DALYs) and 96.9 % of deaths due to 
infectious diseases occur in middle and low income countries [5]. Importantly, infectious 
diseases disproportionately affect the youngest populations. 54 % of DALYs and 43 % 
of deaths from infectious diseases occur in children less than 5 years of age [5]. 
According to 2010 estimates by WHO, approximately 7.6 million children die each year 
before reaching the age of five [6]. As shown in Figure 1, the greatest burden is caused 
by respiratory diseases, such as pneumonia, diarrheal diseases and malaria [6]. 
Malnutrition is a contributing factor in more than one third of all child deaths and the links 
between lack of nutrition and infectious diseases are already well established. 
Interestingly, this excess of morbidity and mortality in poor and young populations is not 
seen with non-infectious diseases [5]. Research has played a huge role in efforts to 
understand, control and prevent the spread of infectious diseases. For some diseases, 
such as smallpox, vaccination campaigns have led to eradication [7]. However, for many 
infectious diseases of poverty no effective and affordable treatments exist or existing 
interventions are not readily available or accessible in communities where the need is 
greatest [3]. Investment in controlling the spread of infectious and parasitic diseases will 
have a powerful impact on global human, social and economic development.  
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Figure 1 
 
Figure 1: Infectious diseases causing the greatest burden in < 5 year old children. Global DALYs 
(Reproduced from [8]). 
3.1.1 Diarrheal diseases 
With the exception if perinatal conditions (e.g. prematurity and low birth weight), diarrhea 
remains the second leading cause of death among children under 5 years of age [9]. In 
some settings in developing countries, the average morbidity attack rate can increase 
from 3.2, estimated globally, to 12 episodes of diarrhea per child per year. Importantly, 
over the past two decades, treatment and prevention measures including fluid 
replacement, zinc treatment or promotion of hand washing have been responsible for 
the decline of mortality from diarrhea from an estimated 5 million deaths among young 
children to about 1.5 million deaths in 2004 [10]. However, although the number of 
deaths is decreasing, the high incidence is still a major issue. A contributing factor is that 
long-term consequences on physical and mental development of children have been 
reported, as a result of childhood diarrhea [11–13]. Among the principal bacterial agents 
of diarrheal diseases are Vibrio cholerae (cholera), multiple serovars of Salmonella 
enterica, including S. Typhi (typhoid fever), and a variety of serotypes of Shigella spp., 
the agents of shigellosis (bacterial dysentery), Campylobacter spp. (especially C. jejuni) 
and enteropathogenic Escherichia coli strains, including the enterotoxigenic Escherichia 
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coli (ETEC) strains [14]. Among the enteric viruses, rotaviruses remain the leading 
cause of diarrheal disease in young children in the world [15]. 
Diarrheal diseases not only represent a major health problem in developing countries 
but also a high risk to travellers who visit these countries, especially in the tropics [16]. 
Up to 80 % of diarrheal episodes in travellers are bacterial in nature, caused principally 
by ETEC strains, followed by Shigella, Campylobacter and Salmonella spp. [14]. The 
increased frequency of antibacterial drug-resistance among these pathogens is a source 
of major concern [17,18]. While in the long term access to clean water, better hygiene, 
adequate nutrition, and improvement of sanitary measures would have the greatest 
impact on diarrheal diseases, immunization against specific diseases is the best 
strategy for the short- and mid-term [19]. The development of vaccines against enteric 
diseases, however, has been a serious challenge because of the large number of 
pathogens and serotypes, and the requirement to induce mucosal immunity in the gut 
[20,21].  
3.2 Shigella 
Members of the genus Shigella are Gram-negative, non-sporulating, rod-shaped, 
facultative anaerobe bacteria that belong to the family Enterobacteriaceae. The genus is 
divided into four serogroups, historically treated as species [22]: 
- S. dysenteriae (serogroup A);  
- S. flexneri (serogroup B); 
- S. boydii (serogroup C); 
- S. sonnei (serogroup D). 
These species are further divided into serotypes, on the basis of the antigen specificity, 
the structure and the biochemical differences of the oligosaccharide repeating unit (RU) 
that forms the O antigen (OAg), the polysaccharide portion of their lipopolysaccharide 
(LPS) [23]. At present, the species S. flexneri is known to comprise 14 serotypes and 
subserotypes, S. dysenteriae 15 serotypes, S. boydii 20 serotypes and S. sonnei a 
single serotype. Shigella spp. are facultative intracellular pathogens that show a high 
specificity for the human host in which they cause bacterial dysentery, shigellosis. The 
first report on the isolation and characterization of bacteria causing bacillary dysentery, 
later named Shigella, was published by Kiyoshi Shiga at the end of the 19th century [24]. 
Shigella spp. share common characteristics with members of the genus Escherichia. In 
addition, the genetic relatedness suggests that they are a subtype of E. coli [25,26]. The 
whole-genome sequencing of E. coli and all four Shigella species revealed that they 
share a common DNA backbone of approximately 3.9 Mb, interrupted by E. coli-specific 
and Shigella-specific sequences. The differentiation of Shigella and E. coli is 
complicated and the borders appear to be fluid with strains that share characteristics 
with either speciesm e.g. enteroinvasive E. coli (EIEC), sharing biochemical 
characteristics, essential virulence factors, and clinical symptoms with Shigella spp. 
Comparative genomics indicates that EIEC is genetically more related to Shigella than 
to non-invasive E. coli [27] and suggests that they evolved from multiple non-invasive E. 
coli strains by convergent evolution [27,28]. The most striking difference between the 
genomes of E. coli and Shigella is the presence of many IS-elements in Shigella which 
contributes to a very dynamic genome [26,29]. The easy acquisition and loss of genes 
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promote the success of Shigella as a pathogen, because fast genetic adaptation is 
needed to survive in different circumstances in the host [30,31]. 
3.2.1 Bacteriology, disease burden and global impact 
Estimates by the World Health Organization indicate that the world’s population suffered 
from 4.5 billion incidences of diarrhea causing 1.8 million deaths in the year 2002 [32]. 
Shigellosis is endemic throughout the world and Shigella species are among the most 
frequent causes of diarrhea. A study of the WHO in 1999 estimated that 164.7 million 
cases of shigellosis occur per year, of which 1.1 million cases result in death [33]. More 
recent estimates state a global Shigella disease burden at 90 million episodes and about 
108-122 thousand deaths per year [34,35]. Approximately 99 % of all cases occur in 
developing countries, where poor hygiene, limited access to clean water and 
malnutrition promote the spread and the high mortality rate of enteric diseases. 
Importantly, 69 % of all shigellosis episodes and 61 % of all deaths involve children 
under the age of five [33]. As mentioned before, Shigella spp. are also one of the 
primary causes of troops and traveler’s diarrhea, with about 500 000 cases of shigellosis 
reported each year among military personnel and travellers from industrialized countries 
[36]. Three major species are responsible for bacillary dysentery: S. flexneri (all 14 
serotypes are considered of global importance), S. sonnei, and S. dysenteriae type I 
[33]. The fourth species, S. boydii, is responsible for scattered disease foci [34]. 
Distribution of serotype differs between industrialized and developing countries and 
change over time [37]. S. flexneri is endemic in developing countries (60 %) and is the 
most frequently isolated species worldwide. The predominant serotypes are S. flexneri 
2a, followed by 1b, 3a, 4a and 6 [34]. Untypable Shigella isolates have also recently 
emerged as a significant cause of diarrhea [38]. S. sonnei is the causative agent of most 
of the shigellosis in industrialized countries where it accounts for 77 % of cases 
(compared to 15 % in developing countries in 2009) [34]. However, in recent years, it 
has also become predominant in Thailand and a shift in Shigella dominance from S. 
flexneri to S. sonnei in developing countries has been documented [34,39,40]. A 
possible explanation for this shift has been proposed to be related to the decreased 
prevalence of the environmental bacterial species Plesiomonas shigelloides. P. 
shigelloides shares the O antigen composition with Shigella sonnei. As natural immunity 
to Shigella is mainly targeted to the O antigen [41] (see following section about 
Polysaccharide conjugate vaccines), exposure to water contaminated with Plesiomonas 
shigelloides has the potential to cross-protect humans from S. sonnei infection [42]. As 
countries develop economically and water quality improves, humans are less likely to be 
exposed to P. shigelloides. Cross-protection by environmental immunization with P. 
shigelloides therefore declines, which might explain the increase in S. sonnei infections 
[43]. High-case fatality rates of shigellosis have been associated with S. dysenteriae 
type 1 (Sd1) infections that occur in epidemic disease outbreaks. Sd1 is of particular 
concern since it is the only Shigella type carrying a chromosomal gene encoding the 70-
KDa heterodimeric protein known as Shiga toxin [44]. Shiga toxin is cytotoxic for a 
variety of cell types and is responsible for the development of vascular lesions in the 
colon, the kidney, and the central nervous system [45]. This results in more severe 
disease manifestation than in shigellosis caused by other serotypes. A major obstacle to 
the control of Sd1 is its resistance to antimicrobial drugs [46]. However, recent 
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surveillance data from Bangladesh and India show that Sd1 has not been isolated from 
these regions in the last years [34]. 
3.2.2 Shigellosis: definition, transmission and pathogenesis  
Shigella spp. are the etiological agents of shigellosis. Shigellosis is an acute intestinal 
infection that is transmitted by persontoperson contact through the fecaloral route or 
indirectly through contaminated food or water. Transmission by house flies has also 
been documented [47]. Shigella is highly infectious, since as few as 10 to 100 
microorganisms may be sufficient to cause disease [48]. This low infective dose is in 
part attributed to bacterial ability to survive the acidity of the host’s stomach, through 
specific acid resistance systems [49]. In addition, Shigella can decrease the expression 
of antibacterial peptides that are constantly released from the mucosal surface of the 
intestinal tract [50]. After passage through the stomach and the small intestine, the 
bacteria reach the large intestine and invade the colonic and rectal epithelium causing 
the acute mucosal inflammation characteristic of shigellosis [51]. The infection is usually 
confined to the superficial layer of the colonic mucosa where severe tissue damage 
leads to abscesses and ulceration. Clinical symptoms range from mild watery diarrhea 
to severe inflammatory bacillary dysentery characterized by strong abdominal cramps, 
fever, nausea, anorexia, dehydration and stools containing blood and mucus. The 
disease is normally self-limiting. A combination of oral rehydration and antibiotics 
administration can reduce the period of bacterial excretion from the patient and leads to 
the rapid resolution of infection. However, shigellosis may become life-threatening, 
especially in immunocompromised patients, including neonates and children with 
underlying immune deficiencies (including HIV infections) or malnutrition, or if there is no 
adequate medical care. In these cases, patients may develop secondary complications 
and long term effects can occur, such as peritonitis, septicaemia, the severe Haemolytic 
Uremic Syndrome (HUS) with kidney failure, reactive arthritis, pneumonia [52]. 
The current model of Shigella pathogenesis is derived from studies of S. flexneri [53] 
(Figure 2). The infection is a multi-step process. When the bacteria reach the mucosa of 
the terminal ileum and colon, they are taken up by M cells which are specialized 
epithelial cells that sample the luminal content and deliver it to the underlying mucosal 
lymphoid tissue in a process called transcytosis. After passing the epithelium, the 
bacteria are phagocytosed by resident macrophages. However, Shigella evades 
phagosome-mediated killing and induces apoptotic death of the macrophages [54]. Free 
bacteria, released from dead macrophages, invade the epithelial cells from the 
basolateral side and spread laterally to adjacent cells. The bacteria multiply in the 
cytoplasm and eventually kill the host cell while moving towards adjacent epithelial cells 
by a process of polymerisation/depolymerisation of the actin tubules [55], and through 
the alteration of the tightjunction proteins composition [56]. Apoptosis of infected 
macrophages and epithelial cells invasion is accompanied by the release of many pro
inflammatory cytokines, as IL 1β, IL 18, and IL 8, inducing an acute and massive 
inflammatory response. How Shigella causes epithelial inflammation is still not fully 
understood. As Gram-negative bacterium, Shigella possesses two most studied 
pathogen-associated molecular patterns (PAMPs): the lipopolysaccharide (LPS) and the 
peptidoglycan (PGN). Their synthesis is controlled by chromosomal genes in all 
serogroups but in S. sonnei, in which the OAg gene cluster resides on the large 
virulence plasmid [57,58]. These molecules are located respectively on the bacterial 
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surface (LPS) and between the inner and outer membrane (PGN). Two major pathways 
have been shown to be involved in inflammation: sensing of the LPS by the cell-surface 
expressed receptors TLRs (Toll-like Receptors), and in particular, of the lipid A region of 
the LPS by TLR4 [59], and sensing of the PGN by the intracellular receptors Nod 
(Nucleotide oligomerization domain) [60]. IL 1β and IL 8 induce the recruitment of 
polymorphonuclear neutrophilic leukocytes (PMNs), that infiltrate the infected site and 
destabilize the intestinal epithelium [61,62]. The influx of PMN, at a first stage, 
compromises the integrity of epithelial barrier facilitating the invasion of further 
organisms from the colonic lumen. Ultimately, however, the PMNs phagocytose and kill 
Shigella contributing to the resolution of infection. This is aided by the generation of an 
effective antibacterial response which is likely supported by the released IL 18. IL 18 
activates natural killer (NK) cells and induces and promotes the production of IFNγ, 
responsible for the activation of macrophages, thus amplifying the innate immune 
response [63,64]. However, the role of IL 18 in shigellosis has not been yet confirmed. 
The alteration and destruction of tissues in the early stages of the infection causes an 
impaired adsorption of solutes, nutrients, and water, which is subsequently followed by 
watery diarrhea and presence of blood and mucus in stools. 
 
Figure 2 
 
Figure 2: Cellular pathogenesis of Shigella. S. flexneri passes the epithelial cells (EC) barrier by 
transcytosis through M cells and encounters resident macrophages. The bacteria evade degradation in 
macrophages by inducing an apoptosis-like cell death, which is accompanied by proinflammatory 
signaling. Free bacteria invade the EC from the basolateral side, move into the cytoplasm by vectorial 
actin polymerization, and spread to adjacent cells. Proinflammatory signaling by macrophages and EC 
further activates the innate immune response involving NK cells and attracts PMN. The influx of PMN 
disintegrates the EC lining, which initially exacerbates the infection and tissue destruction by facilitating 
the invasion of more bacteria. Ultimately, PMN phagocytose and kill Shigella, thus contributing to the 
resolution of the infection. (Figure and figure legend reproduced from [53]). 
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3.2.3 Shigella virulence factors 
Shigella are capable of colonizing the intestinal epithelium by exploiting epithelial cell 
functions and avoiding the host innate immune response. The ability of Shigella to 
invade epithelial cells and cause dysenteric disease is mainly related to the presence of 
high molecular weight and low copynumbers virulence plasmids, collectively termed 
invasion plasmids, pINV, with minor variations between serotypes [65]. These virulence 
plasmids are approximately 230 Kb large, are nonconjugative [66,67], and encode for 
the major virulence determinants [68], including invasins (invasive plasmid antigens, Ipa 
proteins), molecular chaperones, motility factors, regulators, and a specialized type III 
secretion system (T3SS) [69]. The virulence plasmid also encodes several 
autotransporters (Type V-secretion-system, T5SS), including SepA and VirG (also 
referred to with the synonym IcsA) [26]. The T3SS is composed of about 22 proteins 
(see Figure 3), including a needle-like protein oligomer (composed of MxiH) anchored in 
the membrane through a complex consisting of a series of protein rings connecting the 
inner and outer bacterial membranes. The tip of the needle is composed of an IpaB/IpaD 
complex [70]: in particular, IpaD represents the needle tip forming protein and IpaB 
together with IpaC, the translocation pore. IpaB and IpaC have been shown to have a 
strong affinity for the CD44 hyaluronic acid receptor [71], and to form pores in the 
basolateral membrane of epithelial cells, allowing the bacterium to penetrate into the 
cytoplasm of the cell [72]. The T3SS also allows for the injection of a set of molecules 
into the host cells. The functions of those molecules have been characterized to 
antagonize both innate and adaptative immune responses and of virulence factors, 
leading to bacterial invasion and its corollary, the inflammatory destruction of the 
epithelial lining [60,73]. Additional virulenceassociated genes are located in 
pathogenicity islands on the chromosome and contribute directly or indirectly to the 
pathogenic process [74]. Shigella, depending on serotype, also produce one or more 
toxins that contribute to virulence [75], including Shigella enterotoxin 1 (ShET-1), which 
is encoded by chromosomal gene set present in S. flexneri strains 2a [76], enterotoxin 2 
(ShET-2), the product of gene sen, which is carried by the virulence plasmid [77], and 
the Shiga toxin, which is encoded by the stx gene from a phage of S. dysenteriae [78]. 
The capacity of Shigella to carry out virulence functions and manipulate host cells is a 
counterbalance between the bacteria’s attack and the host response. The study of 
Shigella virulence modulation in vivo has focused on Shigella flexneri. The multi-steps 
infectious process (See previous paragraph) represents an array of successive 
environmental conditions to which the bacteria need to successfully adapt. The LPS is a 
major bacterial surface antigen in face of the adaptive immune response and a main 
target for the innate immunity. A potential role in pathogenesis, especially for its O side 
chain, has been proposed [70]. As demonstrated previously in the case of oxygen 
sensing and T3SS structure and function [79], a crosstalk exists between the activation 
of various environmental sensors and the T3SS, as well as LPS structural modifications 
[70,80,81]. The LPS molecules of S. flexneri 2a and 5a have O antigen polysaccharides 
with two modal chain length distributions: short (S) type chains (11–17 OAg repeating 
units (RUs)), and very long (VL) type chains (>90 OAg RUs) ([80]). It has been shown, 
for example, that the size distribution pattern of the O antigen changes in favor of longer 
chains when bacteria are grown at 30 °C, as compared to 37 °C [82]. In addition, OAg 
chains can mask VirG (IcsA) and interfere with its function in the actin-based motility 
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(ABM) [83]. These observations suggest that S. flexneri has evolved to synthesize LPS 
with the two OAg modal chain lengths, as S-type OAg chains allow VirG (IcsA) to 
function in ABM in the presence of VL-type OAg chains that confer resistance to serum 
[83]. Moreover, S. flexneri 5 M90T LPS glucosylation is reported to facilitate invasion of 
target cells by altering the conformation of LPS to optimize the exposure of TTSS 
needles while retaining resistance against host defenses [80]. Less is known about S. 
sonnei LPS: the typical O antigen ladder shows a predominant population with 20-25 
OAg RUs [84], but studies about the relationship of OAg length distribution and virulence 
are not documented. With regards of other common surface virulence factors, Shigella is 
characteristically devoid of flagellar expression [85]. Importantly, Shigella so far is 
reported to be uncapsulated. 
 
 
Figure 3 
 
Figure 3: S. flexneri PAMPs and T3SS. The T3SS consists of four main parts. The basal body spans the 
bacterial inner membrane (IM), the periplasm, and the outer membrane (OM). The hollow needle 
protrudes from the basal body to the bacterial surface. Contact with host cell membranes (HM) triggers 
the IpaD-guided membrane insertion of the IpaB-IpaC translocon at the needle tip. The T3SS is 
completed by the cytoplasmic ring, which is comprised of proteins that energize the transport process and 
mediate the recognition of substrates, chaperone release, and substrate unfolding. The LPS and the 
peptidoglycan (PGN) molecules are located respectively on the bacterial surface and between the inner 
and outer membrane with the LPS being a major bacterial surface antigen (Reproduced from [53]). 
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3.3 Current status of Shigella vaccine development 
The continuously high incidence rate imply that shigellosis is still an unsolved global 
health problem [86]. The ever increasing frequency of antimicrobial-resistant Shigella 
strains worldwide has become a major source of concern [46]. Conventionally, the 
fluoroquinolones, as Ciprofloxacin, have been the mainstay of the treatment for 
shigellosis and have been recommended as the drug of choice for all the patients, 
irrespective of their ages [87]. With the emergence of fluoroquinolone resistance among 
the Shigellae [88–93], the choice of the antibiotics had shifted to other alternatives, 
namely third generation cephalosporins, e.g. ceftriazone. Although not readily available 
as ceftriaxone has to be administered intraveneuosly, the recent reports of 
cephalosporin resistance [94–96] have now really limited the options for the therapy. In 
addition, the extended spectrum beta-lactamases (ESBLs) are on the rise both in terms 
of frequency of occurrence as well as the type of the class of the enzyme and have been 
noted in Shigella [97,98]. Considering the ability of these organisms to acquire 
resistance genes on mobile elements, as the ESBL genes are, and the continuous 
selective pressure which results from the high levels of the antibiotic consumption and 
the presence of the poor quality unlicensed antibacterial agents in some areas, the 
likelihood of the development of resistance is enhanced [99]. The emergence of drug 
resistance strains can become a serious threat to public health, as their spread among a 
population in which diarrheal diseases are one of the major causes of childhood 
morbidity and mortality [99]. Vaccination could offer an effective and sustainable 
preventive measure against this enteric illness. Currently, there is no Shigella vaccine 
available and the large number of relevant serotypes with O antigen diversity makes 
development of a vaccine challenging [75]. Several strategies have been developed or 
are under development and are being tested in different clinical phases [100]. Among 
the vaccine candidates, two different approaches have mainly focused on: attenuated 
strains of Shigella used as live oral vaccines and O polysaccharides of Shigella 
covalently linked to carrier proteins and used as parenteral conjugate vaccines [75]. 
Other strategies have also been evaluated.  
3.3.1 Live attenuated vaccines 
Live Shigella vaccine candidates are given by needle-free routes and are easier to 
manufacture than other potential vaccines. However there is only a small margin 
between excessive reactogenicity, especially in children, caused by insufficient 
attenuation, and poor immunogenicity, especially in developing countries, by over-
attenuation [101]. The S. flexneri 2a vaccine strain SC602 developed at the Institut 
Pasteur, for example, carries deletions in the virG (icsA) gene involved in cell-to-cell 
spreading, and in the iuc locus, which is involved in iron uptake. SC602 was tested in 
adult volunteers in the USA and in adults and children in Bangladesh in collaboration 
with the Walter Reed Army Research Institute (WRAIR) and the International Vaccine 
Institute (IVI). A remarkable efficacy against challenge was observed in USA volunteers, 
however, SC602 was safe only at very low doses [102]. In contrast, in adults and 
children in an endemic population (Bangladesh) even 100-fold higher doses did not 
induce adverse events but also did not induce any significant immune responses 
indicating intestinal barriers for live attenuated strains in endemic populations [103]. A 
live hybrid attenuated Shigella strain expessing both S. flexneri 2a and S. sonnei O 
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antigens was developed as an oral vaccine using the T32 attenuated S. flexneri strain 
initially produced by Istrati in Romania [104]. Large field studies in China have 
demonstrated 61-65 % protection against S. flexneri 2a and 57-72 % protection against 
S. sonnei. A protective efficacy against heterologous Shigella species was also claimed 
[104]. However, due to the need of three immunizations with high dose of bacteria 
(>2*1010 CFU) the vaccine was never clinically evaluated outside China [101]. 
Numerous approaches at attenuating S. flexneri 2a have been carried out at the Center 
for Vaccine Development (CVD) in Maryland, USA. The vaccines strain CVD1203 
carrying deletions of aroA (involved in intracellular proliferation) and virG was well 
tolerated at a dose of 106 CFU when tested in a phase I trial in North American adults, 
but caused unacceptable reactogenicity when administered at doses of 108 CFU or 109 
CFU [105]. CVD1207 vaccine carrying deletions of virG, guaBA (encoding enzymes 
involved in guaninenucleotide biosynthesis), sen (encoding ShET2) and set (encoding 
ShET1) genes was shown to be overattenuated and well tolerated in phase I clinical 
trials with North American volunteers, but was not sufficiently immunogenic [101]. 
CVD1208 and CVD 1208S vaccine strains, harbouring deletions of guaBA, sen and set 
genes showed a better balance between clinical acceptability and robust 
immunogenicity than most attenuated strains tested so far, representing attractive 
vaccine candidates [75,106]. A bivalent vaccine containing a combination of attenuated 
S. flexneri 2a and 3a was tested in the guinea pig keratoconjunctivitis model [107]. The 
mixture induced the production of serum and tear antibodies to the included OAg 
serotypes. Interestingly, the raised sera also crossreacted with LPS from heterologous 
Shigella flexneri serotypes 1a, 1b, 2b, 4b, 5b, Y but not with LPS from serotype 6. 
Moreover, the vaccine candidate conferred significant protection against challenge with 
the homologous serotypes and S. flexneri serotypes 1b, 2b, 5b, and Y, but not serotype 
6 in accordance with the crossreactivity data. Thus, despite the fact that natural 
infection results in predominantly serotype-specific protection, the cross-reactivity could 
be linked to common antigenic groups in the S. flexneri OAg of different serotypes. 
However, given the antigenic diversity of type and group factors within the S. flexneri 
serotypes, a high variation of cross protection was observed [107]. No protection was 
observed against serotypes 1a, and 4b despite the confirmation of crossreactive LPS
antibodies. Thus, the combination of S. flexneri 2a and 3a serotypes showed a broad 
cross protection in the keratoconjunctivitis model, albeit not complete. 
3.3.2 Polysaccharide conjugate vaccines 
In area where shigellosis is endemic, the children who are less than 5 years of age have 
the highest rate of incidence. After the age of 5 years, the incidence declines, thus 
suggesting that a protective immunity develops after the exposure [87,88]. 
Lipopolysaccharide and specifically the outer domain of the LPS, the O antigen, is 
generally accepted as a protective antigen of Shigella [41]. Epidemiology and volunteer 
studies have shown that infected patients are protected against reinfection with the 
homologous Shigella strain. This protective immunity is narrowly type-specific. The sero-
specificity of natural immunity indicates that immune response to the serotype-specific 
OAg play a role in protection. Further studies indicated that protection is mediated, at 
least in part, by serum or mucosal antibodies to the O antigen [41,108,109]. Due to the 
correlation of antibody responses to the OAg and protection after natural infection, the 
OAg is an attractive target for subunit vaccine development. However, given its 
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polysaccharidic nature, O antigen is recognized as a classical T-independent antigen 
with lower induction of antibody response, immunological memory and affinity of 
maturation [110,111]. Therefore, in order to overcome these limitations and to induce a 
T-dependent memory immune response, the O polysaccharide requires conjugation to a 
protein carrier. O antigen-specific IgG antibodies elicited by conjugate polysaccharide 
vaccines have been shown to prevent in vitro invasion of Shigella into Caco-2 cells in 
culture [112], suggesting that systemic antibodies can interrupt the pathogenic cycle of 
Shigella infection. Based on these observations O antigenconjugates were developed 
as vaccine candidates against multiple Shigella serotypes. In particular, the O antigen 
from S. dysenteriae type 1 was conjugated to tetanus toxoid, and O antigens from S. 
flexneri and S. sonnei were conjugated to the recombinant exotoxin A from 
Pseudomonas aeruginosa (rEPA) or to the CRM9mutant diphteria toxin [75]. They were 
shown to be safe in volunteers in phase I clinical trials. A phase II clinical study in Israeli 
volunteer soldiers revealed that parenteral vaccines consisting of S. sonnei or S. flexneri 
2a O antigens conjugated to rEPA induced high concentrations of antiLPS antibodies, 
similarly to those present after natural infection. The levels of serum IgG and IgA anti
LPS remained elevated 2 years after vaccination [108]. In the following phase III trial, 
vaccination with S. sonnei O antigenrEPA conjugate protected against homologous 
infection with 74 % efficacy in adults [113]. In age deescalation studies both of the S. 
sonnei and S. flexneri 2a rEPAconjugates were shown to be safe and immunogenic in 
47 years old children, but only S. flexneri conjugate elicited a booster effect after the 
second vaccination [114]. A recent phase III trial in 1-4 years old children revealed that 
S. sonnei and S. flexneri O-SP-rEPA conjugates were safe in this age group. However, 
the immunogenicity and efficacy were agerelated, as 71.1 % of efficacy was observed 
in the 34 years old, 35.5 % in the 23 years old, while no efficacy was observed in the 
12 years old children [115]. This data indicate that the effectiveness of Shigella O 
antigen conjugate vaccines has to be improved to be useful in young children in the 
field. Initial experiments in animals suggests that Shigella OAg conjugates with shorter 
OAg chain length are more immunogenic and thus might provide a strategy for 
improving the immunogenicity in young children [116]. A similar strategy is followed in 
the development of polysaccharide conjugates with synthetic oligosaccharides that 
mimic the O antigen protective epitopes onto appropriate carriers. In a test study, three 
repeating units of the S. flexneri 2a O antigen were shown to induce an efficient anti
LPS antibody response [117]. Another innovative approach to produce a Shigella 
conjugate vaccine is the GlycoVaxyn’s technology, that allows the synthesis of 
bioconjugates via a biological process in E. Coli. This in vivo glycosylation platform led 
to the synthesis of GVXN SD133 vaccine, consisting of Shigella dysenteriae O1 
polysaccharide conjugated to a protein carrier. The GVXN SD133 candidate vaccine 
underwent through a Phase I clinical study in 2010 to demonstrate its safety and 
immunogenicity [118].   
3.3.3 Other vaccine candidates 
Additional strategies to develop a Shigella vaccine have been pursued. These include 
the Shigella invasion complex (Invaplex 50), a subcellular macromolecular complex 
prepared from pathogenic S. flexneri, containing LPS and the invasion plasmid antigen 
B (IpaB), IpaC and IpaD [119]. It showed a robust and protective immune response in a 
guinea pig model and a clinical Phase I intranasal vaccination study in adult volunteers 
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revealed that the Invaplex was safe and immunogenic. Studies on dose optimization and 
improvement of vaccine uptake are currently ongoing [120,121]. Other approaches are 
based on the association of LPS or O antigen, prepared for example from a Shigella 
strain that has been genetically attenuated by an msbB mutation to detoxify the lipid A 
portion of the Shigella endotoxin [122], with proteosomes and ribosomes [101] to amplify 
the immune response to the carbohydrate. Vaccines containing S. flexneri 2a and S. 
sonnei LPS complexed with meningococcal outer membrane protein proteosomes were 
tested by oral and intranasal vaccination [123]. Immunization studies in mice showed 
that the proteosomesLPS complexes induced specific homologous antiLPS antibodies 
in serum and mucosal secretions. Further, challenge studies using a keratoconjunctivitis 
guinea pig model showed that the orally or intranasally administered proteosomeLPS 
complexes protected against homologous bacteria. An intranasal immunization study 
conducted in healthy adults showed that S. flexneri 2a proteosomeLPS was well 
tolerated and elicited S. flexneri 2a LPSspecific antibodies (IgA, IgG and IgM) [124]. 
The level of the antibody responses was similar to those observed with live vaccine 
candidates associated with protective efficacy in human challenge models. As an 
alternative strategy, several groups have attempted to express Shigella O antigens in 
well-tolerated live vectors such as E. coli, generating strain EcSf2a-2, or attenuated S. 
Typhi strain Ty21a, but with only limited efficacy so far [75]. Newer approaches also aim 
to generate cross-protective responses based on highly conserved virulence factors, 
such as the T3SS apparatus proteins IpaB and IpaD. Mice immunized in the presence of 
the double mutant heat-labile toxin (dmLT) from Escherichia coli, used as a mucosal 
adjuvant, with IpaB alone or IpaB combined with IpaD were fully protected against lethal 
pulmonary infection with Shigella flexneri and Shigella sonnei, indicating that IpaB and 
IpaD are promising antigens for the development of a cross-protective Shigella vaccine 
[125]. 
3.3.4 The lack of animal models 
No Shigella animal model currently satisfies the ideal criteria of being easy to set up, 
resembling as closely as possible the conditions met by Shigella in the human gut and 
mimicking the human bacillary dysentery. This lack of a relevant animal model is 
another obstacle for the development of a successful Shigella vaccine. The closest 
model to human infection is a nonhuman primate model. In Rhesus macaque monkeys, 
oral infection with S. flexneri without pretreatment with antibiotics or starvation results in 
the development of an acute colitis similar to the disease observed in humans [101]. 
However, infection of Rhesus monkeys requires 1011 bacteria compared to 
approximately 100 in humans. In addition, ethical, financial, and logistical considerations 
limit the testing of vaccine candidates in nonhuman primates. Therefore, different 
animals have been considered as possible models for Shigella infection: guinea pigs, 
rabbits, mice [101]. The Sereny test is a keratoconjunctivitis assay conducted on guinea 
pigs and it was long considered to be the gold standard test for strain virulence and 
protective immunity upon vaccination. However, this model is irrelevant for the target 
organ and provides just a quantitative description of the inflammatory response [101]. A 
currently widely accepted small animal model is the murine model of pulmonary Shigella 
infection. In this model, mice are infected with Shigella via the intranasal route resulting 
in bacterial invasion of bronchial and alveolar epithelia. This leads to the development of 
acute bronchiolitis and subsequent lethal pneumonia [126]. The characteristics of the 
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pulmonary lesions observed in infected mice are similar to the colitis developed in 
humans and non-human primates with shigellosis. In addition, it has been used for the 
characterization of cellular and humoral immune responses against Shigella infection 
[126], and it has been found to present similar immune responses as those detected in 
intestinal shigellosis. Thus, even though the lung structure and microenvironment are 
significantly different compared to the colon, the model has been used to assess 
protective immune response [101,126] and good protection has been achieved using 
intranasal immunization with subunit vaccines. More promising models have been 
developed in small animals to study the pathogenesis of Shigella but many of these 
have limitations to assess active immunization against Shigella. The intestine of adult 
mice is not susceptible to Shigella infection (via oral, intragastric and intrarectal 
inoculation) [60]. However, recently, a model of intragastric infection in newborn mice 
has been developed. Although mice show inflammatory destruction of the mucosa and 
infiltration of PMNs into the gut, this model cannot be used to evaluate protective active 
immunity, as the mice must be infected within 45 days after birth [127]. Another model 
uses the subcutaneous human colon xenograft in severe combined immunodeficient 
(SCID) mice. Mice express high levels of human IL1β and IL8 and injection of Shigella 
into the lumen of the intestinal xenograft [128] results in a marked infiltration of 
neutrophils. Thus, this model is a viable option for studying the interactions between 
Shigella and the human intestine. But so far, no protection studies have been reported. 
The rabbit ligated ileal loop model is permissive to intestinal infection by Shigella and 
results in rupture, invasion and inflammatory destruction of the epithelium. The influx of 
PMNs observed in this model allows reliable quantification of the invasive phenotype. 
Therefore, if on one hand it is a good model for the validation of the 
invasive/inflammatory phenotype of Shigella mutants compared to wild type strain [70], 
on the other hand, the likelihood to use it for protection studies has still to be determined 
[101]. Recently, a new guinea pig model for bacillary dysentery has been investigated. 
Guinea pigs were infected by intrarectal route with S. flexneri 2a or 5a strains and 
developed severe and acute rectocolitis mimicking human shigellosis [129]. In order to 
test the usefulness of this model for assessing the protective efficacy of Shigella 
vaccines, intra-rectal immunization with the live attenuated SC602 strain was performed 
and resulted in protection of the guinea pigs against challenge with S. flexneri 2a, 
suggesting that it may be useful for evaluating protective immunity of other Shigella 
vaccine candidates [101]. Finally, the Shigella human challenge model has also been 
used since 1946. The majority of the studies were conducted between 1989 and 1999 
and with the aim to evaluate vaccine efficacy [130], although one of the studies was also 
an infective dose-finding study [131]. An additional study was conducted to assess the 
cross reactivity of S. flexneri 2a antibodies generated subsequent to challenge [132]. 
However, significant variability in study protocols, including the methods utilized to 
administer the challenge inoculum, the outcome definitions and variable challenge 
strains, confound result interpretation. Moreover, experimental challenge studies 
conducted so far have not been documented in endemic regions where Shigella 
vaccines would be targeted, with the exception of a recent report described in reference 
[133]. As a matter of fact, as all clinical trials, the human model must weigh the ethical 
dilemmas involved with placing human subjects at risk against the potential benefit of a 
future drug, vaccine or other product designed to treat or prevent disease [130]. 
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3.3.5 Need for alternative approaches:  
As described in the previous paragraphs, most of the vaccines currently under 
development are serotype-specific. There is a widespread agreement that future 
Shigella vaccines must protect against a broad spectrum of Shigella serotypes: 16 
different serotypes are considered to be globally important for an epidemiologically valid 
global vaccine, S. dysenteriae 1, all 14 types of S. flexneri, and the S. sonnei single type 
[26,134]. The recently completed GEMS study (Global Enteric Multicenter Study, [135]) 
will update the knowledge about the current distribution of serotypes and the need of 
serotypes to be targeted by a Shigella vaccine. A combination of different O antigens 
might possibly be able to cover a large percentage of Shigella strains. However, the 
recent emergence of non typable strains and the possibility of strain replacement will 
likely require constant updates of a multivalent O antigen vaccine. An alternative 
strategy to develop a vaccine with broadcoverage will be to focus on bacterial 
structures that are conserved among different serotypes, such as highly conserved outer 
membrane proteins. Although attractive vaccines have entered clinical trials, further 
studies are needed to assess protection in humans and, most importantly, to understand 
if they can protect pediatric populations in developing countries [75]. As expected, the 
multifactorial nature of Shigella virulence suggests that any vaccine, either alive, 
inactivated or subunit candidate, must contain a plethora of antigens to lead to the right 
protective immune response. In addition, considering shigellosis results from an enteric 
infection, optimal protection is likely to require both mucosal and systemic immune 
effectors [136].  
3.4 Outer membrane particles as Generalized Modules for Membrane 
Antigens (GMMA) 
Pathogenic and nonpathogenic species of Gramnegative bacteria release particles 
from their surface into the extracellular space. These particles are usually called outer 
membrane vesicles (OMV) [137]. Naturally secreted OMV are closed spherical blebs of 
heterogeneous size (10-300 nm diameter) produced by growing cells, not products of 
cell lysis or death [138] and are characterized by a bilayer membrane containing 
electrondense luminal content [139]. They form when a portion of the outer membrane 
is selectively “blebbed” off into round particles. The particles are proteoliposomes and 
reflect the composition of the bacterial outer membrane, containing LPS, 
glycerophospholipids, outer membrane proteins in their natural conformation, and 
enclosing periplasmic components [140,141]. The release of vesicles has been 
observed for a wide variety of Gramnegative bacteria including Escherichia coli, 
Neisseria meningitidis, Pseudomonas aeruginosa, Shigella, and Helicobacter pylori 
[142–144] and has been observed in all stages of growth and in a variety of growth 
environments, including liquid cultures, solid culture, and biofilms [141]. McBroom and 
Kuehn (in 2007) demonstrated that vesicles production is strongly related to bacterial 
stress response, and that it increases during periods of bacterial stress, such as the 
colonization of host tissues [145]. As part of the bacterial envelope, OM blebs are 
enriched in envelope components and contain also adhesins, toxins, invasins, and 
immunomodulatory compounds [141]. In many cases, specific proteins have been 
shown to be enriched or excluded from these blebs, suggesting a specific sorting 
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mechanism [146,147]. These observations, together with the presence of PAMPs (such 
as LPS) and virulence factors, suggest different roles for the OMV as secretory pathway 
for the transport of bacterial lipids, membrane or soluble proteins and virulence factors 
to host cells and other bacteria and for the modification of extracellular environments 
[148]. Some bacteria use vesicles to gain a survival advantage over competing bacteria: 
the presence of periplasmic peptidoglycan hydrolases, for example, can lead to the 
killing of co-cultured bacteria [149]. Vesicles can fuse to the outer membrane of several 
Gram-negative bacteria [144] and release their luminal content into the receiving strain, 
so they can be involved in horizontal transfer of antibiotic resistance proteins [150]. OMV 
act also as bridging factors in biofilms, mediating the co-aggregation of bacteria and 
producing a more permissive environment [151]. In addition they are used for 
communication in environments with mixed pathogen populations, by participating in 
quorum sensing [152]. The discovery of blebs released from pathogenic bacteria in 
fluids [153] and tissues [154] of infected hosts, demonstrates that they are able to 
disseminate away from the direct site of bacterial colonization. Therefore, they may play 
a role in the pathogenic process, and may be beneficial for the bacteria (e.g. mediating 
the inflammatory damage, delivering toxins and virulence factors) or for the host (e.g. 
being an indicator of infection) [140]. Interactions with host cells through a membrane 
fusion event or via the interaction adhesin/adhesinreceptor molecules present on the 
surface of the host cells have been reported [140]. Immunomodulatory blebs-associated 
LPS and outer membrane porins can be recognized by immune cells via Tolllike 
receptors (TLRs), and other molecules, which are able to activate the host innate and 
acquired immune response pathways [155,156]. On the other hand, vesicles can allow 
the escape of the bacteria from the immune detection during colonization. The gingipain 
protease on Porphyromonas gingivalis blebs, for example, degrades the 
lipopolysaccharide receptor on the surface of human macrophageslike cells 
deactivating the responsiveness of the immune system in the periodontal disease [157]. 
The general composition of Gram-negative OM particles seems to modulate the host-
pathogen interaction in two synergic but opposite processes: stimulation of pathogen 
clearance on one side, and enhancing of the virulence of the infection on the other side 
[140]. 
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Figure 4 
 
Figure 4: Model of vesicle biogenesis. Naturally secreted outer membrane (OM) vesicles are 
proteoliposomes consisting of OM phospholipids and LPS, a subset of OM proteins, and periplasmic (Pp) 
(luminal) proteins. Proteins such as LT (red) [158] that adhere to the external surface of the bacteria are 
associated with the external surface of vesicles. Proteins and lipids of the inner membrane (IM) and 
cytosolic content are excluded from OM vesicles. Vesicles are likely to bud at sites where the links 
between the peptidoglycan (PG) and OM are infrequent, absent, or broken. (Reproduced from [141]). 
 
Proteoliposomes can also be artificially generated by sonication or detergent treatment 
of bacteria [159]. These detergentextracted proteoliposomes are usually referred to as 
bacterial OMV, as the natural secreted ones, or d-OMV (detergent extracted-OMV). 
While the same term has been used the composition of naturally released blebs and 
detergent-extracted vesicles are very different. It has been shown that the chemical 
detergent treatment causes the removal of lipooligosaccharides and lipoproteins and 
alters the general composition of the vesicles in terms of protein profile, enriching the 
preparations in cytoplasmatic and inner membrane proteins [160]. Interestingly, genetic 
modification of producing bacteria allows the increase of outer membrane vesicles 
release, without affecting their resemblance with naturally secreted blebs [160,161]. For 
example, Extraintestinal pathogenic E. coli strains (ExPEC) have been shown to release 
a high amount of vesicles enriched in outer membrane components when mutated in the 
Tol-Pal protein complex that cross-links the inner and the outer membranes [162].  
Terminology: Generalized modules for Membrane Antigens (GMMA) 
As mentioned above, the term OMV has been used for naturally released outer 
membrane particles, mutant derived-outer membrane vesicles (m-OMV) that are also 
released from the cell surface and resemble the naturally released blebs, and detergent-
extracted outer membrane vesicles with a very different composition. This has resulted 
in some confusion and often d-OMV are used as example for the development of native 
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and m-OMV. In our Institute, the Novartis Vaccines Institute for Global Health (NVGH), 
the use of particles released from the surface of intact Shigella bacteria that have been 
genetically manipulated to increase vesicles release is under investigation as candidate 
vaccine [163]. In order to differentiate these particles from the substantially different 
detergent extracted-OMV, we chose the term GMMA, for Generalized Modules for 
Membrane Antigens [163]. 
GMMA as vaccine candidates 
 As GMMA originate from the outer membrane of intact and live bacteria without being 
modified by chemical treatments, their composition reflects the surface composition of 
the donor bacteria and this make GMMA good candidates as vaccine agents [160]. 
Recently, studies focusing on surface-released outer membrane particles and 
detergent-extracted outer membrane vesicles as vaccination strategies have 
progressively been receiving more interest [164]. For instance, a d-OMV containing 
vaccine, the MeNZBTM vaccine, has been successfully used to control Neisseria 
meningitidis type B infections in New Zealand [165]. However, since the dominant 
antibody response triggered by the MeNZBTM vaccine is directed against the outer 
membrane protein (OMP) PorA, the coverage is specific to the strains expressing the 
same PorA variant [166]. On the contrary, N. meningitides GMMA, engineered to over-
express protective antigens, have been shown to be more immunogenic and to elicit a 
broader bactericidal antibody response, than d-OMV [167]. GMMA also represent 
promising vaccine candidates for several other pathogens such as Pseudomonas [168], 
Vibrio [169], Salmonella [170]. Several studies revealed that GMMA can additionally be 
used as delivery system for heterologous antigens and can enhance the protective 
efficacy of other vaccine candidates through their adjuvant activity [171].  
Limitations in the use of GMMA have been related to the endotoxic activity of LPS, 
the low yield obtained and the determination of defined composition [136]. A detoxified 
LPS would be needed to administer GMMA especially by parenteral vaccination [137]. A 
variety of strategies has been examined to attenuate the pyrogenicity of LPS by 
modifying genes required for the complete acylation of lipid A, e.g. msbB and htrB in 
Shigella [172] and E. coli [173] or lpxL in Neisseria [174]. By affecting the synthesis of 
the lipid A portion of the LPS in the GMMA donor bacteria, it is possible to obtain 
vesicles with reduced reactogenicity that can be safely administered to non-human 
primates [175]. Regarding the last two aspects, in NVGH, Shigella Program, we recently 
developed an easy and cost-affordable process, based on high-density cultivation of 
Shigella hyper-blebbing strains followed by two-steps tangential flow filtration, providing 
the basis for a large scale manufacturing process of GMMA that can be applied for 
production of vaccines from Gram-negative bacteria [163]. Moreover, we performed an 
extensive qualitative and quantitative proteomic analysis of Shigella GMMA, showing 
that they are highly enriched in OMPs, and we identified immunogenic and conserved 
surface proteins under native conditions [176]. When tested in a murine model of 
pulmonary Shigella infection, our GMMA produced from S. sonnei and S. flexneri 2a 
conferred cross-protection against heterologous serotypes if administered by mucosal 
route [177]. This work further supports the characterization of GMMA also as a protein-
based vaccine against Shigella. Other groups are evaluating the employment of GMMA 
for the production of a Shigella vaccine. S. flexneri 2a GMMA-candidate containing LPS, 
Ipa proteins, as well as other outer membrane components previously described as 
immunogens, such as porins and other major OMPs, has been successfully tested in 
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mice. One single dose of the antigenic complex administered by nasal, ocular or oral 
route induced very high levels of protection (90–100 %) against the homologous strain 
[178,179]. In another study, GMMA of Shigella boydii type 4 conferred passive 
protection in neonatal mice against homologous and heterologous strains [180]. In 
conclusion, the presence of virulence factors and native bacterial surface molecules, 
together with the adjuvanticity effect make GMMA a good vaccine candidate for broad 
spectrum protection against Gramnegative bacteria. Importantly, GMMA also represent 
an ideal tool to study Gram-negative periplasm and outer membrane compartments 
[162] and to shed light on new mechanisms of bacterial pathogenesis. 
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 PhD PROJECT HYPOTHESIS and 4.
AIMS 
The present work originated from the program at the Novartis Vaccines Institute for 
Global Health (NVGH) to develop a broadly protective vaccine against Shigella using 
Generalized Modules for Membrane Antigens (GMMA) as candidate antigens. GMMA 
might induce serotype-specific responses when produced from bacteria expressing a 
wild type LPS, as the OAg has been reported to be the immunodominant antigen in 
Shigella natural infection. However, the possibility to induce broadly-protective immune 
responses directed to highly-conserved outer membrane antigens can be investigated 
by producing GMMA lacking the OAg on their surface. In this context, different Shigella 
LPS mutants were generated and the immunogenic properties of deriving GMMA were 
evaluated in mice. Surprisingly, an LPS deep rough mutant of Shigella sonnei (S. sonnei 
galU null mutant) still elicited a serotype-specific response, indicating the presence of an 
OAg material, different from the LPS O side chain. A group 4 capsule (OAg capsule, 
G4C) consisting of the same repeating units as the OAg side chain of the LPS has been 
recently described in several Gram-negative bacteria. Shigella so far is reported to be 
uncaspulated, but possesses an operon homologous to the one responsible for capsule 
secretion and assembly in pathogenic E. coli.  
 
Our hypothesis is that S. sonnei produces a group 4 capsule and that this capsule is 
still present in the galU mutant. The main aims of the present work are: 
• the verification of the presence of a group 4 capsule in Shigella sonnei; 
• the biochemical and structural characterization of the capsule polysaccharide; 
• the functional characterization of the capsule, in relation to S. sonnei 
pathogenicity; 
• the assessment of the G4 capsule distribution in other Shigella species.  
 
The establishment of the expression and the understanding of the role of a capsule 
polysaccharide is a new and interesting finding in the Shigella field. As primary outcome 
of this research, we can achieve a better comprehension of the pathogenic mechanism 
of Shigella and the function of extracellular polysaccharides as virulence factors. As 
secondary outcome we can define potential implications of a novel surface 
polysaccharide on the design of a vaccine against Shigella spp. 
 

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 MATERIALS and METHODS 5.
5.1 Shigella strains and mutant construction 
Shigella sonnei (Ss) 53G [181] wild type (WT) was chosen as parent strain in order to 
construct the following genetically modified strains (Table 1): Ss ∆galU, Ss -pSS 
(phaseII), Ss -pSS NAR, Ss ∆wbg, Ss ∆cps, Ss ∆cps(cps), Ss ∆virG, Ss ∆tolR, Ss ∆tolR/ 
∆galU, Ss ∆tolR/ -pSS, Ss ∆tolR/ ∆wbg, Ss ∆tolR/ ∆virG, Ss ∆tolR/ ∆virG/ ∆cps. 
Shigella flexneri 2a (Sf2a) 2457T [25] wild type was chosen as parent strain to produce 
the following null mutant strains (Table 1): Sf2a ∆galU, Sf2a ∆rfbG. 
The deletion of S. sonnei tolR [162], virG [182,183] and galU [184] genes was obtained 
by substitution of the single gene coding sequence with an antibiotic marker. In 
particular, kanamycin was used to replace the tolR gene giving rise to the hyper-
blebbing tolR::kan strain [163]; chloramphenicol resistance cassette was used for the S. 
sonnei galU::cat LPS deep rough mutant, and for the S. sonnei virG (icsA)::cat mutant in 
which the presence of the Shigella sonnei virulence plasmid (pSS) is selected and the 
virulence is attenuated by inactivation of the IcsA invasion protein [183]. S. sonnei ∆wbg 
was produced by substituting genes of the O antigen (OAg) wbg gene cluster on the S. 
sonnei virulence plasmid (pSS) [57] with the chloramphenicol resistance gene in the 
wbg::cat LPS rough mutant strain. Erythromycin resistance gene was used to replace 
the whole group 4 capsule (G4C) gene cluster [185] in the S. sonnei cps::erm capsule 
mutant, and to replace three genes of the OAg rfb gene cluster [58] in the S. flexneri 2a 
rfbG::erm LPS rough mutant. Antibiotic resistance cassettes used for the generation of 
gene replacement mutants were obtained by from the following plasmids. The 
kanamycin cassette was amplified from pUC4K [186], the chloramphenicol gene from 
pKOBEG [187], and the erythromycin gene from pAT110 [188]. 
Shigella strains are listed and briefly described in Table 1. 
S. sonnei ∆tolR, Ss ∆galU, Ss ∆tolR/ ∆galU, Ss ∆tolR/ -pSS were produced in our 
laboratory (NVGH, Exploratory program, Shigella program) as described in reference 
[163]. S. flexneri 2a ∆galU was obtained by random transposon Tn10 mutagenesis as 
described in ref. [184] and was kindly provided by the laboratory of Maria Lina 
Bernardini, Dipartimento di Biologia Cellulare e dello Sviluppo, Università La Sapienza, 
Rome. The production of the other strains is described in the following paragraphs.  
 
Table 1: List of Shigella strains used in this study, their abbreviation and a 
brief description of their phenotype 
 
STRAIN 
Abbreviation 
DESCRIPTION SOURCE 
Ss WT S. sonnei 53G, phase I, +pSS Bibliography [184] 
Ss ∆galU galU deletion, LPS deep rough mutant, 
+pSS 
Bibliography [163] 
Ss -pSS phase II, LPS rough mutant, OAg deficient, 
-pSS 
This study 
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Ss -pSS NAR phase II, resistant to Nalidixic acid This study 
Ss ∆wbg OAg gene cluster deletion, LPS rough 
mutant, OAg deficient, + pSS 
This study 
Ss ∆cps G4C gene cluster null mutant, +pSS This study 
Ss ∆cps(cps) Ss ∆cps mutant complemented with 
plasmid carrying functional G4C gene 
cluster, +pSS 
This study 
Ss ∆virG virG(icsA) deletion, growth on Cm allows 
selection for the presence of pSS, 
attenuated, WT LPS 
This study 
Ss ∆tolR tolR deletion, hyperblebbing strain, +pSS Bibliography [163] 
Ss ∆tolR/ ∆galU tolR and galU deletion, hyperblebbing 
strain, LPS deep rough mutant 
Bibliography [163] 
Ss ∆tolR/ -pSS tolR deletion, hyperblebbing strain, phase 
II, LPS rough mutant, OAg deficient, - pSS 
Bibliography [163] 
Ss ∆tolR/ ∆wbg tolR and galU deletion, hyperblebbing 
strain, LPS rough mutant, OAg deficient, 
+pSS 
This study 
Ss ∆tolR/ ∆virG tolR and virG(icsA) deletion, hyperblebbing 
strain, growth on Cm allows selection for 
the presence of pSS, WT LPS 
This study 
Ss ∆tolR/ ∆virG/ ∆cps tolR, virG(icsA) and G4C gene cluster 
deletion, hyperblebbing strain, growth on 
Cm allows selection for the presence of 
pSS 
This study 
Sf2a WT S. flexneri 2a  2457T Bibliography [25] 
Sf2a ∆galU Tn10 insertion in the galU gene, LPS deep 
rough mutant 
Bibliography [184] 
Sf2a ∆rfbG OAg gene cluster null mutant, LPS rough 
mutant, OAg deficient, + pINV 
This study 
 
Electrocompetent cells and Recombination-prone Shigella cells  
Electrocompetent cells were prepared as follows: over night (ON) cultures were diluted 
1:50 in 50 mL LB medium and grown until OD600= 0.6. Bacteria were collected by 
centrifugation at 4000 g for 10 min at 4 °C and washed 2 times in cold milliQ water. An 
additional washing step with cold 10 % glycerol was performed and bacteria were finally 
resuspended in 500 µL of 10 % glycerol. 
Recombination-prone Shigella cells were produced by using the highly proficient 
homologous λ red recombination system as previously described [163]. λ red 
recombinase genes under the control of an arabinose inducible promoter (red operon, 
[189]) are encoded on pAJD434 [190]. pAJD434 was inserted in electrocompetent cells 
by electroporation. The electrocompetent and recombination-prone cells, carrying the 
pAJD434, were prepared as follows. Over night cultures were diluted at OD600= 0.03 in 
150 mL of LB + trimethoprim 100 µg/mL and grown at 30 °C, until OD600= 0.2. 0.2 % 
arabinose (Sigma-Aldrich) was added to the culture to induce the expression of the 
recombinases, and cultures were grown until OD600= 1.0. Bacteria were then recovered 
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and washed as described before. After the completion of the genetic mutation requiring 
homologous recombination, pAJD434 was removed from the mutant strains by ON liquid 
growths at 37 °C. 
 
S. sonnei -pSS (phase II) and -pSS NAR 
S. sonnei comprises a single serological group expressing the form or phase I O 
somatic antigen [191]. The O antigen synthetic gene cluster resides on the large 
virulence plasmid pSS [57]. During cultivation in vitro phase I colonies spontaneously 
lose the pSS and undergo a morphology transition from smooth and even-edged to 
uneven-edged, rough-appearing phase II colonies. When plated on Congo red TSB agar 
plates, the color of the S. sonnei colonies varies accordingly to the presence of the 
virulence plasmid from pigmented red (phase I) to white (phase II) [192]. Transition to 
the form II cell type results in the loss of the form I O antigen and of the virulence [193]. 
S. sonnei -pSS strain used in this study was selected by the white appearance on 
Congo red plates. The curing of the virulence plasmid was confirmed by the absence of 
PCR products when probing for the pSS origin of replication and the wzy gene [57], 
using primers pS.so53G.oriF/pS.so53G.oriR and pS.so53G.wzyF/pS.so53G.wzyR, 
respectively (primer sequences are listed in Table 2). 
In order to generate a S. sonnei -pSS strain that could be identified using selective 
medium, experimentally induced Ss -pSS Nalidixic Acid resistant (NAR) strain [194] was 
isolated by serial passages of Ss -pSS on LB agar plates supplemented with increasing 
concentrations of Nalidixic Acid (from 10 to 50 µg/mL). The antibiotic resistant 
phenotype was confirmed by liquid growth in LB + NA 50 µg/mL. 
 
S. sonnei ∆wbg and ∆tolR/ ∆wbg  
A S. sonnei O antigen deficient strain still carrying the virulence plasmid was 
engineered, as alternative to the Ss -pSS phase II strain. This O antigen knock out was 
obtained by deletion of the plasmid-borne gene cluster encoding the biosynthesis of the 
O repeating units (RU) [57] from gene wzz to wbgZ (see Figure 5). The mutant has been 
abbreviated as Ss ∆wbg and was generated as follows. Internal fragments of the genes 
wzz and wbgZ were amplified by PCR using primers wzz-5_Sac, wzz-3_Sam, and 
wbgZ-5_Sma and wgbZ-3_Sal, respectively. The cat gene was amplified from pKOBEG 
using primers, EcoRV.Cm.F and EcoRV.Cm.R. PCR products were digested with SacI 
and SmaI (wzz), SalI and SmaI (wbgZ) and EcoRV (cat) (Restriction Endonucleases, 
New England BioLabs®), ligated in a 4-way ligation into pBluscript SK + (Stratagen) 
vector digested with SacI and SalI, and transformed into E. coli DH5αTMT1R 
Competent Cells (Invitrogen). The wzz-cat-wbgZ fragment of the obtained plasmid pSK-
wbg::cat was amplified using the primers wzz-5_Sac wgbZ-3_Sal. The PCR product was 
transformed into recombination prone S. sonnei 53G or S. sonnei ∆tolR to yield S. 
sonnei ∆wbg and S. sonnei ∆tolR/ ∆wbg (primer sequences are listed in Table 2). 
 
Figure 5 
 
Figure 5: Schematic representation of S. sonnei plasmid-borne O antigen gene cluster. 
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S. sonnei ∆cps, ∆tolR/ ∆virG/ ∆cps and ∆cps(cps) complemented strain 
∆cpsKO::erm fragment was constructed to delete the whole G4C gene cluster (See 
Figure 6, [185]) in S. sonnei by conventional cloning and homologous recombination. 
The resulting mutant was abbreviated as Ss ∆cps. 
 
 
Figure 6 
 
Figure 6: S. sonnei G4C operon, schematic representation with flanking genes (appA and cspH) 
Upstream (495 bp) and downstream (526 bp) flanking regions of the G4C gene cluster 
were amplified from a S. sonnei WT colony, by PCR with the EcoRV.cps.3’.F/ 
XhoI.cps.3’.R and XbaI.cps.5’.F/ EcoRV.cps.5’.R primers, respectively. The two PCR 
products were digested with EcoRV/ XhoI and XbaI/ EcoRV (Restriction Endonucleases, 
New England BioLabs®) and cloned into the pBluescript SK + (Stratagen) vector. The 
ligation was performed in a molar ratio of 1:6 between the plasmid and each fragment 
using the T4 DNALigase (Roche). 10 µL of the reaction were transformed in 50 µL of 
Max Efficiency® E. coli DH5αTMT1R Competent Cells (Invitrogen) according to the 
manufacturer specificities. Transformed colonies were selected on 100 µg/mL ampicillin 
and grown ON in LB + amp at 37 °C to do a mini plasmid preparation (QIAprep Spin 
Miniprep kit, QIAGEN, cat. #27106). The purified plasmid was controlled by XbaI/ XhoI 
and EcoRV digestions and by PCR with XbaI.cps.5’.F/ XhoI.cps.3’.R primers to contain 
the G4C flanking regions. The erythromycin resistance gene, erm [188] was amplified 
with primers EcoRV.Ery.F/ EcoRV.Ery.R. After EcoRV digestion, the purified cassette 
was ligated into the EcoRV site between the G4C operon flanking regions, generating 
the p∆cpsKO::erm plasmid (see Figure 7). The plasmid was transformed in 50 µL of 
DH5α competent cells and bacteria were selected on LB + 100 µg/mL erythromycin 
plates. Minipreps of p∆cpsKO::erm were screened by XbaI/ XhoI and EcoRV digestions 
and by PCR with XbaI.cps.5’.F/ XhoI.cps.3’.R primers. Finally, KpnI linearized 
p∆cpsKO::erm was used as template to amplify the linear fragment ∆cpsKO::erm 
(primers XbaI.cps.5’.F/ XhoI.cps.3’.R). 1 µg of purified ∆cpsKO::erm (QIAquick PCR 
purification kit, QIAGEN, cat. #28106) was used to transform electrocompetent, 
recombination-prone Shigella sonnei WT and ∆tolR/ ∆virG (see following paragraph) 
cells to generate the G4C knock out strains Ss ∆cps and Ss ∆tolR/ ∆virG/ ∆cps. Mutant 
colonies were subsequently controlled by PCR with different combinations of primers 
(cps.ext-5/ cps.ext-3, Ery.ctr.int.F/ cps.ext-3) (primer sequences are listed in Table 2). 
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Figure 7 
 
Figure 7: G4C operon knock out. Schema of pBluescript vector carrying the ∆cpsKO::erm construct. 
Upstream (495 bp) and downstream (526 bp) regions of the group 4 capsule gene cluster are cloned 
using EcoRV/ XhoI and XbaI/ EcoRV enzymes, erythromycin resistance cassette is subsequently cloned 
in the plasmid using EcoRV enzyme. 
The G4C operon was complemented in the Ss ∆cps KO mutant as follows. The G4C 
gene cluster with the 280 bp upstream region was amplified using primers 
XbaI.COMPLcps.5’.F/ SalI.COMPLcps.3’.R (LongRange PCR Kit, QIAGEN, cat. 
#206401) (primer sequences are listed in Table 2). The XbaI/ SalI digested fragment 
was cloned into pACYC184 (New England BioLabs®) vector, inactivating the 
tetracycline resistance cassette while leaving the chloramphenicol cassette intact. Due 
to the large size of the amplified operon (8032 bp) the ligation was performed in a 1:3 
molar ratio of fragment to plasmid, to generate the p∆cpsCOMPL plasmid (see Figure 
8). 10 µL of the reaction were transformed in DH5α competent cells, selected on 20 
µg/mL chloramphenicol. Purified plasmid preparations were controlled by double XbaI/ 
SalI and single SalI digestions. The correct product was used to transform 
electrocompetent Ss ∆cps cells carrying the G4C cluster deletion to generate the 
complemented strain called Ss ∆cps(cps). G4C gene cluster complementation was 
subsequently controlled by different analyses of exopolysaccharide expression.  
 
Figure 8 
 
Figure 8: G4C operon complementation. Schema of pACYC184 vector carrying the G4C operon cloned 
with the 280 bp upstream region using XbaI and SalI enzymes (p∆cpsCOMPL). Chloramphenicol 
resistance is used to select positive clones. 
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S. sonnei ∆virG and ∆tolR/ ∆virG  
As mentioned before, during cultivation in vitro, S. sonnei spontaneously loses the 
virulence plasmid giving rise to phase II OAg deficient colonies [193]. In order to avoid 
the loss of the pSS and consequently of the ability to synthetize the OAg repeating units, 
a mutant selectable for the presence of the pSS was produced by inactivating one of the 
plasmid-encoded virulence factor [183]. Upstream and downstream flanking regions of 
the virG gene were amplified by PCR using primers virGup-5_Sac, virGup-3_Sam and 
virGdown-5_Sma, virGdown-3_Sal, respectively. The cat gene was amplified from 
pKOBEG using primers, EcoRV.Cm.F and EcoRV.Cm.R. PCR products were digested 
with SacI and SmaI (upstream flanking region), SalI and SmaI (downstream flanking 
region) and EcoRV (cat), ligated in a 4-way ligation into pBluscript digested with SacI 
and SalI, and transformed into E. coli DH5α sub-cloning cells, resulting in plasmid pSK-
virG::cat. The insert containing the cat gene and the adjacent flanking regions of virG 
was amplified using primers virGup-5_Sac and virGdown-3_Sal. The PCR product was 
transformed into recombination prone S. sonnei 53G or S. sonnei ∆tolR to yield S. 
sonnei ∆virG and S. sonnei ∆tolR/ ∆virG (primer sequences are listed in Table 2).  
S. flexneri 2a ∆rfbG 
The S. flexneri 2a O antigen deficient strain was generated by inactivating three genes 
in the chromosomal OAg synthetic operon [58], in particular the rfbG gene and parts of 
the flanking genes rfbF and rfc (see Figure 9). Internal fragments of the genes rfbF and 
rfc were amplified by PCR using primers rfbF1-stop_Sma, rfbF-2_Sal, and rfc-1_Sac, 
rfc-2_XbaSma2, digested with SacI and SmaI (rfbF), SalI and SmaI (rfc), inserted into 
pBluscript SK+ digested with SacI and SalI, and transformed into E. coli DH5α, to yield 
pSK-rfb-flank. The erm gene was amplified from pAT110 using primers EcoRV.Ery.F 
and EcoRV.Ery.R, digested with EcoRV, and inserted into the SmaI site between the 
rfbF and rfc framgents in pSK-rfb- flank. The resulting plasmid pSK-rfb::erm was used to 
amplify the rfbF-erm-rfc fragment with primers rfbF-2_Sal and rfc-1_Sac. The PCR 
product was transformed into recombination prone S. flexneri 2a or S. flexneri 2a ∆tolR 
to yield S. flexneri 2a ∆rfbG and S. flexneri 2a ∆tolR/ ∆rfbG (abbreviations). 
 
Figure 9 
 
 
Figure 9: Schematic representation of S. flexneri 2a chromosomal O antigen gene cluster. 
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Primers and plasmids 
Shigella mutants were constructed using combinations of primers listed in the following 
Table 2. 
 
Table 2: List of primers used in this study for generation of Shigella mutants 
MUTANT/ 
GENE 
PRIMER SEQUENCE 
Ss -pSS pS.so53G.oriF CGTAACCGTAATTACAGCCG 
 pS.so53G.oriR GATTTCACCTTACCCATCCC 
 pS.so53G.wzyF CGTTGAGGTTTCACGTTTCT 
 pS.so53G.wzyR TTACCAATATACCCTCCGCA 
Ss ∆wbg wzz-5 Sac ACTCGAGCTCGGCAGACTCAGCGCAAG 
 wzz-3 Sma CTAACCCGGGCATTGACACAACAATACGTAACCCAG 
 wgbZ-5 Sma CTAACCCGGGTGCGATTTGGTAATGTACTCGG 
 wgbZ-3 SalI ACGCGTCGACATTGCTCGCTTGTGATAACAGC 
Ss ∆cps EcoRV.cps.3’.F AGCTTGATATCCGCATGGACAATACGTACGC 
 XhoI.cps.3’.R CCGCTCGAGACGTGTGGAATTTTGCCGCG 
 XbaI.cps.5’.F CTAGTCTAGAGATCAAGACAGCGTTGACGC 
 EcoRV.cps.5’.R AGCTTGATATCAACTGAAAGTGGCCGGATGC 
 cps.ext-5 GCCACCCCGTTATTAGATTTG 
 cps.ext-3 GCAGAAGTGCTTATACCAGG 
Ss 
∆cps(cps) 
XbaI.COMPLcps.5’.
F 
CTAGTCTAGACATCCGGCCACTTTCAGTTTTAC 
 SalI.COMPLcps.3’.
R 
ACGCGTCGACCAGCCAGTTATAGTACCACTTG 
Ss ∆virG virGup -5 Sac ACTCGAGCTCTGTAGTTGATTTGACAGTTGACATCC 
 virGup -3 Sma CTAACCCGGGCACTATATTATCAGTAAGTGGTTGAT
AAACC 
 virGdown-5 Sma CTAACCCGGGCGTGTTGATGTCCTGC 
 virGdown-3 Sal ACGCGTCGACAGTTCAGTTCAGGCTGTACGC 
Sf2a 
∆rfbG 
rfbF-1stop Sma CTAACCCGGGCTAAGCATCTAAGACACCATTCTGTA
TC 
 rfbF-2 SalI ACGCGTCGACAATATCCTGGAGCATACGTGT 
 rfc-1 SacI ACTCGAGCTCACCAATAACGCCTGTTTTCTG 
 
rfc-2 XbaSma2 
CTAGTCTAGAAACCCGGGTTTGATGTGCAACCATAC
CTTTT 
erm EcoRV.Ery.F AGCTTGATATCAGAGTGTGTTGATAGTGCAGTATC 
 EcoRV.Ery.R AGCTTGATATCACCTCTTTAGCTTCTTGGAAGCT 
 Ery.ctr.int.F CGTACCTTGGATATTCACCGA 
cat EcoRV.Cm.F AGCTTGATATCTGTGACGGAAGATCACTTCG 
 EcoRV.Cm.R AGCTTGATATCGGGCACCAATAACTGCCTTA 
 Cm.verif-5 CATCATGCCGTTTGTGATGG 
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Plasmids used in this study are listed in the following Table 3. 
 
Table 3: List of plasmids used in this study 
PLASMID Description SOURCE 
pKOBEG Containing Chloramphenicol 
resistance cassette 
Bibliography [187] 
pAT110 Containing Erythromycin resistance 
cassette 
Bibliography [188] 
pAJD434 Containing λ red recombinase genes Bibliography [190] 
pBluescript SK + Cloning vector Stratagen 
pSK-wbg::cat pBluescript containing wbg region 
knock out construct 
This study 
p∆cpsKO::erm pBluescript containing G4C operon 
knock out construct 
This study 
pSK-virG::cat pBluescript containing virG knock out 
construct 
This study 
pSK-rfbG::erm pBluescript containing rfb region 
knock out construct 
This study 
pACYC184 Cloning vector New England BioLabs® 
p∆cpsCOMPL pACYC184 expressing the G4C 
operon 
This study 
5.2 PCR conditions 
Standard PCR reactions were performed using the PCR SuperMix (Invitrogen, cat. 
#10790-020) with 100 pmol of primers. The conditions for the amplification of the 
products were: initial denaturing step at 94 °C for 30 sec, followed by 30 cycles of 
denaturing step at 94 °C for 30 sec, annealing step at 52-54 °C for 30 sec, and a 
variable elongation step at 72 °C (1 minute every 1000 bp), and a final elongation step 
at 72 °C for 30 sec. For the amplification of the group 4 capsule operon, the LongRange 
PCR Kit (QIAGEN, cat. #206401) was used accordingly to producer specifications. In 
particular, the conditions for the amplification were: initial denaturing step at 94 °C for 3 
min followed by 35 cycles of denaturing step at 94 °C for 15 sec, annealing step at 62 °C 
for 30 sec, elongation step at 68 °C for 9 min, and a final elongation step at 72 °C for 30 
sec. 
5.3 Bacterial growth and fermentation conditions 
E. coli and Shigella strains were routinely cultured in Luria-Bertani (LB) medium or in 30 
g/L tryptic soy broth (TSB, BD BBLTM), respectively, at 37 °C, 200 rpm, unless specified 
in the particular method. Tryptic soy agar (30 g/L TSB, 15 g/L agar) supplemented with 
150 mg/L congo red (Sigma-Aldrich) was used to evaluate the presence of the virulence 
plasmid in Shigella. Inactivated bacteria for mice immunization study were produced in 
low-osmolarity Luria-Bertani medium with NaCl omitted (LBON), containing 10 g/L 
BactoTryptone (BD BBLTM) and 5 g/L yeast extract (BD BBLTM), pH adjusted to 7.0 with 
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NaOH [195]. For the production of GMMA, Shigella hyperblebbing strains were grown in 
30 g/L TSB, in yeast extract medium (HTMC) or in S. sonnei Defined Medium (SSDM) 
[163]. HTMC was prepared as follows: 30 g/L yeast extract, 5 g/L KH2PO4, 20 g/L 
K2HPO4, 1.2 g/L MgSO4*7H2O, 15 g/L glycerol, and 0.25 g/L polypropylene glycol 
(PPG), pH adjusted to 7.2 with 4 M ammonium hydroxide. SSDM was prepared as 30 
g/L glycerol, 13.3 g/L KH2PO4, 4 g/L (NH4)2HPO4, 1.2 g/L MgSO4*7H2O, 1.7 g/L citric 
acid, 2.5 mg/L CoCl2*6H2O, 15 mg/L MnCl2*4H2O, 1.5 mg/L CuCl2*2H2O, 3 mg/L 
H3BO3, 2.5 mg/L Na2MoO4*2H2O, 13 mg/L Zn(CH3COO)2*2H2O, 2 µM ferric citrate, 50 
mg/L thiamine, 10 mg/L nicotinic acid, 2.5 g/L L-aspartic acid, 0.25 g/L PPG, pH 
maintained at 6.7 with 4 M ammonium hydroxide. For fermentation, starter cultures were 
grown from glycerol stocks to OD600= 0.8 and subsequently transferred to a 5 L 
fermenter (Applikon) to reach a starting OD600 of 0.02. Dissolved oxygen was 
maintained at 30 % saturation by controlling agitation and setting maximum aeration, pH 
was maintained at 6.7 by a pH controller and temperature was kept constant at 37 °C. 
When needed, growth media were supplemented with Kanamycin (Kan, 30 µg/mL), 
Chloramphenicol (Cm, 20 µg/mL), Erythromycin (Ery, 100 µg/mL), Nalidixic Acid (NA, 50 
µg/mL), Trimethoprim (Tmp, 100 µg/mL), Ampicillin (Amp, 100 µg/mL). 
5.4 Generalized Modules for Membrane Antigens (GMMA) 
preparation 
GMMA purified from liquid culture supernatant of Shigella hyperblebbing strains (tolR 
null mutants) were used as outer membrane preparation to extract the Shigella 
exopolysaccharides (EPS) and as antigens for mice immunization studies. For low 
density preparations, bacteria were grown in TSB medium in 1 L flasks. Culture 
supernatants were collected by 10 min centrifugation at 4000 g and sterilized by 0.22 
µm filtration. After concentration using a 100 KDa regenerated cellulose membrane 
(Millipore) in a Stirred Ultrafiltration Cells (Amicon, model 8400), GMMA were separated 
from soluble proteins by 2 h ultracentrifugation at 186000 g at 4 °C (OptimaTM Lseries, 
45Ti rotor, Beckman Instruments) and resuspended in cold phosphate buffer saline 
(PBS). Preparations were sterilized by 0.22 µm filtration. For high density productions, 
GMMA were prepared in flasks or in a 5 L fermenter (Applikon) in HTMC medium or in 
SSDM and purified from sterile culture supernatants by a two step-Tangential Flow 
Filtration (TFF) preocess [163]. 
5.5 Preparation of inactivated whole cell Shigella 
Bacteria inactivated by formalin fixation or by heat inactivation were used as antigens for 
mouse immunization studies. In particular, formalin fixed (FF) Ss WT, Ss ∆galU, Ss -
pSS, Ss ∆wbg, Sf2a WT, Sf2a ∆galU, Sf2a ∆rfbG and heat killed (HK) Ss ∆galU were 
prepared as follows. ON cultures were grown in LBON supplemented with antibiotics, 
when needed, starting from colonies selected on congo red plates. The following day, 
cultures were diluted to OD600= 0.07 in 150 mL and grown until OD600= 1 (bacterial 
concentration is 5*108 CFU/mL). For heat inactivation, cells were collected by 10 min 
centrifugation at 4000 g and concentrated 20 times in PBS (bacterial concentration is 
1010/mL) and the mix was incubated at 100 °C for 2 min. The preparation was stored at 
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4 °C until use. For formalin fixation, cells were collected by 10 min centrifugation at 4000 
g and resuspended in 15 mL Hank's Balanced Salt Solution (HBSS, GIBCO®), 
supplemented with 0.5 % formalin solution (Sigma-Aldrich). The mixture was incubated 
for 36 h at room temperature in slow agitation. Subsequently, the inactivated bacteria 
were collected by centrifugation, resuspended in 7.5 mL PBS (concentration of 1010 
CFU/mL) and stored at 4 °C until use. 100 µL of each preparation were plated on LB to 
confirm the absence of bacterial growth. 
5.6 Quantification of GMMA-associated proteins 
GMMA-associated protein concentration was quantified by Bradford Assay (Bio-Rad 
Protein Assay, cat. #500-0002). 100 µL of each sample were diluted 1:2 in 6 M 
guanidine hydrochloride pH 7.8 and boiled at 100 °C for 10 min. Samples were 
subsequently diluted in the Bradford reagent according to the manufacturer instructions. 
Bovine Serum Albumin (BSA) was used as standard (Thermo Scientific Pierce, cat. 
#23209) to build the standard curve (range 1 µg/mL  9 µg/mL in the assay). Absorbance 
was measured at wavelength of 595 nm. 
5.7 Mouse immunization studies 
CD1 female mice of 4 to 6 weeks of age were immunized subcutaneously on days 0, 21, 
and 35. Blood samples for sera analysis were collected before the first immunization 
(preimmune sera) and 14 days after the third injection (bleed out, post 3 immune sera). 
Groups of 8 mice were used for mice immunizations with GMMA. In particular, GMMA 
obtained from Ss ∆tolR, Ss ∆tolR/ ∆galU, and Ss ∆tolR/ -pSS hyperblebbing strains 
were used. Each injection contained 2 ug of GMMA (as quantified by protein amount) 
formulated in PBS in a final volume of 100 µL. Groups of 5 mice were used when 
formalin-fixed bacteria were administered. Each injection contained 109 CFU formulated 
in PBS in a final volume of 100 µL. Control mice received PBS alone. The animal 
experiments complied with the relevant guidelines of Italy and the institutional policies of 
Novartis. The animal protocol was approved by the Animal Welfare Body of Novartis 
Vaccines and Diagnostics, Siena, Italy, approval number AEC 2009-05. 
5.8 1D SDS-PAGE 
GMMA, Formalin Fixed bacterial preparations and hot-phenol LPS extracts (See 
paragraph ) were analyzed by 1D SDS-polyacrylamide gel electrophoresis using an 
XCell SureLockTM Mini-Cell system (Invitrogen). Samples were boiled for 10 min at 95 
°C in NuPAGE® LDS Sample Buffer (Invitrogen) containing 10 mM DLDithiothreitol 
(DTT, Sigma-Aldrich, cat. #D9779) and loaded on NuPAGE® 12 % BisTris gels (10 
wells, 1 mm thick, Invitrogen, cat. #NP0341BOX). Precision Plus Protein™ All Blue 
Standard (Bio-Rad, cat. #161-0373) was used as protein molecular mass marker, and 
each gel was run in NuPAGE® 3(Nmorpholino)propanesulfonic (MOPS) acid SDS 
Running Buffer (Invitrogen, cat. #NP0001) at 30 mA per gel. Gels loaded with GMMA or 
bacterial preparations were stained with Coomassie Brilliant Blue G250 solution (40 % 
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ethanol, 10 % acetic acid, 1 g/L G250, Thermo Scientific Pierce, cat. #20279), and 
distained with 40 % ethanol, 10 % acetic acid. Gels loaded with LPS extracts were silver 
stained using the SilverQuest™ Silver Staining Kit (Invitrogen, cat. #LC6070) 
accordingly to manufacturer instructions. 
5.9 WESTERN BLOT 
Samples resolved by 1D SDSPAGE were transferred to nitrocellulose membranes 
using the iBlot® Gel Transfer Device (Invitrogen, cat. #IB1001). Membranes were 
washed in PBS, blocked ON with 3 % (w/v) milk in PBS, and after 3 washing steps for 
10 min in 3 % milk, 0.05 % (v/v) Tween20 in PBS, they were incubated with the 1:1000 
dilution of primary antibody (GMMA polyclonal mice antisera, IpaB H16 mouse 
monoclonal antibody [196] [kindly provided by the laboratory of Armelle Phalipon, Unité 
de Pathogénie Microbienne Moléculaire, Institut Pasteur, Paris, France] or Ss phase I 
monovalent rabbit antiserum, Denka Seiken Co., Ltd. cat. #295316) in blocking buffer, 
for 2h at room temperature. The membranes were then washed as before, and 
incubated with a 1:5000 dilution in blocking buffer of the appropriate secondary 
antibodies (Goat anti-Mouse IgG-Alkaline Phosphatase antibody, Sigma-Aldrich, cat. 
#A3562, or Goat anti-Rabbit IgG-Alkaline Phosphatase conjugate, Invitrogen, cat. #G-
21079) for 1 h at room temperature. Immunoblots were washed three times and 
developed using the SIGMAFASTTM BCIP®/NBT tablet (Sigma-Aldrich, cat. #B5655) 
solution, as described by the manufacturer. 
5.10 Transmission Electron Microscopy (TEM) 
GMMA were diluted to a concentration of 100 µg/mL in PBS. 5 µL were placed on 
copper carboncoated grids and GMMA were absorbed for 5 min at room temperature. 
Grids were then washed with 3 consecutive drops of distilled water and blotted with a 
filter paper. For negative staining the grids were treated with 2 % uranyl acetate for 50 
seconds and airdried. The grids were subsequently analyzed using a TEM (tr) FEI 
Tecnai G2 Spirit operating at 80 kV equipped with a 2Kx2K CCD camera Olympus SIS 
Morada. 
Bacteria were prepared by processing for TEM and ultrathin resin sectioning. The 
primary fixation was performed with the addition of alcian blue to highlight 
polysaccharides. A sample of size=20 was used to measure the thickness of alcian blue 
stain extending beyond the outer membrane. 
5.11 Bacteria surface staining coupled with Flow cytometry (FACS) 
analysis 
Over night Shigella cultures were diluted in TSB medium to OD600= 0.05 and grown to 
early exponential phase at OD600= 0.5 (bacteria are 2.5*108 CFU/mL). Cells were 
collected and diluted to a concentration of 2*107 CFU/mL. For formalin-fixed Shigella 
staining procedure, bacteria were diluted in 0.5 % formalin solution in PBS and fixed in 
agitation over night at room temperature. Live or fixed bacteria were washed, 
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resuspended in TSB and aliquoted in 96 well plates (Corning® Costar® cell culture 
plates, round bottom). The incubation with the desired dilutions of mouse immune sera, 
IpaB monoclonal antibody (H16, mouse monoclonal Ab, kindly provided by the 
laboratory of Armelle Phalipon, Unité de Pathogénie Microbienne Moléculaire, Institut 
Pasteur, Paris, France [196]) or the rabbit Ss phase I monovalent antiserum (OAg-
specific antiserum) was performed in a final volume of 50 uL for 1 h, at 4 °C. For 
competitive staining experiments, prior to bacterial incubation, Ss ∆galU GMMA immune 
serum was incubated with 11.25 µg of LPS (as quantified by phenol-sulfuric assay) 
extracted from Ss WT or -pSS bacteria, for 1 h at 4 °C, at a 1:1000 dilution in PBS. After 
washing with 1 % BSA in PBS, bacteria were incubated with Allophycocyanin-
conjugated AffiniPure F(ab') 2 Fragment Goat Anti-Mouse IgG (Jackson 
ImmunoResearch®) or with Alexa Fluor® 488 F(ab′)2 fragment of goat anti-rabbit IgG 
(H+L) (Invitrogen) for 1 h, on ice to detect antibody binding. Bacteria were washed, fixed 
with 4 % formalin in PBS for 20 min, on ice and finally analyzed for cell-bound 
fluorescence using a FACScanto II flow cytometer (BD Biosciences). 
5.12 Hot-phenol extraction of total cellular and outer membrane 
lipopolysaccharides 
Lipopolysaccharides were extracted by the method of Westphal and Jann [197], with 
some modifications. 
For total cellular lipopolysaccharides extraction, ON Shigella cultures were diluted in 
50 mL LB supplemented with antibiotics, if needed, to OD600= 0.1 and grown until 
OD600= 1. Bacteria were collected by centrifugation and the pellet was resuspended in 
500 µL PBS. After 5 min boiling, the mixture was treated with 0.5 µg/µL of Proteinase K 
(Thermo Scientific Pierce, cat. #17916) at 60 °C ON. An equal volume of saturated 
phenol solution (pH 8.0) (Sigma-Aldrich, cat. #P4557) was added and incubated for 30 
min at 70 °C with occasional mixing. After 1 h centrifugation at 10000 g, the upper 
aqueous phase was recovered and 2 volumes of absolute ethanol were added. The 
polysaccharides were allowed to precipitate for 1 h at -70 °C. Samples were centrifuged 
at 12000 g for 30 min and the pellet containing LPS and capsule polysaccharide was 
dried in a rotary vacuum drier (SpeedVac) and dissolved in distilled water. 
For outer membrane lipopolysaccharides extraction, purified GMMA were used as 
starting outer membrane preparations. After Proteinase K incubation step, samples were 
treated as described before. 
5.13 Lipid A removal and exopolysaccharides (EPS) isolation 
In order to remove the lipid A moiety of LPS, outer membrane lipopolysaccharide 
samples extracted from GMMA were treated by mild acid hydrolysis with 1 % acetic acid 
for 1.5 h at 100 °C. The reaction was neutralized by adding few drops of ammonium 
hydroxide to adjust the pH to 6.5. Samples were centrifuged at 15000 g over night and 
the supernatant, containing pure polysaccharides, was collected and dialyzed against 
distilled water.  


5.14 Phenol-sulfuric acid assay 
Phenol sulfuric assay was used for total sugar content quantification, using glucose 
(Glc) as standard, as previously described in ref. [198]. 
5.15 High Performance Liquid Chromatography-Size Exclusion 
Chromatography (HPLC-SEC) 
HPLC-SEC analysis was used to analyze the molecular size distribution of EPS 
populations and to isolate polysaccharide (PS) fractions of different molecular weight. 
Samples were run on a TSK gel G3000 PWXL column (30 cm x 7.8 mm; particle size 7 
µm; cod. #808021) with a TSK gel PWXL guard column (4.0 cm x 6.0 mm; particle size 
12 µm; cod. #808033) (TosohBioscience). The mobile phase was 0.1 M NaCl, 0.1 M 
NaH2PO4, 5 % CH3CN, pH 7.2 at the flow rate of 0.5 mL/min (isocratic method for 30 
min). Polysaccharides peaks were detected by differential refractive index (dRI). 
5.16 1H Nuclear Magnetic Resonance (NMR) spectroscopy 
NMR analysis was performed to confirm the identity of the PS samples by detecting 
typical signals of the OAg residues, to confirm the molar ratio of FucNAc4N to L-AltNAcA 
and to calculate the number of OAg repeating units (RUs) attached to the core [116]. 
Dried PS samples were solubilized in 650 uL deuterated water (D2O, Sigma-Aldrich) and 
transferred to 5 mm NMR tubes. Proton NMR experiments were recorded at 25 °C on 
Varian VNMRS-500 spectrometer, equipped with a Pentaprobe. Acquisition time of 5 
sec, relaxation delay of 15 sec and number of scans of 64 were set for recording the 
spectra. For data acquisition and processing VNMRJ ver. 2.2 rev. C and Mestrenova 6.1 
(Mestrelab Research) were used respectively. 1D proton NMR spectra were collected 
using a standard one-pulse experiment. Chemical shifts were referenced to hydrogen 
deuterium oxide (HDO) at 4.79 ppm. 
5.17 KDO quantification by semicarbazide derivatization coupled with 
HPLC-SEC  
Presence of 3-deoxy-D-manno-octulosonic acid (KDO) at the reducing end of isolated 
EPS population [199] was estimated by HPLC-SEC after derivatization with 
semicarbazide. Derivatization was performed using the semicarbazide assay for α-
ketoacids determination, with minor modifications [200]. EPS samples (100 µL of total 
volume in water), were added to 100 µL of semicarbazide solution (100 mg 
semicarbazide hydrochloride + 90.5 mg of sodium acetate anhydrous in 10 mL of water). 
Samples were heated at 50 °C for 50 minutes and then analyzed by HPLC-SEC (80 µL 
injected), on a TSK gel G3000 PWXL column with guard column in 0.1 M NaCl, 0.1 M 
NaH2PO4, 5% CH3CN, pH 7.2 mobile phase at the flow rate of 0.5 mL/min (isocratic 
method for 30 min). Detection was done at 252 nm.  
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5.18 Gentamicin protection assay (HeLa cells invasion assay) 
Invasiveness of the various S. sonnei strains was evaluated in vitro by using a 
gentamicin protection assay conducted on HeLa semiconfluent monolayers. Each 
condition was tested at least in triplicates. Briefly, 5*105 HeLa cells/well (HeLa ATCC®, 
CCL-2TM) were seeded ON in 6 well cell culture plates (Corning® Costar®) in 
Dulbecco’s Modified Eagle Medium (D-MEM) high Glucose (Invitrogen, cat. #61965), 
supplemented with 10 % FBS (New Zealand, Invitrogen). The following day, Shigella ON 
cultures were diluted in TSB medium (supplemented with antibiotics, if needed) and 
grown to OD600= 0.5 (bacteria are 2.5*108/mL). Bacteria were collected, diluted in D-
MEM and used to infect HeLa cells with a Multiplicity of Infection of 10 bacteria/cell (MOI 
10). After the addition of the bacteria, the infected cells were centrifuged 18 min at 1100 
g and 37 °C and incubated for 1 h at 37 °C. Subsequently, the monolayers were washed 
with PBS and the medium was replaced with D-MEM containing 80 µg/mL gentamicin, 
to kill extracellular bacteria. After 2 h of incubation in gentamicin-containing medium, 
cells were washed and lysed by the addition of cold 0.5 % sodium deoxycholate (DOC, 
Sigma-aldrich) in water. Suitable dilutions were plated in triplicates on congo red agar to 
determine the number of recovered viable bacteria. 
5.19 Rabbit ligated ileal loops model 
Virulence of the various S. sonnei strains was evaluated in vivo by testing their ability to 
induce a Shigella-dependent pathology in the rabbit model of ligated ileal loops [201]. In 
the single challenge experiment, each loop was infected for 8 h with a single strain dose 
of 3*109 bacteria/loop in 500 µL of physiological saline buffer (0.9 % NaCl). Each 
condition was tested in 2 rabbits, 3 loops per rabbit. A preliminary experiment was 
performed in 2 rabbits to establish the lower S. sonnei infective dose giving a clear 
Shigella-induced pathology manifestation (doses tested: from 109 to 5*109 
bacteria/loop). Bacteria for the single challenge experiment were prepared as follows: 
1.5 mL of OD600= 0.6 Shigella glycerol stocks were diluted in 50 mL TSB medium 
(supplemented with antibiotics, if needed), and grown ON at 37 °C, 200 rpm. Bacterial 
pellets were collected by centrifugation at 4000 g, for 10 min at room temperature, the 
OD600 was adjusted to 12 (bacteria are 6*109/mL) in physiological saline buffer and 
bacterial suspensions were stored at room temp until use. In the competitive challenge 
model, each loop was infected for 16 h with two strains resulting in a total dose of 3*107 
bacteria/loop (1.5*107 bacteria of each strain/loop in 250 µL) in a total volume of 500 µL 
of physiological saline buffer. Each condition was tested in 2 rabbits, in 4 loops per 
rabbit. Bacteria for the competitive challenge experiments were prepared as follows: 500 
µL of OD= 0.6 Shigella glycerol stocks were diluted in 7 mL TSB medium (supplemented 
with antibiotics, if needed), and grown ON at 37 °C, 200 rpm. The following day, ON 
cultures were diluted in 20 mL to start at OD600= 0.05 and grown for 5 h. Bacterial pellets 
were collected, the OD600 was adjusted to 0.12 (bacteria are 6*107/mL) in physiological 
saline buffer and bacterial suspensions were stored at room temp until use. The rabbit 
illeal loop model protocol was approved by the Comite Regional d’Ethique pour 
l’Experimentation Animale in Paris 1 (protocol #20070004) and reviewed by the Global 
Animal Welfare Board of Novartis. Surgery was performed as described previously with 
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minor modifications [62]. New Zealand white rabbits weighing 2.4–2.6 Kg (Charles River 
Laboratories, St. Aubin, France) were treated for 7 days with Mucoxid (2.8 g/L sodium 
sulfadimethoxine salt in the drinking water) (CEVA Sante Animale, France) until the day 
prior to surgery to minimize infection with Coccidia parasites. Rabbits were fasted 24 h 
before infection, sedated intravenously by ear vein injection with 0.05 mL/Kg Calmivet 
(Vétoquinol) containing 0.5 % acepromazine and anesthetized by the same route with 
0.2 mL/Kg of Imalgene® 1000 (containing 10 % ketamine HCl) (Merial, France). Prior to 
laparotomy, 2 mL Xylovet (CEVA Sante Animale, France) containing 2.1 % lidocaine 
was injected intradermally in the abdomen along the site of incision. The small intestine 
was exteriorized and the cecum was localized. 12 loops of 5 cm segments of ileum 
starting at the ileum-cecum transition were ligated, avoiding all Peyer’s patches, while 
maintaining the existing vasculature. Each loop was injected with 500 µL of bacterial 
suspension using a 26-gauge needle. The injection order was randomized for each 
rabbit. Loops were returned into the abdominal cavity, the abdomen was closed and the 
animals were returned to their cage for the defined incubation time. Animals were 
sacrificed by intravenous injection of 120 mg/Kg sodium pentobarbital (Doléthal, 
Vétoquinol, France). After euthanasia of single challenged rabbits, the exudate of loops 
was measured and collected to recover bacteria for gene expression analysis. Loops 
were dissected and processed for RNA extraction, histology and bacterial counting; as 
control, uninfected tissues were collected as well. Spleen, liver and mesenteric lymph 
nodes (MLNs) were collected and processed for bacterial counting. After euthanasia of 
competitive challenged rabbits, loops, spleen, liver and mesenteric lymph nodes were 
dissected and processed for bacterial counting. Homogenized tissues were serially 
diluted and appropriate dilutions were plated on selective media to determine the 
number of recovered viable bacteria. 
5.20 Histopathological analyses of tissue samples 
For histopathological analysis of Shigella infected ileal loops and bacterial immune-
localization, intestinal biopsies were fixed at 4 °C in 4 % paraformaldehyde in PBS, 
embedded in paraffin and sectioned into 7 µm slices using a microtome. Sections were 
deparaffinated, rehydrated and used for Hematoxylin and Eosin (H&E) staining, 
GIEMSA staining or for Shigella immune staining. Immune staining was performed as 
follows. Sections were permeabilized for 15 min with the antigen unmasking solution (10 
mM Tris, 1 mM EDTA, 0.05 % Tween20, pH 9), treated with 3.3 % H2O2 for 10 min and 
washed. Samples were blocked for 15 min with Ultra V block (Lab Vision Corp; Thermo 
Scientific, cat. #TA-125UB) and incubated overnight with an in-house mouse polyclonal 
anti-S. sonnei serum (mouse polyclonal antiserum raised against Ss ∆tolR GMMA). 
Samples were then incubated with a peroxidase labelled polymer conjugated to goat 
anti-mouse immunoglobulins (DAKO, cat. #K4000) for 1 h, revealed with the 3-amino-9-
ethylcarbzole AEC+ Substrate-Chromogen (DAKO, cat. #K3461), counterstained with 
hematoxylin and mounted with aqueous mounting medium (Merck). 
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5.21 Real Time-quantitative PCR (RT-qPCR) gene expression 
analyses of rabbit cytokines and bacterial G4C operon 
Real Time-quantitative PCR (RT-qPCR) analyses were performed to measure cytokine 
genes expression in rabbit infected loops and G4C operon expression in bacteria 
collected from intestinal fluids.  
In order to measure cytokine genes expression, single challenged loop samples were 
submerged in TRIzol® Reagent (Invitrogen), homogenized with a Precellys tissue 
homogenizer (Bertin Technologies) and stored at -20 °C until further processed for RNA 
extraction. A volume of 1 mL of each sample was mixed with 200 µL chloroform, 
incubated at room temp for 5 min and centrifuged for 2 min at 12000 g at 4 °C. RNA was 
precipitated by adding 500 µL of the upper aqueous phase to an equal volume of 
isopropanol. After a centrifugation step, the pellet was washed twice with 800 µL of 70 % 
ethanol, dried and subsequently dissolved in 100 µL DEPC-treated H2O (Ambion) by 
heating the samples at 60 °C for 10 min. Subsequent RNA purification was performed 
by using the RNeasy Mini Kit (QIAGEN, cat. #74104), including the on-column digestion 
of DNA. The final RNA concentration was determined using a spectrophotometer 
(Nanodrop 2000). cDNA synthesis was performed on 10 µg of RNA in a 10 µl sample 
volume using SuperScript® II Reverse Transcriptase (Invitrogen, cat. #18064-014) as 
recommended by the manufacturer. The RNA was incubated with 0.5 µg/µL of oligo(dT) 
12-18 mer primers (Fermentas, cat. #397Y9) for 10 min at 70 °C and then transferred on 
ice. 9 mL of a master mix containing 4 µL of SuperScript II buffer, 2 µL of 0.1 M DTT 
(Invitrogen), 1 µL each of dNTPs stock (10 mM) (Invitrogen), Rnasin (40 UI) (Promega, 
cat. #N2511) and SuperScript II (Invitrogen) were added to the RNA sample, mixed and 
incubated at 42 °C for 60 min followed by 5 min at 70 °C to inactivate the enzyme. cDNA 
was stored at 4 °C until use. Rabbit primer pairs used in this study are described in ref. 
[202]. RTq-PCR reactions were performed in MicroAmp® Optical 384 Well Reaction 
Plates with Barcode (Applied Biosystems®) in a total volume of 15 µL containing 12 ng 
of cDNA, primers (0.2 µM each) and 7.5 µL of FastStart Universal SYBR Green Master 
(Roche, cat. #4913914001). Reactions were run in duplicate on an ABI PRISM 7900HT 
(Applied Biosystems) using the universal thermal cycling parameters (2 min at 50 °C, 10 
min at 95 °C, 40 cycles of 15 sec at 95 °C and 60 sec at 60 °C; dissociation curve: 15 
sec at 95 °C, 15 sec at 60 °C and 15 sec at 95 °C). Results were obtained using the 
sequence detection software ABI 7900HT SDS2.2 and analyzed using Microsoft Excel. 
For all samples, dissociation curves were acquired for quality control purposes. The 
comparative threshold cycle (Ct) method was used for gene expression quantification 
[203]. First, for each sample, the gene expression levels were normalized to the 
expression levels of the housekeeping gene encoding Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (∆Ct). Following, the difference between Ct values of samples 
from loops infected with the different S. sonnei mutants and samples from loops infected 
with S. sonnei WT was used to determine the ∆∆Ct. To determine the relative fold 
increase in gene expression in loops infected with S. sonnei mutants versus the 
condition in WT infected loops, the log2∆∆Ct was calculated.  
In order to measure Shigella G4C operon expression, exudates from single 
challenged loops were processed as described before, with minor modifications. For the 
synthesis of cDNA, purified RNA was incubated with 3 µg/µL random primers 
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(Invitrogen, cat. #48190-011) instead of oligo(dT) primers. Moreover, for gene 
expression quantification, the ∆Ct was calculated by normalizing to the expression level 
of the housekeeping gene encoding the lysine transporter LysP [204]; the ∆∆Ct was the 
difference between the ∆Cts of each mutant to the WT. The log2∆∆Ct gave the relative 
fold increase in gene expression of the mutant strain versus the WT. 
Shigella sonnei primer pairs used in this study are listed in Table 4. 
 
Table 4: List of primers used in this study for RTqPCR analysis of Shigella 
G4C operon expression 
Shigella TARGET GENE FORWARD and REVERSE PRIMER SEQUENCES 
lysP lysP.F: CCGAAACTAAAACTACAGAAGCGC 
lysP.R: CCTTCTTCAACATAGTTCTGACCG  
ymcD ymcD.F: CTTTCTGCAATCCTTATGGCCTTC 
ymcD.R: GACGTGGTGGTTGAGGTGTTATG 
ymcC ymcC.F: CACTATTTCTTGCGGGATGTACG 
ymcC.R: GTCCATTGTGGGTAACCAGCATG 
ymcB ymcB.F: CAGTCGTATTTCATTGCCAGCG 
ymcB.R: GACATGTTGGTAGTCTTTAAGCGC 
ymcA ymcA.F: CTTATCTTTTAAGCTGCCTGGCC 
ymcA.R: CCACTGGCTATATTTGCGTGTGC 
yccZ yccZ.F: GTACTGACATTGGCTGTTCTGTC 
yccZ.R: GATCCCAGACCGTAACCATCAAC  
yccY (etp) yccY.F: CTCAATCCTGGTGGTTTGTACCG 
yccT.R: GACTCCATTGCCAGAATCAGATC 
yccC (etk) yccC.F: CAGGCAGCACTCAGGAAAATGAG 
yccC.R: GATTGCAGCAGTTGGATCTCCG 
5.22 Statistical analysis 
The nonparametric Mann-Whitney test was used for two-way comparison and 
determination of the statistical significance of the differences in villi atrophy intensity 
using GraphPad (PRISM) software. Values of p< 0.001 were considered statistically 
significant and are marked on figures as ***. 
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 RESULTS 6.
6.1 Generation and immunogenicity of GMMA from S. sonnei LPS 
mutants 
The present work originated from the program at the Novartis Vaccines Institute for 
Global Health (NVGH) to develop a broadly protective vaccine against Shigella. Our 
group has engineered GMMA over-producing Shigella sonnei strains by deleting the 
tolR gene that encodes for a Tol-Pal system protein [163] from a wild type S. sonnei 
53G strain. The Tol-Pal system is a supramolecular complex in Gram-negative bacteria 
which spans the periplasm and connects the outer and inner membranes, playing a role 
in maintaining the stability of the outer membrane [205]. Previously, the deletion of tolR 
was reported to result in overproduction of GMMA without loss of membrane integrity in 
E. coli [162]. Studies focused on the characterization of S. sonnei GMMA as vaccine 
candidate against shigellosis are being performed. As already mentioned, GMMA might 
induce serotype-specific responses when produced from bacteria expressing a wild type 
LPS, as the OAg has been reported to be the immunodominant antigen in natural 
infection [41]. However, the possibility to induce broadly-protective immune responses 
directed to highly-conserved outer membrane antigens can be investigated by producing 
GMMA lacking the OAg on their surface. Figure 10, shows the schematic structure of S. 
sonnei LPS. The LPS consists of lipid A, core oligosaccharide (OS), and O-specific 
polysaccharide (O antigen) that is made of repeating saccharide subunits. In particular, 
the lipid A is embedded in the lipid bilayer of the outer membrane and consists of β-
glucosaminyl-1,6-glucosamine units interlinked by pyrophosphate bridges and O-
substituted by six fatty acids residues (lauryl-, 3-d-myristoxymyristoyl-, 3-d-
hydroxymyristoyl- and palmitoyl-  chains) [206]. The core oligosaccharide can be 
subdivided into inner and outer core domains. The outer core consists of five hexoses, 
whereas the inner core is composed of three residues of 3-deoxy-D-manno-octulosonic 
acid (Kdo), three heptoses and a glucosamine (GlcN) residue [207]. Finally, the S. 
sonnei O antigen is composed of a disaccharide repeating unit containing two unusual 
amino sugars, 2-amino-2-deoxy-L-altruronic acid (LAltNAcA) and 2-acetamido-4-amino-
2,4,6-trideoxy-D-galactose (2-acetamido-4-amino-2,4-dideoxy-D-fucose, FucNAc4N) 
[208]. The biosynthesis of LPS is a complex process involving various steps that occur 
at the plasma membrane, followed by the translocation of LPS molecules to the bacterial 
cell surface [209]. The core oligosaccharide is assembled on preformed lipid A by 
sequential glycosyl transfer of monosaccharides, while the O antigen is assembled on 
undecaprenol-phosphate (Und-P), a polyisoprenoid lipid to which O antigen is linked via 
a phosphodiester bond. These pathways eventually converge by the ligation of the O 
antigen onto the outer core domain of the lipid A-core OS acceptor, with the concomitant 
release of Und-P [210]. Mutations in the core biosynthesis genes [211] lead to deep 
rough mutants with an incomplete core, which lacks the site for the attachment of O 
polysaccharides. Mutations in wb* (formerly rfb, [211]) genes, which are involved in the 
synthesis of the O polysaccharide, give rise to rough mutants lacking the OAg but 
having a complete core. Typically, wb* gene clusters encode nucleotide sugar 
synthases (for biosynthesis of the nucleotide sugar precursors specific to O antigens), 
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and glycosyltransferases (for the sequential and specific addition of sugars that make 
the O repeating unit) [210]. Additional genes encoding functions involved in the 
assembly of the O polysaccharide are also present in the O antigen synthetic clusters, 
such as wzy (O antigen polymerase) and wzx (putative O antigen flippase) [210]. In S. 
sonnei, nine genes have been recognized to be essential for the OAg biosynthesis [84]. 
These genes include two (wbgW and wbgY) for putative glycosyl transferases and two 
(wzx and wzy) for proteins that function in the transport and polymerization of the O 
repeating units. The remaining five genes (wbgT, wbgU, wbgV, wbgX, wbgZ) of the 
cluster function to convert available nucleotide-linked sugars to the FucNAc4N and 
LAltNAcA-containing precursors of the OAg disaccharide repeating unit [84]. Moreover, 
an additional gene, wzz, participates in the Wzy-dependent biosynthetic pathway, in 
regulating chain length of LPS-linked glycans. 
With the aim to avoid GMMA serotype-specific immunogenicity, different S. sonnei 
LPS mutants were generated by deleting genes involved in LPS core and OAg synthesis 
and assembly (See Figure 10). Initially, a galU deletion mutant (∆galU) was generated 
[163]: this mutation blocks the biosynthesis of UDP glucose from glucose-1-P, a 
precursor needed for the glucosyl residues into the core region [212]. The result is the 
synthesis of an incomplete LPS core leading to a truncated LPS composed of lipid A 
and inner core [213]. In literature, S. flexneri 2a and 5a ∆galU have been characterized 
to be OAg deficient [80,184]. As a second approach, mutant strains unable to synthesize 
the repetitive unit of the OAg were generated. S. sonnei differs from the other Shigella 
strains in having a major deletion in the chromosomal O antigen gene cluster between 
the genes galF and gnd (see Figure 9), and a functional gene cluster on the virulence 
plasmid (pSS) [214]. As mentioned above, S. sonnei WT bacteria (expressing the form 
or phase I O somatic antigen) can spontaneously lose the pSS during cultivation in vitro, 
originating phase II, OAg-negative cells [193]. Therefore, in order to obtain S. sonnei 
LPS rough mutants, we either isolated colonies that had lost the virulence plasmid (S. 
sonnei 53G phase II, abbreviated as Ss -pSS) or we inactivated the OAg gene cluster 
on the virulence plasmid (Ss ∆wbg). These mutations were combined with the deletion 
of the tolR gene with the aim to obtain OAg-negative S. sonnei hyper-blebbing strains. 
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Figure 10 
 
Figure 10: S. sonnei LPS structure and sites of genetic modification. Scheme of the structure of the LPS 
molecule indicating its various regions composition: O antigen, outer core, inner core, and lipid A. 
LAltNAcA: 2-acetamido-2-deoxy-L-altruronic acid; FucNAc4N: 2-acetamido-4-amino-2,4-dideoxy-D-
fucose; Gal: galactose; Glc: glucose; GlcN: glucosamine; Hep: heptose; EtA: ethanolamine; Kdo: 3-deoxy-
D-manno-2-octulosonic acid; P: phosphate. Ss ∆galU deep rough mutant has an incomplete core, which 
lacks the site for the attachment of O polysaccharides; Ss ∆wbg and -pSS strains do not synthesize the 
repetitive unit of the OAg (Modified from [210]). 
 
 
A large amount of GMMA from the different S. sonnei mutants was purified from 
bacterial culture supernatant and characterized in respect to protein content, by 
proteomic studies. In Figure 11, Panel A, the protein pattern of S. sonnei GMMA 
carrying a WT LPS (Ss ∆tolR) or a mutated LPS (Ss ∆tolR/ -pSS; Ss ∆tolR/ ∆galU), is 
shown in a Coomassie Blue stained-SDS-PAGE. Purified GMMA were also analyzed by 
transmission electron microscopy, revealing the presence of round particles with a 
diameter ranging from 50 nm to 80 nm (Figure 11, Panel B).  
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Figure 11 
 
Figure 11: S. sonnei GMMA preparations. Panel A) 12 % Bis-Tris SDS-PAGE stained with Coomassie 
Blue; All Blue molecular weight standard. The gel is loaded with 10 µg of proteins associated to S. sonnei 
∆tolR GMMA with WT LPS, and GMMA from the LPS mutant strains, -pSS and ∆galU. Panel B) 
Representative electron micrograph of S. sonnei ∆tolR GMMA. Bar length= 200 nm. 
S. sonnei GMMA were used as antigens in different immunization studies in mice. 
Immune sera were firstly analyzed by ELISA to determine antibody titers, showing high 
levels of GMMA specific IgG [163]. In order to test the ability of the sera raised against 
GMMA to recognize surface epitopes on live bacteria and to cross react with different 
Shigella serotypes, we performed experiments of surface staining of live homologous (S. 
sonnei 53G) and heterologous (S. flexneri 2a) bacteria followed by flow cytometry 
(FACS) analysis. In particular, immune sera were tested both on S. sonnei and S. 
flexneri WT strains and on their OAg-negative isogenic mutants (Ss -pSS; Sf2a ∆rfbG). 
In fact, we produced the S. flexneri 2a 2457T strain lacking the ability to synthesize the 
OAg residues, by inactivating three genes (rfbF, rfbG, rfc) (35) of the OAg synthetic 
gene cluster on the bacterial chromosome (strain abbreviated as Sf2a ∆rfbG). The 
results of the FACS analyses are reported in Fig. 12, Panel A. We observed that sera 
against S. sonnei GMMA with OAg (α-Ss ∆tolR GMMA) stained the surface of S. sonnei 
but not of S. flexneri suggesting an O antigen-dependent serotype-specific response. 
The same sera reacted with O antigen-deficient S. sonnei and S. flexneri indicating that 
antibodies against conserved surface structures - likely proteins - were raised but that 
these proteins were not accessible in the WT strains, in the context of this in vitro assay. 
In accordance with this finding, sera raised against O antigen-deficient GMMA from S. 
sonnei (α-Ss ∆tolR/ -pSS GMMA) neither stained S. sonnei nor S. flexneri WT bacteria 
but only the surface of OAg-deficient strains. Surprisingly, sera against S. sonnei ∆galU 
GMMA, that were also thought to be O antigen-deficient, stained the homologous WT 
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strain in a serotype-specific manner. Two key observations and hypotheses result from 
these experiments. 
Firstly, S. sonnei GMMA contain conserved and immunogenic proteins but these 
surface antigens are masked in live Shigella grown in vitro under the conditions tested 
so far. Similar results have been obtained with other Gram-negative bacteria in which 
exopolysaccharide structures (EPS), either capsule or LPS, have been shown to 
interfere with antibodies binding in in vitro experiments, probably by steric hindrance 
[215]. Therefore, the staining of the surface of Ss WT in vitro is likely possible only in the 
presence of OAg-specific antibodies. Our hypothesis is that the masking effect caused 
by exopoloysaccharides is likely to be temporally and/or spatially regulated in vivo. This 
because surface proteins, e.g. iron uptake systems, must be accessible to allow survival 
of the bacteria in the host environment [216]. It has also been reported in literature that 
the accessibility of the T3SS varies on the basis of the oxygen gradient in the host’s GI 
tract [79].  Moreover, in a Shigella challenge study, we observed that immune responses 
raised by GMMA lacking the OAg protected mice from infection with S. flexneri 2a, 
suggesting that surface epitopes other than OAg must be accessible during the 
infection. Regarding S. sonnei, the situation is still unclear. A recent paper showed that 
mice immunized with IpaB alone or combined with IpaD, two components of the tip of 
the T3SS, were fully protected against lethal pulmonary infection with S. flexneri and S. 
sonnei [125].  
The second key observation of the experiment shown in Figure 12 is that GMMA from 
Ss ∆tolR/ ∆galU raised a serotype specific immune response. This response could be a 
response to proteins of S. sonnei that are not present or not conserved in S. flexneri and 
avoid the masking effect described above. Possible candidates for a protein response 
could be again proteins at the tip of the T3SS that has been reported to extend into the 
extracellular space beyond the LPS layer, at least in S. flexneri [80]. Alternatively, 
GMMA from Ss ∆tolR/ ∆galU raised an OAg response, suggesting that unlike in S. 
flexneri, the galU mutation in S. sonnei might not result in complete loss of O antigen.  
We focused our attention on the unexpected positive signal by FACS analysis 
obtained when we stained S. sonnei WT with sera raised against Ss ∆tolR/ ∆galU 
GMMA. In order to test that this positive signal was due to the presence of antibodies 
against OAg in the antisera, we performed a competitive FACS experiment. By using the 
water-phenol extraction method of Westphal and Jann [197], we purified LPS from Ss 
WT and, as control, from the Ss -pSS strain, lacking the OAg (See Figure 15, Panel A, 
Lanes b and d, respectively). We used the LPS extracts to pre-absorb Ss ∆tolR/ ∆galU 
GMMA antisera before staining the Ss WT bacteria. As shown in Fig. 12, Panel B, we 
could observe a shift of the positive signal to the left part of the plot when we tested the 
serum absorbed with the WT LPS (central histogram, dashed line). This effect was not 
detected when we used the OAg-lacking LPS extract to absorb the sera (right 
histogram, dotted line). The pre-absorption with Ss WT LPS extract abolished the 
antibody binding to the surface of WT bacteria: these results indicate that antibodies 
against OAg-containing material are present in the sera raised against Ss ∆tolR/ ∆galU 
GMMA. Our hypothesis is that Ss ∆galU is not completely OAg deficient but possess an 
immunogenic source of OAg, different from the LPS O side chain. 
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Figure 12 
 
 
Figure 12: Live Shigella surface staining and flow cytometry analysis. Representative results of three 
experiments are shown. Panel A) Surface staining of Ss WT, Ss -pSS (∆OAg), Sf2a WT, Sf2a ∆rfbG 
(∆OAg) bacteria with immune sera raised against GMMA from Ss ∆tolR (+OAg), Ss ∆tolR/ -pSS (∆OAg), 
Ss ∆tolR/ ∆galU strains. Gray profiles: staining with preimmune sera; Blue profiles: staining with GMMA 
antisera. Sera dilution is 1:1000. Panel B) Surface staining of Ss WT live bacteria with immune sera raised 
against GMMA from Ss ∆tolR/ ∆galU strain and competitive FACS analysis. Gray profiles: staining with 
preimmune sera; Blue, solid profiles: staining with Ss ∆galU GMMA antisera; Blue, dashed profile: 
staining with Ss ∆galU GMMA antisera absorbed with Ss WT LPS extract; Blue, dotted profile: staining 
with Ss ∆galU GMMA antisera absorbed with Ss -pSS LPS extract; Sera dilution is 1:10000. Bacteria 
were fixed after staining.  
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6.2 Immunogenicity of whole cell S. sonnei LPS mutants 
The previous experiment unexpectedly showed that GMMA derived from the Ss ∆tolR/ 
∆galU strain are able to raise an immune response to the OAg. We wanted to verify that 
not only GMMA but also the S. sonnei ∆galU parent strain is able to induce a serotype-
specific response by using bacteria instead of GMMA for immunizations. Therefore, we 
performed an immunogenicity study in which mice received three doses of whole 
inactivated bacteria (either heat killed, HK, or formalin fixed, FF). In particular, mice were 
immunized with S. sonnei wild type bacteria (positive control for OAg-specific 
responses), S. sonnei ∆galU and the two S. sonnei rough mutants, -pSS and ∆wbg 
(negative controls for OAg-specific responses). The rational for using the two different 
OAg-negative bacteria was their difference in the presence of the virulence plasmid and 
thus the control if there is a contribution of virulence plasmid-encoded proteins to the 
immunogenic properties of the different S. sonnei mutants. In addition, one group 
received Ss ∆galU GMMA from a new lot to confirm our previous results. We were also 
interested in analyzing if in other Shigella serotypes, specifically S. flexneri 2a, the LPS 
mutant strains are able to induce a serotype-specific response as S. sonnei ∆galU. 
Therefore three groups received inactivated bacteria of S. flexneri 2a WT, ∆galU and 
∆rfbG, respectively. The following Table (Table 5) summarizes the groups of 
immunization.  
Table 5: Immunogenicity of whole Shigella, groups of immunization 
 
Table 5: Six weeksold CD1 mice (5 mice/ group) were immunized subcutaneously on days 0, 21 and 35 
with three doses of 109 inactivated bacteria or 10 µg of Ss ∆tolR/ ∆galU GMMA. Control group received 
PBS alone. Antisera were collected before the first immunization (preimmune sera) and on day 49 (post 3 
sera).   
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Immune sera obtained from this immunization study were tested for their ability to stain 
the surface of Shigella WT by FACS analysis, as performed in the previous experiments. 
In Figure 13, Panel A, representative results of live S. sonnei WT staining with sera from 
mice immunized with formalin-fixed homologous WT and mutant bacteria are reported. 
As expected, sera raised against OAg-carrying bacteria (α-Ss WT) positively reacted 
with the surface of live S. sonnei WT (Panel A, first histogram). Sera raised against 
OAg-lacking bacteria (α-Ss ∆wbg; α-Ss -pSS) did not stain the surface of S. sonnei WT 
(Panel A, second and fourth histograms), even though they strongly reacted with S. 
sonnei bacteria lacking the OAg (Ss ∆wbg, data not shown). Again, in our in vitro 
conditions, the presence of surface polysaccharides on the bacteria used in the FACS 
experiments appears to interfere with the binding of antibodies recognizing surface 
proteins. Thus, only OAg-specific antibodies can result in a positive labeling by FACS 
analysis. This observation is also true for antibodies raised against surface exposed 
proteins encoded by the Shigella virulence plasmid, since both pSS-positive (∆wbg) and 
pSS-negative (-pSS) OAg-lacking bacteria raised immune sera not able to react with the 
surface of S. sonnei WT. Immune sera raised against the new lot of Ss ∆galU GMMA 
confirmed our previous results and strongly reacted with Ss WT (data not shown). 
Importantly, sera raised against Ss ∆galU were also able to stain the surface of 
homologous WT bacteria (Panel A, third histogram), in accordance with the results 
obtained with Ss ∆tolR/ ∆galU GMMA. Therefore, the results described in Figure 12, are 
not an artifact of GMMA immunization since similar results are obtained when we 
analyze sera from mice immunized with whole inactivated bacteria. Together these 
observations support our hypothesis that an OAg-containing material, different from the 
LPS O side chain, is expressed by S. sonnei ∆galU. This material is immunogenic in 
mice and is incorporated into or attached to the surface during the process of vesicles 
formation.  
In Figure 13, Panel B, representative results of live S. flexneri 2a WT staining with 
sera from mice immunized with formalin-fixed homologous WT and mutant bacteria are 
reported. As expected, sera raised against OAg-carrying bacteria (α-Sf2a WT) gave 
positive staining results (Panel B, first histogram), while sera against OAg-lacking 
bacteria (α-Sf2a ∆rfbG) gave negative staining results (Panel B, second histogram). 
However, in contrast to the observation that sera raised against Ss ∆galU bacteria 
reacted with the homologous WT strain, antisera against Sf2a ∆galU bacteria were not 
able to stain the surface of the homologous S. flexneri 2a WT bacteria (Panel B, third 
histogram). This indicates that the galU mutation in the S. flexneri background results in 
a complete OAg knock out, as it was previously reported in literature for S. flexneri 2a 
and 5a  [80,184,213]. 
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Figure 13 
 
Figure 13: Live Shigella surface staining and flow cytometry analysis. Representative results of three 
experiments are shown. Panel A) Surface staining of Ss WT bacteria with immune sera raised against Ss 
WT (+OAg), Ss ∆wbg (∆OAg, +pSS), Ss ∆galU, Ss -pSS (∆OAg) FF-inactivated bacteria. Panel B) 
Surface staining of Sf2a WT live bacteria with immune sera raised against Sf2a WT (+OAg), Sf2a ∆rfbG 
(∆OAg), Sf2a ∆galU FF-inactivated bacteria. Gray profiles: staining with preimmune sera; Blue profiles: 
staining with FF bacteria antisera. Sera dilution is 1:500. Bacteria were fixed after staining. 
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6.3 S. sonnei galU knock out is not a complete OAg-deficient strain 
In order to evaluate the presence of OAg in the S. sonnei galU null mutant, S. sonnei 
lipopolysaccharides were characterized by different means.  
As first step, we tested the reactivity of S. sonnei ∆galU with a commercial antiserum 
to S. sonnei O somatic antigen. The rabbit monovalent antiserum (Denka Seiken) is a 
typing antiserum for Ss phase I and has been reported to react specifically with the OAg. 
As the conventional nomenclature, the descriptor ‘phase I’ indicates a WT strain 
containing the virulence plasmid and expressing O antigen. As described below, we 
controlled that the phase I serum is OAg-specific, also in order to ensure that it does not 
cross-react with Shigella proteins. We tested the monovalent antiserum by immunoblots 
on bacterial lysate (boiled liquid cultures).  As shown in Figure 14, it did not react with S. 
sonnei OAg deficient strains, neither the strain carrying the virulence plasmid (Ss ∆wbg, 
Panel B, Lane c) nor the one lacking the plasmid (Ss -pSS, Panel B, Lane e), confirming 
that the monovalent antiserum does not react with proteins or with the LPS core. As 
expected, the antiserum strongly reacted with Ss WT lysate (Panel B, Lane b). It also 
reacted with Ss ∆galU lysate (Panel B, Lane d), where it recognized a HMW material 
with low mobility. Giving that the proteins present in Lanes b, c and d are theoretically 
equivalent and no signal is detected on S. sonnei OAg knock out strains lysates, these 
results show that the commercial antiserum against Ss phase I is OAg-specific. They 
also indicated that a high molecular weight material is present and is detected in the WT 
and the ∆galU mutant. This material is phase I-immune reactive, thus likely contains 
OAg. 
 
Figure 14 
 
Figure 14: Immunoblot analysis of Ss bacterial 
lysates with Ss phase I monovalent antiserum 
(AS) (OAg specific AS). Panel A) 12 % Bis-Tris 
SDS-PAGE and Coomassie staining of bacterial 
lysates (5*107 bacteria/lane); Panel B) WB with 
Ss phase I monovalent antiserum (Dilution is 
1:1000). Lane a= All Blue molecular weight 
standard; Lane b= Ss WT; Lane c= Ss ∆wbg; 
Lane d= Ss ∆galU; Lane e= Ss -pSS.  
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To characterize the HMW OAg-containing material detected in S. sonnei WT and 
galU mutant strains, we then purified the total cellular lipopolysaccharide from S. sonnei 
WT and LPS mutant strains, optimizing a previously described method [197] based on 
water-phenol extraction followed by ethanol precipitation. In Figure 15, Panel A, the 
characterization of LPS extracts by silver-stained SDS-PAGE is reported. The LPS 
extract from Ss WT showed the typical O antigen ladder pattern with the predominant 
chain length of 20 to 25 repeating units (O units) [84], as detected by silver stain (Fig. 
15, Panel A, Lane b). The stain also detected additional material of lower mobility, above 
the position of 25 O units. As expected, only a band corresponding to the core region 
was detected in the extract of the S. sonnei LPS rough mutant (Ss -pSS, Fig. 15, Panel 
A, Lane d). Interestingly, the extract from the Ss ∆galU strain showed slowly migrating 
material (Fig. 15, Panel A, Lane c). This material is likely not ligated to the core-lipid A 
portion since this mutant is not able to synthesize the entire core region, but only the 
inner core region [213]. The LPS extracts were extensively treated with Proteinase K 
and protein contamination should not be present in a significant concentration. Thus, the 
low mobility material likely corresponds to a high molecular weight polysaccharide.  
LPS extracts were characterized by immunoblot analyses using the Ss phase I 
monovalent antiserum and the sera raised against S. sonnei GMMA that were 
previously used in FACS experiments (Figure 15, Panel B). As the OAg-specific 
antiserum detected HMW material in the total lysates of Ss WT and ∆galU bacteria, our 
aim was to test if the HMW material detected in the lipopolysaccharide extract from Ss 
∆galU was also recognized by this serum. As expected, the monovalent AS strongly 
reacted with LPS from phase I Ss WT (Panel B, Lane b) but not with the extract from the 
phase II rough mutant (Ss -pSS, Panel B, Lane d). Interestingly, the antiserum also 
recognized the material extracted from Ss ∆galU (Panel B, Lane c), indicating that the 
slow migrating material detected by silver stain is phase I immune reactive. This 
observation is in accordance with our previous results that a HMW OAg-like material is 
expressed by S. sonnei ∆galU mutant. Subsequently, we performed the immunoblot 
analysis using the GMMA antisera. The aim was to test if the sera against Ss ∆tolR/ 
∆galU GMMA were able to stain the LPS extract from Ss WT strain. The results are 
reported in Figure 15, Panel D: Ss ∆galU GMMA antiserum clearly reacted with the WT 
extract. This result correlates with the results of the FACS experiments shown above 
and indicates the presence of antibodies against the OAg in the Ss ∆galU GMMA 
immune sera. Interestingly, antisera against Ss ∆tolR GMMA with a WT LPS (+OAg) 
reacted with the slowly migrating material of the Ss ∆galU LPS extract (Fig. 15, Panel 
C). Considering again that the LPS extracts were extensively treated with Proteinase K, 
this reaction is an additional indication that OAg-reactive material can be extracted from 
Ss ∆galU bacteria. 
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Figure 15 
 
Figure 15: S. sonnei LPS extracts and immunoblot analyses. Panel A) 12 % Bis-Tris SDS-PAGE and 
silver staining; Panel B) WB with Ss phase I monovalent antiserum (AS); Panel C) WB with Ss ∆tolR 
GMMA (+OAg) AS; Panel D) WB with Ss ∆tolR/ ∆galU GMMA AS. Sera dilution is 1:1000. Lane a= All 
Blue molecular weight standard; Lane b= Ss WT LPS; Lane c= Ss ∆galU LPS; Lane d= Ss -pSS LPS. 
The results described so far indicate that S. sonnei ∆galU, although being an LPS 
deep rough mutant, still possesses OAg. The following experiment further supported this 
observation. We tested the ability of Ss OAg-specific antiserum to stain the surface of S. 
sonnei ∆galU strain in order to verify that the OAg material previously characterized in 
SDS-PAGE and Western blot analyses is exposed on the surface of the bacteria. The 
experiment was performed with formalin fixed bacteria and the results are shown in Fig. 
16. As expected, the antiserum strongly reacted with Ss WT surface (left panel) while it 
did not stain the surface of the OAg-deficient strain Ss ∆wbg (right panel). In the central 
panel the positive staining of S. sonnei ∆galU by the Ss OAg-specific antiserum is 
shown. This result confirms that Ss ∆galU mutant express an OAg material on the 
surface, likely not the LPS O side chain. We repeated the surface staining experiment 
with live bacteria and found that the staining of live S. sonnei ∆galU bacteria with the 
OAg-specific AS is variable and much less pronounced (data not shown). Not-fixed S. 
sonnei ∆galU bacteria possibly release the OAg material into the supernatant during the 
washing steps for FACS analysis, indicating that it may be not tightly attached to the 
outer membrane. 
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Figure 16 
 
Figure 16: Surface staining of formalin fixed Ss WT, Ss ∆galU and Ss ∆wbg with Ss phase I antiserum 
(AS) followed by flow cytometry analysis. Gray profiles: staining with uncorrelated antibody (Ab) (S. 
flexneri 2a monovalent AS); Black profiles: staining with Ss phase I monovalent antiserum. Sera dilution is 
1:5000. 
6.4 Generation of S. sonnei 53G group 4 capsule (G4C) mutant 
As mentioned in the paragraph 6.1 of the present chapter, unlike the S. sonnei LPS 
rough mutants (Ss -pSS, Ss ∆wbg), strains defective in the formation of the core region 
of LPS, e.g. the galU mutant, do not possess acceptor for the O polysaccharide. 
However, they still have the ability to synthesize the OAg repeating units, since they 
possess an intact OAg synthetic gene cluster. These O units can be assembled on the 
surface of the bacteria through an alternative pathway that does not involve the linkage 
of the OAg to the LPS. Recently, several Gram-negative bacteria, like enteropathogenic 
E. coli (EPEC) [185], Salmonella enterica serovar Enteriditis [217] and Francisella 
tularensis [218], have been shown to express a capsule that based on its mechanisms 
of synthesis and assembly has been classified as a fourth group of capsule types 
(according to the E. coli capsules classification) [219]. A group 4 capsule (G4C) is a high 
molecular weight (HMW) capsular polysaccharide composed of the same repeating 
units as the LPS O side chain, thus also called ‘OAg capsule’. G4 capsules contain 
more O units than their cognate LPS and are linked to the cell surface by an unknown 
mechanism [219]. So far, Shigella has been reported to be uncapsulated. However 
genes homologous to those identified in EPEC for the group 4 capsule are present in 
different Shigella strains [185]. The results described above so far indicate that S. 
sonnei ∆galU possesses a HMW OAg material on the surface, likely not linked to the 
lipid A-core molecules.  
Our hypothesis is that S. sonnei produces a group 4 capsule and that this capsule is 
still present in the galU mutant. S. sonnei 53G possesses an intact group 4 capsule 
gene cluster (ymcDCBA, yccZ, etp (yccY), etk (yccC)) [185]. The G4C cluster, also 
called 22-minute locus [219], is reported to encode for proteins that constitute a 
polysaccharide secretion and assembly system. Homologs of two proteins of the 
system, Etk (YccC) and Etp (YccY), are frequently associated with capsule expression 
[220–222]. In EPEC, all of the seven genes of the G4C operon have been shown to be 
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required for capsule production [185]. In order to test if the same cluster is also involved 
in capsule formation in Shigella, we inactivated the whole operon in the S. sonnei WT, 
producing the Ss ∆cps mutant. The different steps of mutant generation are summarized 
in Figure 17. To delete the G4C cluster, upstream and downstream regions of the 
operon and the erythromycin cassette were amplified by PCR, producing 3 fragments of 
495 bp, 526 bp and 1150 bp, respectively, flanked by specific restriction sites (Panel A). 
The PCR products of the operon flanking regions were inserted into the pBluescript 
vector and electroporated into E. coli sub-cloning cells. The plasmid was purified and the 
erythromycin cassette was inserted into the EcoRV site between the two flanking 
regions. The resulting plasmid p∆cpsKO::erm (Panel E) was purified and controlled by 
enzymatic digestions (Panel C), obtaining fragments of the expected size. The KpnI 
linearized p∆cpsKO::erm was used as template to amplify the ∆cpsKO::erm fragment 
(2171 bp, Panel B), containing the erythromycin cassette plus the flanking regions. The 
purified product was electroporated into S. sonnei competent cells expressing the 
lambda red recombination system on pAJD434. A mutant colony, selected on 
erythromycin, was controlled by PCR using different combinations of primers, according 
to the scheme described in Panel F. All the combinations produced PCR fragments of 
the expected size (as negative control we used a colony of Ss WT, Panel D), confirming 
the integration of the ∆cpsKO::erm fragment in the correct locus and the deletion of the 
G4C cluster in the Ss ∆cps mutant. 
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Figure 17 
 
 
Figure 17: Generation of the S. sonnei group 4 capsule gene cluster deletion mutant. A) PCR products of 
G4C cluster flanking regions (upstream region= 495 bp, downstream region= 526 bp) and erythromycin 
(ery) cassette (1150 bp). B) PCR amplification of ∆cpsKO::erm construct (F) (expected size ~2171 bp) 
from p∆cpsKO::erm (E). C) Enzymatic digestion of p∆cpsKO::erm. D) Control PCR products of the Ss 
∆cps mutant in comparison with a WT colony. PCR1= control primer internal to the erm gene 
(Ery.ctr.int.F) combined with primer annealing in the external region of the integrated ∆cpsKO::erm 
construct (cps.ext.5) (expected size for the Ss ∆cps mutant is ~964 bp, for the wild type strain no product 
is expected); PCR2= primers external to the integrated ∆cpsKO::erm construct (cps.ext.5, cps.ext.3) 
(expected size for the Ss ∆cps mutant is ~2214 bp, for the wild type strain a fragment of ~8797 bp is 
expected, however due to the large size, it is unlike to obtain a product in the conditions used for the PCR 
reaction). E) Schematic representation of p∆cpsKO::erm with the restriction sites used for the cloning 
procedure. F) Schematic representation of ∆cpsKO::erm construct with the primers used to control the S. 
sonnei ∆cps colony. 
In addition, we produced a hyper-blebbing S. sonnei ∆tolR strain in which the 
presence of the virulence plasmid, pSS, and therefore the ability to synthesize the OAg 
units can be selected. We inserted a chloramphenicol resistance cassette in the 
virulence plasmid locus encoding for the VirG protein [223]. As a result, by growing the 
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Ss ∆tolR/ ∆virG strain on selective medium, we can avoid the spontaneous loss of the 
pSS that naturally occurs during S. sonnei manipulation in vitro [193]. In this background 
we performed the G4C gene cluster knock out, generating the S. sonnei ∆tolR/ ∆virG/ 
∆cps. 
If the gene cluster is essential for G4C synthesis, we expect that Ss ∆cps still 
possess OAg as LPS side chain but not as capsular polysaccharide. We previously 
observed that GMMA from Ss ∆tolR/ ∆galU induced an OAg-specific immune response. 
In the hypothesis that S. sonnei possesses a G4C, this would mean that GMMA 
incorporate the capsular PS expressed by the parent strain during their formation. 
Again, if the G4C operon is functional in S. sonnei, we expect that GMMA produced 
from the S. sonnei ∆tolR/ ∆virG/ ∆cps possess the LPS O side chain but not the OAg 
capsule. Exopolysaccharides obtained from the different S. sonnei mutants were 
biochemically characterized, and results are reported in the following paragraph. 
6.5 Outer membrane polysaccharide analysis: the HMW capsular PS 
As mentioned before, GMMA reflect the outer membrane composition of Gram-negative 
bacteria and are enriched in envelope components as outer membrane proteins and 
also LPS and exopolysaccharides, while they contain only irrelevant impurities of DNA 
and cytoplasmic components [140]. Therefore, these outer membrane particles released 
from intact cells represent an ideal tool to study Gram-negative periplasm and outer 
membrane compartments [162]. Based on these considerations, we used GMMA as 
outer membrane enriched-preparations to extract LPS from ∆tolR mutants of S. sonnei 
with a WT LPS (either the strain with a WT pSS or the ∆virG strain), from the LPS 
mutants ∆galU and ∆wbg and from the ∆virG/ ∆cps strain. Giving the fact that the 
mutation in the virG gene only has the function to avoid the loss of the pSS in in vitro 
grown S. sonnei without affecting the quality of the LPS, the virG null mutation is not 
mentioned in the following paragraphs for simplicity. LPS extracts from the outer 
membrane particles were then used in further biochemical analyses. In Figure 18, the 
experimental design is schematically described. Ss WT, ∆OAg (either the ∆wbg or the  
-pSS strain), ∆galU and ∆cps strains are represented on the basis of the expected 
phenotypes: wild type Ss can form both LPS O side chains (thick black broken line) and 
O antigen capsule (gray zone around the bacteria). Mutants deficient in repeat unit 
synthesis or polymerization (wbg mutant), are expected to lack both LPS O side chains 
and O capsule (the thin dotted line represents the smooth outer membrane). G4C gene 
cluster mutants are expected to be deficient in O-capsule formation but to possess LPS 
O side chain (represented by the thick black broken line). In the E. coli background, it 
was shown that G4C mutants possess an increased amount of LPS OAg, probably due 
to the fact that the complex that connects the O side chain to the LPS is no longer 
competing with the capsule forming system for the same substrates, the O-repetitive 
units [185,224]. By transferring the LPS/capsule null mutations in the ∆tolR background, 
highly concentrated GMMA preparations are obtained from these strains. 
Lipopolysaccharides are separated in the water phase during the water-phenol 
extraction and analyzed by SDS-PAGE followed by silver staining and immunoblot, as 
described before. In order to better characterize the polysaccharides, LPS extracts are 
then treated by mild acid hydrolysis to remove the lipid A of the LPS [116]. The resulting 
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samples, containing the exopolysaccharides specifically expressed by each strain, are 
significantly devoid of impurities such as proteins or nucleic acids, and represent 
suitable preparations for further biochemical analyses, such as HPLC-Size Exclusion 
Chromatography (HPLC-SEC) and NMR. 
 
Figure 18 
 
Figure 18: Outer membrane LPS and polysaccharides purification strategy. From the left, schematic 
representation of the expected phenotype of Ss WT and LPS/capsule mutants. LPS/capsule mutations 
are transferred in the ∆tolR background to produce highly concentrated GMMA. GMMA are used as outer 
membrane preparations to extract the lipopolysaccharide samples. Finally, mild acid hydrolysis of LPS 
leads to pure polysaccharides, characterized by negligible amount of proteins and DNA contamination 
(Modified from [210,224]).  
In Figure 19, the results of the surface polysaccharides (PS) analyses are reported. 
SDS-PAGE loading material was normalized to GMMA-associated protein concentration 
of the starting material for the extraction. LPS extracted from S. sonnei GMMA showed a 
similar pattern after silver stain as the LPS from bacterial liquid cultures (Fig. 19, Panel 
B, compared to Figure 15, Panel A). In particular, the typical LPS ladder is revealed in 
the Ss ∆tolR GMMA (WT LPS) extract, while only the band corresponding to the entire 
core or the inner core region is present respectively in the ∆tolR/ ∆wbg (LPS rough 
mutant) and in the ∆tolR/ ∆galU (LPS deep rough mutant) GMMA extracts. In this 
experiment, we did not observe a significant presence of slow migrating material in the 
∆galU extract but we confirmed the presence of HMW phase I immune reactive material 
by performing immunoblot analyses with the Ss OAg-specific monovalent antiserum 
(data not show). We purified the LPS from Ss ∆cps bacteria and GMMA and we 
compared it with the WT LPS pattern. The material extracted from the two different 
sources looked very similar for the corresponding strains (data not shown). In Figure 19, 
Panel D, the silver-stained SDS-PAGE analysis of the GMMA-derived LPS is reported. 
The LPS pattern of Ss ∆tolR/ ∆cps GMMA showed only slight modifications as 
compared to the WT pattern, with bands corresponding to low molecular weight (LMW) 
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LPS species being more intense and with a little shift of the starting site of the smear 
corresponding to the low mobility material above the 25 O units band. In order to better 
characterize the polysaccharide distribution in terms of molecular weight, PS extracts 
were then treated by mild acid hydrolysis in 1 % acetic acid. This reaction was 
previously characterized in the literature to detach the lipid A from the core-OAg portions 
of the LPS, without affecting the polysaccharide moiety integrity [116]. After hydrolysis 
neutralization, we collected the polysaccharide samples, that were analyzed by HPLC-
SEC chromatography coupled with a differential refractive index (dRI) detector. Profiles 
at 214 nm and in the fluorescent emission were also acquired to monitor respectively 
eventual DNA and protein contaminations, indicating that impurities amount was 
negligible (data not shown). Results in the dRI are reported in Figure 19, Panels A and 
C:  
- the chromatogram of the Ss ∆wbg PS (Panel A, dotted line) had a single peak of a 
low molecular weight population and our hypothesis is that this signal corresponds to 
the core sugars of the LPS, as this mutant can not synthesize OAg sugars; 
- the chromatogram of the Ss WT PS (Panel A, solid line) showed the presence of 
three different populations: the population in the LMW range of the graph (retention 
time of 17.8 min) partially overlaps with the one present in the Ss ∆wbg PS and 
could correspond to the core sugars linked to few repeating units of the OAg. The 
major peak in the medium molecular weight (MMW) range (retention time of 15.1 
min) could correspond to the predominant OAg population of 20-25 repeating units, 
as reported in literature [84]. The peak with the lowest elution time of 12.3 min 
corresponds to a HMW-PS population, likely composed of OAg sugars as well, since 
both the MMW and the HMW populations are absent in the PS from the OAg-
deficient strain; 
- two peaks were revealed in the chromatogram of the Ss ∆galU PS (Panel A, dashed 
line): one had a higher retention time than the signal obtained from the Ss ∆wbg PS 
and we hypothesize that it could match with the shorter core region of the LPS (inner 
core) that the Ss ∆galU possesses. Interestingly, the other peak had a similar 
retention time as the HMW population of the Ss WT PS. Therefore this peak could 
correspond to the HMW capsule polysaccharide. 
However, one of the most decisive proofs of the presence of a G4C in Shigella sonnei 
was obtained from HPLC-SEC analysis of the hydrolyzed EPS from Ss ∆cps GMMA 
(Panel C, dashed-dotted line).  
- While the chromatogram of the WT PS (solid line) revealed the presence of three 
major populations, the chromatogram of the ∆cps PS (dashed-dotted line) revealed 
only the MMW and LMW populations, eluting at the same time as the corresponding 
populations of the WT sample. More importantly, the peak corresponding to the 
HMW-PS population was completely absent in the chromatogram of the Ss ∆cps PS. 
These results clearly support the hypothesis that S. sonnei express a capsule, a 
HMW polysaccharide that is no more present in the null mutant for the G4C secretion 
and assembly system. As the Ss ∆cps mutant can still synthesize the OAg side chain 
of the LPS, the major peak in the MMW range is likely raised by the most 
representative population of the OAg of the LPS linked to the core, while the LMW 
population represents a shorter polysaccharide composed of few OAg repeating 
units and core sugars. The LMW-PS is more pronounced in the ∆cps PS in terms of 
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relative amount: as it was shown in literature for EPEC G4C mutants, in the absence 
of the capsular PS the amount of OAg on the LPS seems to increase [185]. 
If the HMW-PS population is the G4 capsule, it should comprise OAg residues. 
Following sugar composition analyses further confirmed our hypothesis. WT and ∆galU 
exopolysaccharide extracts were fractionated by HPLC-SEC and eluted samples were 
collected to isolate the different PS populations (HMW-PS= from 11.5 min to 13 min; 
MMW-PS= from 14 min to 16 min; LMW-PS= from 17 min to 18 min). 1H-NMR analysis 
was performed on isolated fractions in order to understand their composition in terms of 
OAg residues. The structure of the S. sonnei OAg repeating units is reported in Figure 
19, Panel E,  and the composition of the Ss LPS core is reported in Figure 10  [84,116]. 
The spectra of the high, medium and low molecular weight fractions composing the WT 
PS contain the typical signals belonging to protons of the 2-Acetamido-2-deoxy-L-fucose 
(FucNAc4N) and the 2-Acetamido-2-deoxy-L-altruronic acid (L-AltNAcA) residues of the 
Shigella sonnei OAg (Figure 19, Panel F) [116,208]. In particular, signals at 1.34-1.36 
ppm belong to protons of the methyl group of the FucNAc4N (3 protons – round 
symbol), while signals at 2.00-2.04 ppm belong to protons of the N-acetyl groups (2 
groups with 3 protons each – triangular symbol) of the FucNAc4N and the L-AltNAcA. 
Integration of these signals in the spectra of the HMW-PS and the MMW-PS fractions 
confirmed the expected ratio of 6:3 in terms of number of protons per signal. The 
spectrum of the LMW-PS was not optimally resolved, however it likely comprises few 
OAg units and LMW degradation products. By NMR we were able to demonstrate that 
the three PS populations of the Ss WT extract are made up of OAg residues. Similar 
results were obtained when we analyzed the HMW-PS of the ∆galU extract (data not 
shown). Importantly the HMW-PS that we think represents the group 4 capsule 
polysaccharide, comprises OAg residues.  
For the most concentrated fraction corresponding to the MMW-PS we could quantify 
the number of OAg repeating units per core unit in an analysis of 1H-NMR with an 
increased acquisition time (Figure 19, Panel G). Anomeric signals of outer core α-Gal in 
the terminal position (5.82 ppm) and α-Gal in the internal position (5.62 ppm) were 
detected. The ratio between the signals of the FucNAc4N and the L-AltNAcA N-acetyl 
groups (2.00-2.04 ppm) on the signals of the outer core α-Gal residues (5.82-5.62 ppm) 
gives an estimation of the number of the OAg repeating units attached to the core. We 
determined that the MMW-PS fraction possesses about 23 OAg RUs. This result is in 
line with what reported in literature for the predominant OAg species of the S. sonnei 
LPS side chain [84].  
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Figure 19 
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Figure 19: S. sonnei surface lipopolysaccharide and exopolysaccharide (EPS) analyses. Panels A) and 
C) HPLC-SEC analysis of outer membrane preparations of S. sonnei EPS after mild acid hydrolysis; EPS 
from GMMA of Ss ∆tolR/ ∆virG (WT EPS) (solid line), Ss ∆tolR/ ∆galU (dashed line), Ss ∆tolR/ ∆wbg 
(dotted line), Ss ∆tolR/ ∆virG/ ∆cps (dashed-dotted line). Polysaccharide samples run on TSK gel G3000 
PWXL-CP column and peaks are detected by differential refractive index (dRI). Panels B) and D) 12 % 
Bis-Tris SDS-PAGE and silver staining of LPS extracts from GMMA of Ss ∆tolR/ ∆virG (WT LPS, lane a), 
Ss ∆tolR/ ∆galU (Lane b), Ss ∆tolR/ ∆wbg (Lane c), Ss ∆tolR/ ∆virG/ ∆cps (Lane d). Panel E) S. sonnei 
OAg repeating unit; round and triangular symbols highlight the groups detected by NMR analyses. Panel 
F) 1H-NMR spectra of S. sonnei WT exopolysaccharide fractions;  integrals of signals of the N-acetyl 
groups of the FucNAc4N and the L-AltNAcA OAg residues at 2.00 and 2.04 ppm (triangular symbol) and 
of the FucNAc4N methyl group at 1.34–1.36 ppm (circular symbol) are reported (symbols refer to residues 
in Panel E); Panel G) Determination of the number of OAg RUs attached to the core: 1H-NMR spectrum of 
S. sonnei WT MMW fraction; integrals of the signals of the N-acetyl groups of the FucNAc4N and the L-
AltNAcA OAg residues at 2.00 and 2.04 ppm, of the FucNAc4N methyl group at 1.34–1.36 ppm and of the 
core α-Gal residues at 5.82 and 5.62 ppm are reported. 
It has been mentioned before that OAg repeating units that are part of the capsule are 
assembled and linked to the surface of bacteria independently of the LPS [219]. 
Therefore a pure group 4 capsule polysaccharide should not comprise sugars of the 
core region of the LPS. 3-deoxy-D-manno-octulosonic acid (Kdo) is one of the sugar 
residues in the inner core region of the LPS of Shigella and represents the reducing end 
of the LPS polysaccharide side chain upon lipid A removal by acid hydrolysis [207,225]. 
We optimized a Kdo quantification method [199] to be suitable for HPLC-SEC analysis 
and we estimated the presence of Kdo moiety in the three PS fractions isolated from the 
S. sonnei WT EPS. After the derivatization with a semicarbazide reagent, 
polysaccharides containing Kdo absorb at 252 nm (Figure 20, square box). We 
demonstrated that the MMW-PS (Fig. 20, dashed line) and the LMW-PS (Fig. 20, dotted 
line) gave a signal at 252 nm, indicating that they comprise Kdo residues, hence they 
likely derive from the LPS side chain. Conversely, the HMW-PS (Fig. 20, solid line) did 
not absorb at 252 nm, so it doesn’t seem to contain Kdo moieties. It is important to 
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notice that the results of this assay are concentration-dependent and further analyses 
should be performed in order to confirm this observation and to exclude an 
underestimation of the Kdo content in the HMW-PS. However, the current results from 
the semicarbazide assay, together with the NMR results are in accordance with our 
hypothesis that the HMW population of the Ss WT polysaccharide is the G4C 
polysaccharide. 
 
Figure 20 
 
 
Figure 20: Estimation of Kdo moiety in the S. sonnei WT polysaccharide populations. Chromatograms of 
PS fractions derivatized with semicarbazide (reaction is described in the square box) and analyzed by 
HPLC-SEC on TSK gel G3000 PWXL-CP column (peaks are detected at 252 nm); solid line: HMW-PS; 
dashed line: MMW-PS; dotted line: LMW-PS. 
6.6 Electron Microscopy analysis of S. sonnei LPS and capsule 
mutants 
All together results described so far indicate that S. sonnei possess a HMW-capsule 
polysaccharide, comprising the same residues as the LPS O side chain and therefore 
classified in the fourth group of the OAg capsules. The formation of the G4C in S. sonnei 
does not depend on the LPS assembly, since the ∆galU LPS deep rough mutant still 
possess the capsule polysaccharide. The protein complex encoded by the 22-minute 
locus [219] is responsible for the assembly of the G4C in S. sonnei, as it was reported 
for pathogenic E. coli [185]. To further support these notions, we examined the LPS and 
capsule mutants by transmission electron microscopy (TEM) and compared them with 
the WT strain. Representative electron micrographs are reported in Figure 21. A thick 
dark layer of electron-dense material was seen at the surface of wild type S. sonnei 
bacteria (left, upper panel). This layer likely corresponds to extracellular polysaccharides 
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(LPS O side chain and OAg capsule) as it was completely absent in the OAg-deficient 
strain Ss ∆wbg (left, lower panel). S. sonnei ∆cps mutant possessed just a narrow dark 
layer (right, lower panel), likely corresponding to the LPS O side chain. On the contrary, 
Ss ∆galU had a very thick layer (right, upper panel), likely corresponding to the capsular 
polysaccharide. This material protruded from the outer membrane in a way that 
suggests that the EPS in Ss ∆galU is not tightly attached to the bacterial surface. This 
would be in agreement with our previous observation according which the surface 
staining of live S. sonnei ∆galU bacteria with the OAg-specific antiserum is variable and 
much less pronounced of the staining of formalin-fixed bacteria, as S. sonnei ∆galU 
tends to easily release the capsular PS in the environment. 
 
Figure 21 
 
Figure 21: Surface analysis of S. sonnei WT and LPS/capsule mutants. Representative micrographs of 
negative staining-Transmission Electron Microscopy (TEM) and ultrathin resin sectioning analysis after 
samples fixation and treatment with Alcian blue. The electron-dense material at the bacterial surface 
corresponds to extracellular polysaccharides. Scale bars: 100 nm. 
The extension of the dark layer from the surface of the different strains has been 
estimated as the average thickness measured in different positions along the bacterial 
membrane. As it is reported in Table 6, the absolute values were not so impressive, 
probably due to an artifact of the EM technique used in this study, that doesn’t maintain 
the EPS structure in its native form. However the relative differences between the 
strains support the characteristics of the expected phenotypes. The WT polysaccharide 
layer resulted about two times thicker than the ∆cps one, while, as expected, the layer 
was not detected in the ∆wbg OAg-negative strain. Ss ∆galU had a very remarkable 
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surface phenotype with an average layer thickness of about 25 nm. Two hypotheses 
could explain why we observed this big difference with the WT strain (7 nm layer 
thickness): it could be that, with the impossibility of a linkage with the core-lipid A 
molecules, all the O units are assembled to form a higher amount of the capsule 
polysaccharide in Ss ∆galU. Alternatively, it could be that in the presence of the LPS 
side chain, the OAg forms a highly ordered structure with the capsule giving rise to a 
more condensed EPS (as observed in the WT strain), while in the absence of the LPS 
side chain, the capsule protrudes chaotically and with a variable extent from the outer 
membrane (as observed in the ∆galU strain). 
Table 6: Thickness of the outer layer 
 
 
Table 6: Estimated thickness of the EPS outer 
layer measured on electron micrographs of S. 
sonnei WT and LPS and capsule mutant strains 
(nm, average of 20 different measurements).  
 
 
 
 
 
6.7 S. sonnei capsule and type III secretion system (T3SS) exposure 
The present study is the first report of a capsule in Shigella. Bacterial capsules are well 
established virulence factors, often acting by protecting the cell from 
opsonophagocytosis and complement-mediated killing [219]. They have also been 
recognized to play an important role in affecting the functionality of other virulence 
factors. For example, capsule can masks the function of E. coli short adhesins [226] and 
this phenomenon is not restricted to adhesins but it was also reported for other factors in 
different bacteria, including Klebsiella pneumonia fimbriae [227] and Neisseria pili [228]. 
The virulence of Shigella is mainly mediated by the activity of an array of plasmid-
encoded virulence factors among which the type III protein secretion system (T3SS) is 
one of the most important [69]. To establish whether the presence of the capsule affects 
the exposure of T3SS molecules on the surface of S. sonnei, we examined bacteria by 
FACS analysis after immunolabeling with a monoclonal antibody against IpaB, which is 
both secreted and exposed at the T3SS tip [70]. Results are reported in Figure 22, 
Panel A: IpaB monoclonal antibody did not react with the surface of S. sonnei WT 
bacteria, while it reacted with S. flexneri. It is important to notice that the IpaB antibody 
used in this assay was raised against S. flexneri 5a M90T protein (H16, mouse 
monoclonal Ab, [196]). Even if the epitope used to generate the antibody differs only of 
one aminoacid if compared to the corresponding epitope in S. sonnei, it is possible that 
the affinity of the antibody for S. sonnei IpaB is too low and the surface-bound 
S. sonnei
strain
Outer layer
average tickness
(nm)
WT 7.0
∆cps 3.8
∆galU 25.6
∆wbg 0.0
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fluorescence was under the detection limit. This could also explain the weak reaction of 
the Ab with the S. sonnei lysate observed in the western blot analysis, as compared to 
the stronger reaction with the S. flexneri lysate (Panel B, 62 KDa band). Another 
possibility is that S. sonnei possesses less T3SS molecules on the surface per cell, as 
compared to S. flexneri. In any case, when we tested the IpaB Ab on the S. sonnei 
capsule negative strain (∆cps), a small shift of the fluorescent signal towards the 
positive gate of the plot was observed, indicating that, regardless the level of affinity of 
the antibody for the S. sonnei IpaB protein, the T3SS tip was more accessible in the 
absence of the capsule polysaccharide. The accessibility of the IpaB antigen was even 
increased in the S. sonnei and flexneri strains lacking both the LPS O side chain and the 
OAg capsule (Ss ∆wbg, Sf2a ∆rfbG). As expected, S. sonnei -pSS was not recognized 
by the IpaB antibody. Studies on S. flexneri showed that glucosylation of the LPS O 
antigen, via a bacteriophage-encoded enzyme, shortens the OAg and thus enhances 
the T3SS function, indicating that the WT strain has evolved a phenotype in which the 
structure of the surface polysaccharides is optimized for virulence [80]. For S. sonnei 
there is no characterization of the role of exopolysaccharides in relationship to other 
surface virulence factors. The flow cytometry analysis of in vitro grown S. sonnei 
suggests that the presence of a capsule, specifically in S. sonnei, can affect the 
exposure of the T3SS and thus the virulence abilities of the pathogen. Further studies 
are being performed to study more in deep the T3SS accessibility in the different 
mutants by immunogold labeling and TEM analysis. However results reported in this 
paragraph are in agreement with what reported for Enterohemorrhagic and 
Enteropathogenic E. coli (EHEC and EPEC): it has been shown that the group 4 capsule 
can transiently shield the type three secretion systems having an impact on the host-
pathogen interaction [224]. 
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Figure 22 
 
Figure 22: IpaB exposure on the surface of S. sonnei and S. flexneri. Panel A) Surface staining of S. 
sonnei and S. flexneri WT and mutant strains with a monoclonal antibody (Ab) against IpaB and FACS 
analysis (red profiles). Ab dilution is 1:50. Gray profiles: staining with the secondary Ab. Panel B) 12 % 
Bis-Tris SDS-PAGE and Coomassie staining of bacterial lysates (5*107 bacteria/lane) and WB analysis 
with the monoclonal Ab against IpaB (Dilution is 1:1000). All Blue molecular weight standard; Lane a= Ss 
WT; Lane b= Sf2a WT. 
6.8 Complementation of the G4C operon in S. sonnei cps strain 
The S. sonnei capsule mutant complemented with a plasmid expressing the group 4 
capsule gene cluster was produced. In particular, the complementing plasmid 
p∆cpsCOMPL (Figure 23, Panel A) was generated by cloning the whole G4C cluster 
[185] with its promoter region in the low copy number vector pACYC184. The G4C 
operon was amplified with the 280 bp upstream region by using the LongRange PCR Kit 
(PCR product of 8032 bp, Fig. 23, Panel B) and it was cloned in the XbaI and SalI 
restriction sites of the cloning vector (Panel C). After a passage into E. coli sub-cloning 
cells, the plasmid was purified by miniprep and controlled by enzymatic digestions 
(Panel D), obtaining fragments of the expected size. The purified p∆cpsCOMPL was 
		

electroporated into S. sonnei ∆cps competent cells. The complemented colony, named 
Ss ∆cps(cps), was selected on chloramphenicol and on Congo-red supplemented agar, 
in order to verify the compatibility of the pSS virulence plasmid with the complementing 
plasmid. The LPS of the Ss ∆cps(cps) strain was purified, as described before, and 
compared with the WT LPS: the typical LPS pattern was revealed by silver staining in 
the complemented strain extract, with the smear corresponding to the low mobility 
material starting at the very high molecular weight region of the SDS-PAGE, as for the 
WT sample (data not shown). Moreover, a preliminary HPLC-SEC analysis on the total 
cellular polysaccharide confirmed the restoration of the expression of the HMW-PS 
population (data not shown). The Ss ∆cps(cps) possesses a higher copy number of the 
G4C cluster with respect to the WT strain. Electron microscopy analyses are being 
performed in order to verify that it express a WT level, if not a higher amount, of capsule 
polysaccharide. 
 
Figure 23 
 
Figure 23: Generation of S. sonnei cps strain complemented with a plasmid expressing the G4C gene 
cluster with its promoter region. A) Schematic representation of p∆cpsCOMPL complementing plasmid, 
with the restriction sites (XbaI, SalI) used for the cloning procedure and carrying the G4C operon (8032). 
The tetracycline cassette of the cloning vector is inactivated by the insertion of the G4C operon, while the 
chloramphenicol cassette is used for colony screening. B) PCR amplification of the G4C operon by 
LongRange PCR kit from a WT colony of S. sonnei. C) p∆cpsCOMPL miniprep product, compared to 
parent pACYC184 cloning vector. D) Control enzymatic digestion of p∆cpsCOMPL and deriving products 
of the expected size.  
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6.9 G4C functional characterization: in vitro HeLa cells invasion 
assay 
We hypothesized that the expression of the group 4 capsule contributes to the virulence 
of S. sonnei through an effect on its invasive potential. Therefore, to investigate whether 
the capsule plays a role in S. sonnei-host cell interaction, we infected in vitro human 
epithelial cells and we compared the invasiveness of Ss ∆cps and Ss ∆cps(cps) with the 
WT strain. Semi-confluent HeLa cell layers were incubated with a multiplicity of infection 
(MOI) of 10 bacteria/cell for 1 h. After killing extracellular bacteria by adding gentamicin, 
intracellular bacteria were collected by lyzing the infected cells. CFU were counted and 
results are reported in Fig. 24. The S. sonnei G4C mutant exhibited significant increased 
invasiveness, being about 100 times more invasive than the WT strain. Complementing 
the ∆cps mutant with a plasmid expressing the G4C operon restored the WT-like lower 
invasiveness and even reduced it up to 3 folds. As expected, the Ss phase II (-pSS) 
strain was completely avirulent and did not invade HeLa cells [193]. These interesting 
results suggest that the presence of the capsule polysaccharide accounts for the 
changes in cell invasion: Ss ∆cps increased invasive ability could derive from the fact 
that in the absence of the capsule, virulence factors, as the T3SS, are rapidly available 
and exposed and the strain might result in higher cell entry proficiency. On the other 
hand, Ss ∆cps(cps) complemented strain is less invasive than the WT strain and we 
hypothesize that it could be so because this strain is “over-complemented”, expressing a 
higher amount of capsule polysaccharide and resulting in an attenuated phenotype. 
These speculations correlate with several other findings. First of all, if we compare S. 
sonnei and S. flexneri for their invasive potential in vitro, we always observe that S. 
sonnei is much less invasive than flexneri, with at least 10 folds of difference (data not 
shown). The attenuated phenotype of Ss WT could derive not only from its natural 
tendency to lose the virulence plasmid, but also to its peculiar ability to express a 
capsular polysaccharide. It has been reported in literature, for example, that the 
expression of Vi capsule PS is implicated in reducing the invasiveness of S. enterica 
serotype Typhi [229]. Moreover, a recent paper published by Shifrin, Y. et al. reported 
that EPEC mutants in the G4C operon similarly exhibited increased invasiveness at 
early time points postinfection [224]. In the same paper, it has been shown that the 
capsule can transiently shield the T3SS apparatus and other virulence factors. This 
masking inhibits the attachment of EPEC to tissue-cultured epithelial cells and 
attenuates TTSS-mediated protein translocation into host cells. The authors 
demonstrated that reciprocal regulation of capsule and surface virulence factors resulted 
in a more efficient pathogenic phenotype not only in vitro but more importantly also in 
vivo [224]. 
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Figure 24 
 
Figure 24: HeLa cells invasion assay. 
Y axis: Shigella CFU per 105 cells. 
HeLa cells were infected with S. sonnei 
WT, ∆cps, phase II (-pSS), ∆cps(cps). 
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6.10 G4C functional characterization: in vivo rabbit model of ligated 
ileal loops 
Shigellosis is an acute infection of the large intestine of the human being, characterized 
by severe mucosal inflammation, bacterial invasion in the epithelial layer, abscesses 
formation and tissues disruption [53]. The rabbit ligated ileal loop model is permissive to 
intestinal infection by Shigella and results in rupture, invasion and inflammatory 
destruction of the epithelium typical of shigellosis. The influx of PMNs observed in this 
model allows reliable quantification of the invasive phenotype, therefore it represents a 
good model for the validation of the invasive/inflammatory phenotype of Shigella 
mutants compared to wild type strain [70]. In this study, the rabbit ligated intestinal loop 
model of experimental shigellosis was used to investigate whether the G4 capsule 
contributes to the invasive abilities of S. sonnei in vivo and to the induction of 
inflammatory host response during the infection. In this model, severity of tissue 
inflammation can be evaluated by recording qualitative and quantitative alterations of the 
intestinal mucosa and by measuring pro-inflammatory host gene expression. Moreover, 
local and peripheral invasiveness can be estimated by bacterial counts in infected 
tissues. First of all, we determined the lower infectious dose giving rise to the typical 
Shigella-induced pathology by testing increasing doses (from 109 to 5*109 bacteria/loop) 
of different S. sonnei strains. We ended up with an optimal dose of 3*109 bacteria/loop, 
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an amount very similar, even if a little bit higher, to what is commonly used in the S. 
flexneri model [202]. Then, the animal study was designed to perform both a single 
challenge experiment and a competitive challenge experiment. In the single challenge 
experiment, ligated loops were infected with 3*109 bacteria/loop of S. sonnei WT, or Ss 
∆cps mutant, or Ss ∆cps(cps) strains. As negative control, we also tested the Ss phase 
II (-pSS) strain. Each condition was repeated in at least 6 loops, divided in two different 
animals. The infection was conducted for 8 h, after that infected tissues were collected 
for bacterial count, histopathology analysis and gene expression analysis. In the 
competitive challenge experiment, each loop was inoculated with a total dose of 3*107 
bacteria of a 1:1 combination of two S. sonnei strains (Ss WT + Ss ∆cps, Ss WT + Ss 
∆cps(cps), Ss WT + Ss -pSS). Each condition was tested in at least 8 loops, divided in 
two different animals. The infection was conducted for 16 h, after that infected tissues 
were collected for bacterial count on selective media.  
Data obtained from the single challenge experiment describe the specific behavior of 
each strain in the host environment. The analysis starts with loops observation at the 
moment of biopsies collection: the invasive phenotype of wild type S. sonnei correlated 
with the presence of fluids and blood in the infected loops whereas the non-invasive 
strain (Ss -pSS) barely caused fluid production and loops looked flat as the uninfected 
tissue. Interestingly, Ss ∆cps strain caused maximum fluid and blood accumulation, with 
loops having pale outer surface and showing a very intense inflammatory pathology. On 
the contrary, the Ss ∆cps(cps) complemented strain elicited an intermediate phenotype, 
very often less severe than the WT.  
Histopathological analysis supported the qualitative data provided above. 
Representative pictures of Hematoxylin and Eosin (H&E) stained slices showed 
alterations of villi (Figure 25, Panel A). In the characteristic lesions observed after 
infection by the wild type strain (Panel A, first picture), the villi were shortened and 
enlarged, with several indentations forming the characteristic Christmas tree-like shape, 
typical of intestinal inflammation. Several regions of tissue disruption were observed and 
infiltration of inflammatory cells was also detected within the lamina propria and in the 
edematous submucosal tissues. Notably, infection of ileal loops by the Ss ∆cps strain 
led to dramatic alterations of mucosal tissues with rupture and destruction of the 
intestinal epithelium (Panel A, second picture). The lesions included extensive zones of 
epithelial detachment and loss of villi with tissue necrosis, leaving crypts as the only 
identifiable epithelial structure. Often, submucosal tissues were strongly edematous, 
with a large area infiltrated by inflammatory cells between the residual mucosae and the 
muscular layer. In contrast, villi of loops infected by the Ss ∆cps(cps) complemented 
mutant showed a decrease in the pattern of pathology (Panel A, third picture). Villi 
remained in general of a length and a width very similar to those observed following 
infection with the avirulent strain (Ss phase II, fourth picture). A limited edema was 
observed with few cells infiltrating the lamina propria. Regions of tissue lesions were 
rather scarce. Finally, villi of loops infected with the avirulent strain Ss phase II (-pSS) 
appeared long and narrow, with no evidence of rupture of the epithelial lining, no 
significant infiltrate of the lamina propria, and no submucosal edema (Panel A, fourth 
picture). As control, the section of uninfected tissue is reported (Panel A, fifth picture) to 
show the appearance of a normal rabbit epithelial architecture. 
Bacteria were detected by immunostaining with an in-house polyclonal anti-Shigella 
sonnei serum. As shown in Fig. 25, Panel B, a massive amount of bacteria was 
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associated with the lamina propria and the epithelium of the villi, particularly in areas of 
abscesses, rupture/destruction of the epithelial lining and of villi indentation, following 
infection with both Ss WT and Ss ∆cps (Panel B, first and second pictures). This 
indicates that the invasive abilities of S. sonnei in the intestinal epithelium were not 
impaired by the lack of the capsule but rather enhanced, as expected from the in vitro 
data presented in the previous paragraph. Under similar conditions, Ss phase II showed 
no invasion at all, as no bacteria were detected within the villi epithelium (Panel B, fourth 
picture). In intestinal loops infected by Ss ∆cps(cps) (Panel B, third picture), an 
interesting pattern of staining was shown that matched the previous observations: the 
reduced severity of tissue damage observed in H&E-stained slices correlated with a 
reduced amount of bacteria invading the intestinal epithelium as the majority of Ss 
∆cps(cps) bacteria were seen in the lumen. Moreover, no significant lesion was 
observed in regions in which bacteria were found both in the lamina propria and in 
epithelial cells. This might indicate that infected tissues are more tolerant to the 
presence of invasive S. sonnei that express a high amount of capsule polysaccharide, 
as it was shown for Salmonella Typhi expressing Vi capsule [230]. 
Histopathological alterations were quantified and recorded as the average ratio 
between the length and the width (L/W) of the villi that measures villi atrophy on H&E-
stained and GIEMSA-stained (data not shown) tissue sections (Figure 25, Panel C). 
This quantitative estimation is inversely proportional to the inflammatory status of the 
epithelium and reflects the qualitative analysis described above. Again, Ss ∆cps strain 
had the more aggressive phenotype and induced villi atrophy with a significantly higher 
degree than what was measured in Ss WT-infected samples (average L/W ratio of 3.6 
and 5.3, respectively). On the other hand, the entity of Ss ∆cps(cps)-induced atrophy 
was reduced if compared to both the WT-induced and ∆cps-induced atrophy (average 
L/W ratio of 7.0). Ss phase II did not induce significant villi alteration as the extimated 
atrophy value was very similar to the L/W ratio of uninfected tissues (average L/W ratio 
of 7.7 and 8.4, respectively). 
 Summarizing the results reported so far, qualitative biopsies observation and 
histopathological analysis of infected rabbit intestinal tissues indicate that the lack of the 
G4 capsule polysaccharide in the Ss ∆cps strain caused a dramatic increase of 
pathogenicity, that is particularly characterized by the augmentation of mucus and blood 
production in the infected loop, of rupture and destruction of the epithelial lining and of 
tissue inflammatory manifestations. On the contrary, trans-complemented Ss ∆cps(cps) 
strain, showed an attenuated phenotype in vivo, with less bacteria invading the 
epithelium and less tissue inflammation, likely also due to a higher host tolerance to 
encapsulated bacteria. 
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Figure 25 
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Figure 25: Histopathological analyses of S. 
sonnei WT, ∆cps, ∆cps(cps) and phase II 
infected loops in the single challenge rabbit 
model (8 h infection). Control sample is the 
uninfected tissue. Panel A) Hematoxylin and 
Eosin (H&E) staining of 7 µm slices of infected 
ileal loops. The infecting strain is shown in the 
box. Panel B) Immunostaining of 7 µm slices of 
infected ileal loops with a polyclonal Shigella 
sonnei antiserum and counterstaining with 
Hematoxylin to demonstrate bacteria 
localization. Panel C) Histological alteration 
observed in the rabbit model following infection 
by Ss strains. Severity of villi atrophy is 
measured according to the ratio between the 
length and width of 120 villi counted on each 
among at least four different loops (Asterisks 
indicate P< 0.001).
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Further analyses were performed to evaluate the host inflammatory changes to 
infection by the different S. sonnei strains. Portions of the infected ligated loops were 
processed in order to measure mRNA levels of several genes encoding proinflammatory 
cytokines and chemokines [202]. In particular, we focused our attention on those 
interleukins whose mRNA levels are most prominently induced or are most relevant in 
response to Shigella infection [53]: IL 6, IL 8, IL 1β. Real Time-quantitative PCR (RT-
qPCR) analyses were performed to calculate the fold induction of these genes in the S. 
sonnei mutants-infected loops over the WT-infected loops. Results are reported in 
Figure 26, first, second and third plots. All the three interleukins studied, showed a 
similar trend, consistent with what observed in histopathological analyses. Compared to 
the wild type Ss strain, the Ss capsule negative strain elicited increased levels of IL 6, 8 
and 1β, while the Ss ∆cps(cps) complemented strain triggered lower expression levels 
of these proinflammatory genes. As expected, Ss phase II avirulent strain did not 
relevantly induce inflammatory factors, with measured levels similar to those of the 
uninfected tissue. However, these differences were not statistically significant, also due 
to the high variability among the different replicates of the same infective condition and 
between the different animals. It is interesting to notice that differences in the expression 
of proinflammatory cytokines between the Ss WT-infected samples and the Ss ∆cps-
infected samples became more relevant with the increase of the infective dose (Results 
for IL 8 are reported as example in Figure 26, fourth plot): in the samples infected with a 
Ss ∆cps dose of 5*109 bacteria/loop the highest expression levels of IL 8 were 
measured, as compared to the samples infected with lower doses and to the samples 
infected with the same higher dose of Ss WT. Even if not statistically significant, 
collectively these results, together with the previous results obtained from the in vivo 
model, indicate that S. sonnei in the absence of the G4 capsule shows increased 
pathogenicity in the gut and triggers higher intestinal inflammation. This could be the 
result of the fact that virulence factors are no more shielded by the capsule 
polysaccharide and this might facilitate on one hand the bacterial adhesion and entry in 
the epithelial cells, and on the other hand the recognition of invasive bacteria by the 
innate immune system of the host.  
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Figure 26 
 
 
Figure 26: RTqPCR analysis of proinflammatory 
cytokines gene expression in rabbit ileal loops 
infected by S. sonnei WT, ∆cps, ∆cps(cps) and 
phase II strains. IL 6, IL 8 and IL 1β expression 
levels are calculated as fold induction over the 
levels measured in Ss WT-infected loops.
We next investigated how the G4C might contribute to bacterial fitness and host 
colonization. Bacterial translocation is a phenomenon in which enteric bacteria cross the 
intestinal barrier and reach the mesenteric lymph nodes. From there, dissemination 
throughout the body, to liver, spleen and general circulation may occur and cause 
severe consequences as sepsis and multisystem organ dysfunction [231]. We studied 
the influence of the capsule on the ability of S. sonnei to translocate and disseminate to 
establish systemic infection by collecting mesenteric lymph nodes (MLN), liver, spleen 
and blood from animals infected concomitantly with the different S. sonnei strains. 
Infected organs were processed in order to count viable bacteria on selective media. 
The relative percentage of the different S. sonnei strains recovered from MLN, liver, 
spleen and blood is reported in Figure 27: as it is shown in the graph, in each peripheral 
organ we predominantly found S. sonnei WT strain (as about 70 % of all the bacteria 
recovered). S. sonnei capsule mutant strain accounted for about the 26 % of the total, 
while a negligible amount of the other strains (Ss ∆cps(cps), Ss phase II) was 
measured. Similar results were obtained by analyzing tissues from rabbits infected for 
16 h during the competitive challenge experiment (data not shown). Interestingly, these 
data indicate that while in the intestine the Ss ∆cps capsule mutant showed the most 
aggressive/invasive phenotype, it had impaired ability to translocate and disseminate to 
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establish peripheral infection, as compared to Ss WT. A possible reason could be that 
acapsulated bacteria are more susceptible to the host immune responses since they 
lack the protective effect of the capsular polysaccharide. So if in a first moment they 
invade very efficiently the intestinal epithelium, then they might succumb to the strong 
inflammatory response of the host. This aspect has been demonstrated for other 
pathogens [232]. On the other hand, probably due to the fact that the Ss ∆cps(cps) 
complemented strain is less invasive in the gut, we do not find it in peripheral organs. 
 
Figure 27 
 
Figure 27: Systemic spread of S. sonnei WT, ∆cps, ∆cps(cps), phase II strains in liver, blood, spleen and 
mesenteric lymph nodes (MLN). Data are reported as relative percentage of the total bacteria collected in 
each organ in the rabbit model following 8 h of infection. 
Finally, to support our hypothesis that the group 4 capsule has an important role in 
affecting the invasive abilities of S. sonnei and the host response during infection, we 
needed to prove that the G4C operon was indeed expressed by bacteria in vivo. 
Therefore, we measured G4C gene cluster expression in bacteria isolated from infected 
loops. Real Time-quantitative PCR (RT-qPCR) analyses were performed to calculate the 
fold induction of each gene of the cluster in S. sonnei mutants over the levels of the WT 
strain. In Figure 28, the results of etp and etk genes expression analysis are reported 
(similar results were obtained for the other genes of the cluster, data not shown). Ss WT 
bacteria expressed the G4C operon at a similar level as the housekeeping gene 
encoding for the lysine transporter LysP [26]. Moreover, we saw that in the 
complemented strain, the operon was 5 to 6 times more expressed, than in the WT 
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strain. The data are not normalized to gene copy number, however this result supports 
the hypothesis of the ‘over-complementation’ of the Ss ∆cps(cps). S. sonnei phase II 
had lower expression levels, suggesting a mechanisms of gene repression in the 
absence of the OAg units substrates. Ss ∆cps do not possesses the cluster, so no 
expression was detected.   
Figure 28 
 
 
Figure 28: RT-qPCR expression analysis of etp and etk genes of the G4C operon in S. sonnei WT, ∆cps, 
∆cps(cps) and phase II bacteria from infected  loops. Expression levels are calculated as fold induction 
over the levels measured in Ss WT. 
6.11 G4C operon conservation in other Shigella species 
Finally, we studied the conservation of the group 4 capsule operon in different Shigella 
species. Genomes of several isolates of S. boydii, flexneri, sonnei and dysenteriae were 
analyzed for the presence of a G4C cluster homologous to the S. sonnei 53G one. In 
general, we found that the G4C cluster was highly conserved in all the Shigella 
background, but in S. flexneri (except for the S. flexneri 6 serotype) (See Table 7). About 
the 77 % of the genomes of S. boydii, sonnei and dysenteriae analyzed possessed a 
cluster with a 99 % score of homology. On the contrary, S. flexneri very often possessed 
the single genes of the operon, but these genes were not clustered together in the same 
position of the genome. This observation is in agreement with our results showing that 
S. flexneri 2a does not express an OAg capsule, as its ∆galU mutant is completely OAg-
deficient.    
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Table 7: Shigella genome comparison
 
Table 7: Shigella genome comparison to 
evaluate group 4 capsule gene cluster 
distribution within the genus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genomes Operon hits
> 99 %
(% of total)
S. boydii 74.7
S. flexneri 
(other than 6)
7.8
S. flexneri 6 100
S. sonnei 73.3
S. dysenteriae 82.1
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 DISCUSSION 7.
In this thesis we describe the identification and characterization of a group 4 capsule in 
Shigella sonnei important for bacterial pathogenesis in vitro and in vivo.  
Exopolysaccharides, comprising LPS O side chain and all other surface exposed 
polysaccharides [219], play critical roles in interactions between bacteria and their 
immediate environments. In particular, capsules are high molecular weight surface-
enveloping polysaccharides structure attached to the surface of the cells though an 
uncharacterized mechanism. They are important protecting factors that help bacteria 
surviving to desiccation [217] and are well established virulence factors, often acting by 
protecting the cell from opsonophagocytosis and complement-mediated killing [219]. 
Gram-negative bacterial capsules, in particular the exemplifying E. coli capsules, have 
been classified into four groups, based on genetic and biochemical criteria [222]. The 
group 4 capsules (G4C) subclass comprises a subset of former group I K antigens and 
surface polysaccharides known as ‘O antigen capsules’. G4C were first identified in E. 
coli serotype O111 [233], where 50 % of the O111 antigen is in the smooth LPS fraction 
and the remainder is in a LPS-unlinked capsular form. From there, G4 capsules have 
been found in E. coli isolates that cause intestinal infections, including representatives of 
enteropathogenic (EPEC), enterotoxigenic (ETEC) [185] and enterohemorrhagic 
(EHEC) [224] E. coli, as well as in Salmonella enterica serovar Enteriditis [217] and 
Francisella tularensis [218]. The full distribution of G4 capsules is unknown and many 
may have been overlooked because early structural and serological analyses were 
interpreted with the expectations that surface O antigen is only found as LPS side chain, 
in a lipid A-core-linked form [219]. Although E. coli OAg capsules have been 
characterized from long time [234], this is the first report about a capsule in Shigella. Its 
existence has been overlooked, again probably because of its similarity to the cognate 
LPS O side chain and because it can not be identified by standard serological tests. The 
presence of the G4C in S. sonnei has been uncovered by the immunological 
characterization of the LPS deep rough mutant, S. sonnei galU knock out (Ss ∆galU). In 
this mutant, the linkage of the OAg repeating units to the lipid A-core region of the LPS 
is abolished [213]. In S. flexneri 2a and 5a backgrounds, deletion of the galU gene has 
been reported to result in OAg deficiency [80,184]. However, we demonstrated that Ss 
∆galU and its deriving outer membrane particles (GMMA) were still able to induce an 
OAg-specific response in mice. A low mobility material, not linked to the LPS, could be 
extracted from Ss ∆galU and could be visualized in immunoblot analyses with an OAg-
specific antiserum. In 2002, De-Qi, Xu and colleagues [84] firstly observed the presence 
of a phase I-reactive material in immunoblot analyses, above the position 25 OAg 
repeating units, in the context of the characterization of polysaccharides expressed by a 
Salmonella enterica serovar Typhi live vaccine vector candidate. By cloning the S. 
sonnei OAg synthetic operon in the vaccine strain, they found most of the OAg material 
in a LPS-unlinked form. The authors speculated about the possibility of the presence of 
a capsule-like material in S. sonnei. However no further studies followed to clarify this 
hypothesis. In the present study, the surface localization of the OAg-containing material 
in Ss ∆galU was demonstrated by an experiment of OAg surface staining. Moreover, we 
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showed that S. sonnei WT and ∆galU possess a high molecular weight polysaccharide 
comprising the same residues of the LPS O side chain (FucNAc4N, L-AltNAcA).  
Generally, capsule synthesis requires nucleotide diphospho-sugar precursors 
available in the cytoplasm and concludes with an assembled polymer at the periplasmic 
face of the plasma membrane. Capsule formation is completed by surface translocation 
and export, two steps that follows reactions which are unique to capsular 
polysaccharides [219] (see Figure 29). The genes required for G4C formation are 
organized into two loci (for details about proteins involved in G4C biosynthesis, see 
Table 8). The first is responsible for the synthesis of Wzy-dependent O units (see 
paragraph 6.1) [235,236] and determines both the LPS and the capsular O antigen 
portions [237,238]. In this case, the lipopolysaccharide O antigen and the capsule 
antigen are composed of the same repeating units, this is the reason why G4C have 
also been termed ‘O-antigen capsules’ [211]. The genes in the Wzy-dependent synthetic 
locus are required for the synthesis of the repeating unit, its delivery to the periplasm, 
and its polymerization by Wzy into both O antigen and G4C polysaccharide (Fig. 29). 
Accordingly, mutants deficient in this locus are expected to be both rough and 
uncapsulated. S. sonnei OAg synthetic cluster is composed of nine genes, including the 
one encoding for the Wzy polymerase (wbgT, wbgU, wzx, wzy,wbgV, wbgW, wbgX, 
wbgY and wbgZ) [84]. Mutants in the OAg biosynthetic operon (Ss -pSS or Ss ∆wbg) 
resulted to lack both the LPS side chain and the capsule, as expected in case of a Wzy-
dependent synthetic pathway typical of group 4 capsules [219]. The second locus that is 
involved in G4C formation is the G4C operon, also termed the ‘22-minute locus’ 
because it is mapped to min 22 in the E. coli K-12 genetic map [239]. This operon 
encodes for seven proteins (YmcDCBA, YccZ, Etp (YccY), Etk (YccC) [219]. The 
functionality of the G4C operon has been first demonstrated in EPEC serotype O127, in 
which all seven genes in this transcriptional unit are required for group 4 capsule 
assembly [185]. The presence of G4C analogue clusters is also evident in other Gram-
negative pathogens such as K. pneumoniae [240] and Salmonella [217]. Regulation of 
capsular biosynthesis in a number of both Gram-positive and Gram-negative bacteria is 
mediated via a phosphoregulatory system, consisting of bacterial-tyrosine kinases (BY-
kinases), and their cognate phosphatases [219]. In Gram-negative bacteria, the BY-
kinase is expressed as a single membrane-spanning polypeptide, also known as a PCP 
2a protein [236], with the C-terminal kinase domain on the cytoplasmic side. The kinase 
and phosphatase activities of Etk (homologous to Wzc) and Etp (homologous to Wzb), 
two proteins of the G4C operon, have been confirmed [219] and their role in repeating 
unit polymerization into G4C-PS and in capsule assembly has been shown 
[237,241,242]. The G4C locus contains the four additional genes ymcABCD, also 
required for capsule expression. All four are predicted to encode for exported proteins, 
with YmcA and YmcC may being lipoproteins [243]. Their function has not been 
elucidated yet, although databases searches identify hypothetical proteins from 
polysaccharide systems in other bacteria. We demonstrated that the formation of the 
HMW-PS founded in S. sonnei was dependent on the presence of an operon, highly 
homologous (98 % homology) to the G4C cluster identified in EPEC [185]. Peleg, A. et 
al. already suggested in 2005 the existence of an intact G4C gene cluster in some 
genomes of Shigella. Here, we showed that the S. sonnei 53G G4C operon is functional 
and encodes for the formation of an LPS-independent HMW OAg polysaccharide, thus a 
group 4 capsule.  
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Table 8: Proteins involved in group 4 capsule formation, their predicted 
localization and function 
PROTEIN LOCATION FUNCTION 
Wzy Integral inner 
membrane 
Und-PP-linked oligosaccharide repeating unit 
(RU) polymerase  
Wzx Integral inner 
membrane 
O-unit flippase, required for export of und-PP-
linked RUs  in Wzy-dependent synthesis 
YmcD Inner membrane Putative transposase 
YmcC Outer membrane 
(OM) lipoprotein 
Putative regulator 
YmcB Unknown Putative capsule polysaccharide protein 
YmcA OM lipoprotein Putative capsule polysaccharide protein 
YccZ Outer membrane Forms a multimeric putative translocation channel 
and interacts with the periplasmic domain of Etk 
(homologue of Wza) 
YccY (Etp) Cytoplasm Protein tyrosine phosphatase; dephosphorylates 
Etk (homologue of Wzb) 
YccC (Etk) Inner membrane 
with a large 
periplasmic domain 
and cytosolic N and 
C termini 
Cryptic autophosphorylating protein tyrosine 
kinase, participates in high-level polymerization of 
capsular polysaccharide and forms part of a 
trans-envelope capsule translocation complex 
(homologue of Wzc)  
 
Figure 29 
 
Figure 29: A model for biosynthesis and assembly of group 4 capsules. Beginning at the left,und-PP-
linked repeat units are assembled at the interface between the cytoplasm and the inner membrane. Newly 
synthesized und-PP-linked repeats are then flipped across the membrane in a process requiring Wzx. 
This provides the substrates for Wzy-dependent polymerization wherein the polymer grows by transfer of 
the growing chain to the incoming und-PP-linked repeat unit. Continued polymerization requires 
transphosphorylation of C-terminal tyrosine residues in the Wzc oligomer and dephosphorylation by the 
Wzb phosphatase. Polymer is translocated by Wza, which likely acts as a channel (Figure and Legend 
reproduced from [219]). 
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As mentioned before, the linkage of the G4 capsules to the bacterial membrane is still 
not well characterized [219]. We performed compositional analyses and we did not 
identify Kdo, a residue of the LPS core region, as a component of the capsular antigen. 
This again suggests that the G4C is not linked to the bacterial membrane through the 
LPS. The G4 capsule of Salmonella has been shown to possess a lipid anchor [244]. A 
lipidic nature of the carrier of the G4C in S. sonnei could explain the mobility of the hot-
phenol surface polysaccharide extracts that we observed in SDS-PAGE. However, 
studies to clarify this hypothesis have not been performed yet.  
The function of the G4C as potential virulence factor of S. sonnei was investigated 
both in vitro and in vivo. Our results showed that the presence of the capsule 
polysaccharide accounted for changes in cell invasion ability in vitro since the G4C 
mutant (Ss ∆cps) resulted significantly more invasive than the WT on HeLa cells. 
Complementing the ∆cps mutant with a plasmid expressing the G4C operon restored 
the WT-like lower invasiveness or even reduced it. Ss ∆cps increased invasiveness 
could derive from the fact that in the absence of the capsule, virulence factors, as the 
T3SS, are rapidly available and exposed and the strain might result in higher cell entry 
proficiency. On the other hand, Ss ∆cps complemented strain was less invasive than the 
WT strain. We hypothesized that it could be so because this strain is ‘over-
complemented’, as a result of the fact that the plasmid used for complementation, and 
so the G4C gene cluster, is present in multiple copies even though a low copy number 
vector was used. Thus, the complemented mutant likely expressed a higher amount of 
capsule polysaccharide and consequently showed an attenuated phenotype. These 
results are in accordance with the findings reported for EPEC and EHEC, when the 
invasiveness of encapsulated and uncapsulated strains was compared in a similar HeLa 
cells invasion assay [224]. It has been shown that at early time points postinfection, the 
G4C appeared to mask surface structures including intimin and the T3SS and this 
masking inhibited the attachment of EPEC and EHEC to tissue-cultured epithelial cells, 
diminished their capacity to induce the formation of actin pedestals, and attenuated 
T3SS-mediated protein translocation into host cells [224]. Masking by capsule of E. coli 
virulence factors has been frequently reported [224,226]. We also observed that the 
accessibility of the IpaB protein at the tip the type III secretion system was reduced in 
vitro in the Ss WT bacteria, as compared to the uncapsulated strain. Together, in vitro 
studies indicated a role of the capsule in affecting the pathogenic abilities of S. sonnei 
with the WT strain having a disadvantage in invasiveness associated with capsule 
formation. However, the fact that the bacteria maintain the capsule indicates that this 
surface structure contributes to bacterial fitness under some conditions. In support of 
this notion, the rabbit model of intestinal ileal ligated loops was used to evaluate in vivo 
the G4 capsule contribution to the invasive abilities of S. sonnei and to the induction of 
inflammatory host responses during the infection. If compared to the characteristic 
intestinal pathology induced by S. sonnei WT, Ss capsule mutant infection led to a more 
severe intestinal disease and a stronger inflammatory response. In contrast, infection by 
the Ss ∆cps complemented strain displayed a decrease in the pattern of pathology. We 
hypothesized that in the uncapsulated bacteria, virulence factors are no more shielded 
by the capsule polysaccharide and this might facilitate bacterial adhesion and entry in 
the host cells, as it was observed in the in vitro model of infection. Concomitantly, the 
recognition of invasive bacteria by the innate immune system of the host could be 
enhanced in the absence of the capsule. We then investigated the influence of the 
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capsule on the ability of S. sonnei to translocate and disseminate to establish systemic 
infection, in the same rabbit animal model. Interestingly, our results indicated that the 
presence of the capsule is needed for S. sonnei capabilities to disseminate. While in the 
intestine the Ss ∆cps capsule mutant showed the most aggressive/invasive phenotype, 
it had impaired ability to disseminate compared to Ss WT. The reason could be that 
uncapsulated bacteria are more susceptible to the host immune responses since they 
lack the protective effect of the capsular polysaccharide. Thus, while the lack of the 
capsule could be beneficial in the early stages of the infection to very efficiently invade 
into the intestinal epithelium, in the later stages capsule-deficient bacteria have a 
disadvantage in translocation and dissemination and succumb to the strong 
inflammatory response of the host (see Figure 30). This hypothesis is supported by 
literature reports that demonstrated that the expression of the T3SS and the G4C is 
conversely and temporally regulated to be optimized for efficient host colonization by 
EHEC [224]. As demonstrated for EPEC and EHEC [224], the shielding concept leaves 
the bacteria with an obvious dilemma. They cannot translocate proteins or invade host 
cells without the assistance of virulence factors, such as adhesin proteins and the T3SS, 
but at the same time, the polysaccharide shields contribute to bacterial fitness by 
providing protection against countermeasures at the disposal of a mammalian host. As 
an example, Yersinia solved the shielding dilemma by careful adjustment of the 
respective lengths of the T3SS needle and the YadA adhesin, such that the length of the 
T3SS needle is the minimum that still allows efficient protein translocation through the 
YadA shield [245]. We reasonably think that Shigella sonnei has evolved fine regulation 
mechanisms to optimize its virulence during host infection. In our study, we showed that 
the WT, encapsulated bacteria possessed the optimized phenotype which is balanced 
both for the invasive abilities and for the persistence and spread in the host. Studies on 
the regulation of the S. sonnei capsule expression in different stages of the infection 
would shed light on this important aspect. Genome analysis of several isolates of S. 
sonnei, S. flexneri, S. boydii and S. dysenteriae for the presence of a homologous 
operon showed that the G4C cluster is highly conserved in Shigella sonnei, S. boydii 
and S. dysenteriae, suggesting that this could be a common virulence strategy in 
Shigella. An exception is S. flexneri where the LPS O side chain has been characterized 
to be the shielding effector. S. flexneri has optimized its virulence phenotype through 
OAg glucosylation, via a bacteriophage-encoded enzyme, that shortens the O side chain 
3D structure and thus enhances the T3SS function without compromising the protective 
properties of the LPS [80]. Regarding the other serogroups, the functionality of the G4C 
gene cluster still needs to be tested. However, we confirmed group 4 capsule production 
in a different isolate of S. sonnei (S. sonnei 25931, data not shown), indicating that the 
S. sonnei 53G capsule is not a characteristic of a single strain, but likely a common 
feature of most of the S. sonnei isolates.  
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Figure 30 
 
Figure 30: The expression of a G4 capsule (cps) affects the invasive abilities of S. sonnei both in vitro 
and in vivo. The Ss WT encapsulated strain seems to possess the optimized phenotype to efficiently 
invade the epithelial cells but also to persist in the host and establish systemic infection. Uncapsulated (Ss 
∆cps, cps-) or iper-capsulated (Ss ∆cps(cps), cps++) strains are both at a competitive disadvantage 
through a tradeoff between their invasive capacity and their ability to survive innate immune responses. 
In addition to their capacity to mask surface virulence factors, it has been shown that 
capsules possess anti-inflammatory properties. One example is the anti-inflammatory 
effect of Vi capsule polysaccharide of Salmonella enterica serotype Typhi [246]. 
Recently, animals infected with a Vi-positive S. Typhimurium chimera, harbouring the 
Salmonella locus that encodes the Vi polysaccharide, showed a significant reduction in 
cellular trafficking of innate immune cells, including PMN and NK cells, as compared to 
animals infected with a Vi-negative strain [247]. The presence of the Vi capsule also 
correlated with induction of the anti-inflammatory cytokine IL 10 in vivo, a factor that 
impacted on chemotaxis and the activation of immune cells in vitro [247]. What makes 
S. sonnei polysaccharide even more interesting in its ability to regulate the host immune 
response to bacterial infection is its potential to act as a zwitterionic immunomodulating 
polysaccharide. Zwitterionic polysaccharides (ZPS) are in fact a novel class of major 
histocompatibility complex class II (MHC II)- dependent antigens characterized by a high 
molecular weight [248] and by the presence of positive and negative charges within a 
repeating unit, leading to a helical 3D structure of the polysaccharide [249]. The HMW S. 
sonnei G4C (and less likely, the MMW LPS O side chain) possesses this requisite since 
an amino group and a carboxylic group are present on the C-4 of the FucNAc4N and on 
the C-6 of the L-AltNAcA, respectively. These groups are likely to be in the protonated 
form in physiological conditions. ZPS have been already characterized in other bacteria, 
e.g. B. fragilis (capsular PSA) [250] and S. pneumoniae (capsular SP1) [251], and they 
have shown immunomodulatory properties such as the abilities to induce immunological 
tolerance through the activation of IL 10 producing-Treg cells, to modulate the balance 
between Th1 and Th2 host responses and to affect the Th17 response and 
proinflammatory signaling, e.g. during B. fragilis-induced abscess formation [249]. In 
vitro and in vivo studies to evaluate the host adaptive immune response would be 
needed to understand how the S. sonnei capsule polysaccharide modulates the host 
response in relation to its zwitterionic nature. These studies could give an important 
contribution in the understanding of S. sonnei-mediated tuning of the host immunity 
during infection. Based on the OAg sugar composition reported for all the other Shigella 
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strains [208], it seems that the zwitterionic nature is a peculiar feature of the S. sonnei 
polysaccharide. As mentioned in paragraph 3.3.2, the main response in natural 
immunity to Shigella is driven by the OAg, thus it represents a valid antigen for the 
development of a vaccine against Shigella. A study to evaluate the IgG subclass 
response to Shigella sonnei and Shigella flexneri 2a was performed in subjects naturally 
exposed to these organisms. It was reported that IgG2 was the major component in the 
anti-S. flexneri subclass response, as observed also in studies performed on S. 
dysenteriae infected patients, while the anti-S. sonnei pattern of IgG subclass response 
was unique among the genus Shigella, being predominantly composed of the IgG1 
subclass [252]. The relationship between this distinctive immune response and the 
zwitterionic nature of the S. sonnei polysaccharide has not been investigated yet, but 
could be a reasonably explanation. Conventionally, the immune response to bacterial 
carbohydrate antigens is considered to be T cell-independent, and the IgG antibodies 
elicited are primarily restricted to the IgG2 subclass [110]. Therefore, for the 
development of a saccharide-based vaccine, conjugation of the antigen to a carrier 
protein is needed to induce a T-cell dependent response. The zwitterionic properties of 
the S. sonnei capsule in the context of a conjugated molecule could magnify the immune 
response to the potential candidate vaccine. As a support to this proposition, in a recent 
paper by Gallorini, S. et al., the authors showed that ZPS engineered-glycoconjugates 
induce higher T-cell and Ab responses to carrier and PS, respectively, compared to 
control PS-glycoconjugates made with the native polysaccharide form [253]. 
In conclusion, this study describes a new and interesting finding in the Shigella field to 
achieve a better understanding of the pathogenic mechanism of Shigella and in addition 
of the function of extracellular polysaccharides as virulence factors. Results reported in 
this thesis will compose a manuscript about the first isolation, and the biochemical and 
functional characterization of a group 4 capsule in Shigella sonnei 53G. Wzy-dependent 
capsule polysaccharides have been proposed as target for the development of 
antimicrobial compounds against different pathogens [254]. The discovery of new 
targets for virulence seems even more important in Gram-negative pathogens, which 
are traditionally more difficult to treat due to the presence of the outer membrane. 
Moreover, capsular polysaccharides are important factors in bacterial pathogenesis and 
have been the target of a number of successful vaccines [255,256]. Therefore, the 
identification of a capsule in Shigella could have implications on the design of new-
generation anti-Shigella drugs and also on the development of preventive measures, as 
a vaccine against this enteric disease. 
  
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 ANNEX 8.
Communications 
Poster Presentations:  
• O antigen of Shigella masks surface proteins in vitro. Mariaelena Caboni, Pesce, I., 
Maggiore, L., Berlanda Scorza, F., Colucci, A. M., Saul, A., Gerke, C. (Novartis 
Research Days 2010, NV&D, Novartis campus, Siena, Italy). 
• Polysaccharides on the surface – a new coat for Shigella? Mariaelena Caboni, 
Pesce, I., Berlanda Scorza, F., Maggiore, L., Saul, A., Gerke, C. (EBI–Wellcome 
Trust Summer School in Bioinformatics 2011, Wellcome Trust Genome Campus, 
Hinxton, Cambridge, UK). 
• Polysaccharides on the surface – a capsule for Shigella? Mariaelena Caboni, Pesce, 
I., Berlanda Scorza, F., Maggiore, L., Saul, A., Gerke, C. (Novartis Research Days 
2011, NV&D, Novartis campus, Siena, Italy). 
• A deep rough mutant of Shigella sonnei reveals the expression of an O antigen 
capsule. Mariaelena Caboni, Giannelli, C., Maggiore L., Berlanda Scorza F., Saul A., 
Gerke C. (Life Science Symposium LSS 2012 – Global Health meets Infection 
Biology, Swiss Federal Institute of Technology EPFL, Lausanne, Switzerland). 
 
Oral Presentations: 
• Polysaccharides on the surface – a new coat for Shigella? Mariaelena Caboni 
(Novartis PhD students Workshop 2010, NV&D, Novartis campus, Siena, Italy). 
• Protection against Shigella in mice by a novel approach using outer membrane 
particles. Christiane Gerke, Berlanda Scorza, F., Colucci, A. M., Maggiore, L., Pesce, 
I., Caboni, M., Di Cioccio, V., Bloink, K., Saul, A. J. (Vaccines For Enteric Diseases 
(VED) 2011, Cannes, France). 
• Polysaccharides on the surface – a capsule for Shigella? Mariaelena Caboni 
(Novartis PhD students Workshop 2011, NV&D, Novartis campus, Siena, Italy). 
• Developing a Shigella vaccine based on generalized modules for membrane 
antigens. Christiane Gerke, Berlanda Scorza, F., Colucci, A. M., Cole, R., Schrandt, 
T. A., Maggiore, L., Rossi, O., Pesce, I., Caboni, M., Vandenhoek, J., Casanova, H., 
Norais, N., Di Cioccio, V., Bloink, K., Saul, A.J. (Phacilitate Vaccine Forum 
Washington 2012, Washington D.C., USA). 
• A deep rough mutant of Shigella sonnei uncovers the expression of an O antigen 
capsule. Mariaelena Caboni (Novartis PhD students Workshop 2012, NV&D, 
Novartis campus, Siena, Italy). 
 
Publication: 
High Yield Production Process for Shigella Outer Membrane Particles. Francesco 
Berlanda Scorza, Colucci, A. M., Maggiore, L., Sanzone, S., Rossi, O., Ferlenghi, I., 
Pesce, I., Caboni, M., Norais, N., Di Cioccio, V., Saul, A., Gerke, C.  
PLoS ONE (2012), 7(6):e35616. 
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Courses, Conferences and Scientific Visits 
Courses: 
• Enhancing your presentation skills (NIBR training course, 2010, Novartis campus, 
Siena). 
• EBI–Wellcome Trust Summer School in Bioinformatics (Wellcome Trust Genome 
Campus, 2011, Hinxton, Cambridge, UK). 
• 1st Scientific Training Course: Vaccinology (ALTA - EIMIDITN, 2011, Novartis campus, 
Siena). 
• How to write a paper (Novartis Academy course, 2012, Keith Veitch, Head of 
Publications, Novartis Pharma, Novartis campus, Siena). 
 
Conferences: 
• Ageing and immunity: Addressing immune senescence to ensure healthy ageing 
(Novartis conference, 2010, Novartis campus, Siena). 
• The importance of population biology in developing bacterial vaccines (Novartis 
Academy workshop, 2010, Prof. Richard Moxon, Novartis campus, Siena). 
• A chemist's overview of traditional and modern vaccines (Novartis Academy 
workshop, 2010, Prof. Neil Ravenscroft, Novartis campus, Siena). 
• Moving Conjugate Vaccines into the future (Novartis workshop, 2010, Novartis 
campus, Siena). 
• Novartis-Harvard meeting: Minisimposium on Vaccines and Host-Pathogen 
Interactions (Novartis Academy-Harvard medical school simposium, 2012, Novartis 
campus, Siena).  
• Life Science Symposium LSS 2012: Global Health meets Infection Biology (Swiss 
Federal Institute of Technology EPFL, 2012, Lausanne, Switzerland). 
 
Scientific Visits: 
• July, 23rd – August, 5th, 2012: Visiting PhD student, Unité de Pathogénie Microbienne 
Moléculaire, Institute Pasteur, Paris. Supervisor: Prof. Philippe J. Sansonetti. 
• September, 26th – October, 26th, 2012 : Visiting PhD student, Unité de Pathogénie 
Microbienne Moléculaire, Institute Pasteur, Paris. Supervisor: Prof. Philippe J. 
Sansonetti. 
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